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- ADR: Adriamycin (Doxorubicin) 
- AE: Adverse event 
- AIEOP: Associazione Italiana di 
Ematologia ed Oncologia Pediatrica 
- ALL: Acute lymphoblastic leukemia 
- AML: Acute myeloid leukemia 
- AR: Average risk 
- ARA-C: Cytarabine, Cytosine arabinoside, 
Aracytine 
- ARDS: Adult respiratory distress syndrome 
- AUL: Acute undifferentiated leukemia 
- BCG: Bacillus Calmette-Guerin 
- BCNU: Bis-chlorethyl-nitrosureum 
- BFM: Berlin-Frankfurt-Munich group 
- BM: Bone marrow 
- CB: Cord blood 
- CCG: Children’s cancer group 
- CI: Confidence interval 
- CLG: Children’s leukemia group 
- CMV: Cytomegalovirus 
- CNS: Central nervous system 
- COALL: German Co-operative study group 
for treatment of acute lymphoblastic 
leukemia in childhood 
- COPAD: Cyclophosphamide, vincristine, 
prednisolone and doxorubicin.  
- CPH: Group for Pediatric Hematology in 
Czech Republic 
- CPM: Cyclophosphamide 
- CR: Complete remission 
- CRF: Case report form  
- CSF: Cerebrospinal fluid 
- CSI: Craniospinal irradiation 
- CVC: Central venous catheter 
- DBT: Death before treatment 
- DCOG: Dutch Childhood Oncology Group 
- DCR: Death in first complete remission 
- DI: DNA index 
- DIC: Disseminated intravascular 
coagulation 
- DF: Degrees of freedom 
- DFCI: Dana-Farber Cancer Institute 
- DFS: Disease free survival 
- DMSO: Dimethylsulfoxide 
- DNA: Deoxyribonucleic acid 
- DNR: Daunorubicin 
- DS: Down syndrome 
- DXM: Dexamethasone 
- EBV: Epstein Barr virus 
- ECHO virus: Enteric Cytopathic Human 
Orphan virus 
- ED: Early death 
- EFS: Event free survival 
- EG: Exempli gratia 
- EORTC: European organization for 
research and treatment of cancer 
- EU: European Union 
- FAB: French-American-British morphology 
classification 
- G-CSF: Granulocyte colony stimulating 
factor 
- GPR: Good partial response 
- GVHD: Graft versus host disease 
- HBV: Hepatitis B virus  
- HD-MTX: High doses methotrexate 
- HLA: Human leukocyte antigen 
- HLH: Hemophagocytic lymphohistiocytosis 
- HR: High-risk 
- HSCT: Hematopoietic stem cell 
transplantation 
- HSV: Herpes simplex virus 
- ID: Intradermally 
- IE: Id est 
- IM: Intramuscularly 
- INS: Israel National Studies  
- IR: Intermediate risk 
- IT: Intrathecal therapy 
- IU: International units 
- IV: Intravenous 
- JCCLSG: Japanese Childhood Cancer and 
Leukemia Study Group 
- LR: Low risk 
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- M: Methotrexate based consolidation 
(EORTC-CLG Protocol 58741) 
- MAS: Macrophagic activation syndrome 
- MDS: Myelodysplastic syndrome(s) 
- MLL: Mixed lineage leukemia 
- MMUD: Mismatched unrelated donor 
- MMRD: Mismatched related donor 
- MOF: Multiorgan failure  
- MR: Medium risk 
- MRC: Medical Research Council 
- MRD: Minimal residual disease 
- MSD: Matched sibling donor 
- MTX: Methotrexate 
- MTZ: Mitoxantrone 
- MUD: Matched unrelated donor 
- NCI: National Cancer Institute 
- NHL: Non-Hodgkin lymphoma 
- NK: Not known 
- NOPHO: Nordic society of paediatric 
haematology and oncology 
- NRM: Non-relapse mortality  
- OR: Odds ratio 
- OS: Overall survival 
- P: Polychemotherapy based consolidation 
(EORTC-CLG Protocol 58741) 
- PB: Peripheral blood 
- PDN: Prednisolone/Prednisone 
- PE: Pulmonary embolism 
- PNET: Primitive neuroectodermal tumor 
- PO: Per oral 
- POG: Pediatric Oncology Group 
- PR: Partial remission 
- PTLD: Post transplant lymphoproliferative 
disease 
- REAL: Revised European-American 
classification of lymphoid neoplasms 
- RBC(s): Red blood cell(s) 
- RF: Risk factor 
- SE: Standard error 
- SMN: Secondary malignant neoplasm 
- SR: Standard risk 
- SVC: Superior vena cava syndrome 
- SVT: Supraventricular tachycardia 
- TBI: Total body irradiation 
- TCCSG: Tokyo Children’s Cancer Study 
Group 
- TLS: Tumor lysis syndrome 
- TLP: Traumatic lumbar puncture  
- TPOG: Taiwan Pediatric Oncology Group 
- TRD: Treatment related death(s) 
- TRM: Transplant related mortality 
- VANDA: Acronym for an ALL therapy 
including DXM, Ara-C, MTZ, VP-16, 
Asparaginase and IT chemotherapy  
- VCR: Vincristine 
- VDS: Vindesine 
- VHR: Very high-risk 
- VLR: Very low risk 
- VM-26: Teniposide 
- VOD: Veno-occlusive disease 
- VP-16: Etoposide 
- VZV: Virus varicella zoster 
- WBC: White blood cell(s) 
- 6-MP: 6-Mercaptopurine 
- 6-TG: 6-Thioguanin
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SUMMARY  
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most frequent cancer type in 
children. Complete remission is achieved in more than 95% of patients and the five-year survival 
rate exceeds 90% in the developed countries with current protocols. Nevertheless, up to 5% of 
children die due to toxic side effects of anti-leukemic therapy in first line protocols. This study is 
focused on the treatment related deaths (TRD) occurring in pediatric patients with ALL treated in 
frontline trials from the EORTC Children Leukemia Group (EORT-CLG). This study evaluates 
the incidence and type of TRD and investigates the risk factors for increased likelihood of TRD 
in ALL pediatric patients.  
PATIENTS AND METHODS: Retrospective study of patients included in the four EORTC-
CLG trials for newly diagnosed ALL pediatric patients since 1971 to 2008. Treatment related 
deaths were categorized in: 
- Early death or death before first complete remission:  Patients who died after registration in 
the trial and before achieving a first complete remission following pre-phase and 
induction/consolidation therapies.  
- Death in first complete remission: Patients who died in first CR for other reasons than ALL 
during or after having completed first line ALL-CLG therapies.  
Ultimate cause of death was categorized in: tumor burden related deaths, infection, 
bleeding/thrombosis, organ toxicity not induced by infection, secondary malignancies, transplant 
related mortality, ALL progression and others. For the analysis of risk factors for death before 
remission and death in complete remission a multivariate analysis via logistic regression analysis 
was performed. Probabilities of survival were estimated using the Kaplan-Meier method. P 
values were statistically significant if <0.05. 
RESULTS: In the analysis 4916 patients were included from four trials: 58741, 58831/2, 58881 
and 58951 conducted in the decades of the 70´s, 80´s, 90´s and 2000´s respectively. The 58741 
trial only included patients once in first remission. Incidence of treatment related deaths has 
significantly progressively reduced since first trial (p<0.001): 
- All treatment related deaths: All trials (4.5%). By protocol: 58741 (8.1%), 58831/2 
(3.4%), 58881 (3.9%) and 58951 (2.5%).  
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- Early death: All trials (1%). By protocol: 58831/2 (2.2%), 58881 (0.9%) and 58951 
(0.7%).  
- Death in first complete remission: All trials (3.5%). By protocol: 58741 (8.1%), 
58831/2 (1.2%), 58881 (3%) and 58951 (1.8%).  
Most frequent causes of death before remission were infection, bleeding and thrombosis and 
tumor burden related deaths. Bacterial organism mainly represents infections related deaths 
across all trials. In the last trial (58951), no patients died before any anti-leukemia treatment was 
initiated and no tumor burden related deaths were reported. The incidence of 
bleeding/thrombosis related death has progressively reduced. In the multivariate analysis age less 
than one year, female gender, NCI-High Risk and having been treated in the 58831/2 protocols 
were significantly associated with an increased risk of dying before remission. 
Most frequent causes of death in first remission were infection, transplant related toxicities and 
secondary malignant neoplasms (SMNs). Pneumocystis jirovecii was a major cause of death in 
the 58741 before the introduction of systematic prophylaxis. Measles was the most frequent viral 
organism inducing deaths in the 58831/2 and 58881 trials, before implementation of widespread 
MMR vaccination. Transplant related mortality has decreased progressively in the last three 
trials (22%, 26% and 7%). SMNs are represented by acute myeloid leukemia and sarcoma type 
induced tumors. In the multivariate analysis age above ten years, having been transplanted in 
first remission and having been treated in the 58741 trial were significantly associated with an 
increased risk of dying in remission.  
CONCLUSIONS: The progressive reduction in TRD is associated to: 
- Improvement in supportive care measures 
- Better recognition of patients with high-risk features for experiencing toxic events 
- Progressive learning in treating institutions with similar protocols 
- Better selection of patients candidates for transplantation in first remission 
- Increased awareness and early recognition of therapy-induced toxicity 
- Implementation of guidelines to prevent and minimize the toxic side effects of the 
chemotherapeutics used.  
Patients with the characteristics identified in the multivariate analysis should be carefully 
monitored in order to identify early signs of toxicity that may prevent them of experiencing fatal 
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events. The incidence and type of treatment related deaths is similar to that reported from other 
collaborative groups in contemporary clinical trials and has evolved over the last forty years.  
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RESUMEN  
INTRODUCCIÓN: La leucemia aguda linfoblástica (LLA) es el cáncer más frecuente en niños. 
Las tasas de remisión completa alcanzan el 95% y la supervivencia global a los 5 años supera el 
90% en los países desarrollados con protocolos contemporáneos. Sin embargo, hasta un 5% de 
los pacientes fallecen por causas relacionadas con el tratamiento. El objeto de este estudio es la 
mortalidad relacionada con el tratamiento (MRT) en pacientes con LLA tratados en protocolos 
de primera línea del grupo pediátrico de la EORTC (EORT-CLG). Este estudio evalúa la 
incidencia y el tipo de la MRT e investiga los factores de riesgo para fallecer de muerte tóxica en 
pacientes pediátricos con LLA.  
PACIENTES Y MÉTODOS: Estudio retrospectivo de los pacientes incluidos en los cuatro 
protocolos del grupo EORT-CLG para pacientes de nuevo diagnóstico de LLA desde 1971 a 
2008. La mortalidad relacionada con el tratamiento se definió como:  
- Muerte precoz o muerte antes de la primera remisión completa: Pacientes que fallecieron 
entre el momento del registro en el ensayo y antes de haber alcanzado una primera remisión 
completa  tras la pre-fase, inducción y consolidación 
- Muerte en primera remisión completa: Pacientes que fallecieron en primera remisión 
completa por otras causas diferentes a progresión de la LLA durante o después de haber 
completado el tratamiento de primera línea.  
La causa última de muerte se categorizó como: mortalidad relacionada con la carga tumoral, 
sangrado/trombosis, toxicidad orgánica no inducida por infección, segundas neoplasias, 
toxicidad relacionada con el trasplante, progresión de LLA y otras. Para el análisis de los 
factores de riesgo antes de la primera remisión y en primera remisión se realizó un análisis multi-
variante vía regresión logística. Las probabilidades de supervivencia se estimaron usando el 
método de Kaplan-Meier. Los valores p se consideraron estadísticamente significativos cuando 
fueron <0,05.  
RESULTADOS: En el análisis se incluyeron 4916 pacientes de 4 ensayos clínicos: 58741, 
58831/2, 58881 y 58951 llevados a cabo en las décadas de los 70, 80, 90 y 2000 
respectivamente. El ensayo 58741 solo incluyó a pacientes una vez alcanzada la primera 
remisión. La incidencia de mortalidad relacionada con el tratamiento ha disminuido de forma 
progresiva y significativa desde el primer ensayo (p<0,001): 
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- Todas las muertes relacionadas con el tratamiento: Todos los ensayos (4,5%). Por 
protocolo: 58741 (8,1%), 58831/2 (3,4%), 58881 (3,9%) y 58951 (2,5%). 
- Muerte precoz: Todos los ensayos (1%). Por protocolo: 58831/2 (2,2%), 58881 (0,9%) y 
58951 (0,7%). 
- Muerte en primera remisión completa: Todos los ensayos (3,5%). Por protocolo: 
58741 (8,1%), 58831/2 (1,2%), 58881 (3%) y 58951 (1,8%). 
Antes de la primera remisión, las causas más frecuentes de muerte fueron infecciones, sangrado 
y trombosis y muerte relacionada con la carga tumoral. Las bacterias fueron el microorganismo 
más frecuente entre las infecciones en todos los protocolos. En el último protocolo (58951) 
ningún paciente falleció antes de que se iniciase el tratamiento para la enfermedad y no hubo 
muertes relacionadas con la carga tumoral. La incidencia de causas relacionadas con sangrado o 
trombosis se ha reducido progresivamente. El análisis multi-variante mostró que los pacientes 
menores de un año, de sexo femenino, del grupo de alto riesgo NCI y aquellos que fueron 
tratados en los protocolos 58831/2 tenían mayor riesgo de mortalidad precoz.  
En primera remisión completa, las causas más frecuentes de muerte fueron infecciones, toxicidad 
relacionada con el trasplante y segundas neoplasias. La infección por Pneumocystis jirovecii fue 
una causa mayor de mortalidad en el protocolo 58741 previo a la introducción sistemática de la 
profilaxis. El sarampión fue el virus más relacionado con mortalidad tóxica antes de la 
implementación de la vacunación universal en los protocolos 58831/2 y 58881. La mortalidad 
relacionada con el trasplante se ha reducido progresivamente en los últimos tres protocolos 
(22%, 26% y 7%). Las segundas neoplasias más frecuentes son leucemia mieloide aguda y 
sarcomas. El análisis multi-variante mostró que los pacientes mayores de 10 años, los 
trasplantados en primera remisión y aquellos tratados en el protocolo 58741 tenían mayor riesgo 
de mortalidad en remisión.  
CONCLUSIONES: La progresiva disminución de la MRT está asociada a: 
- Mejoría del tratamiento de soporte 
- Mejor identificación de los pacientes con características de alto riesgo para experimentar 
mayor toxicidad 
- Aprendizaje progresivo de las instituciones con protocolos similares 
- Mejor selección de los pacientes candidatos a trasplante 
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- Mejor identificación de signos precoces de toxicidad inducida por el tratamiento e 
implementación de guías para prevenir y minimizar sus efectos secundarios.  
Los pacientes con las características identificadas en el análisis multi-variante deben ser 
monitorizados y vigilados estrechamente con el objetivo de identificar signos precoces de 
toxicidad que permitan prevenir el desarrollo de eventos fatales. La incidencia y el tipo de MRT 
es similar a la descrita por otros grupos colaborativos en ensayos clínicos contemporáneos y ha 
evolucionado y cambiado a lo largo de estas cuatro décadas.  
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I. INTRODUCTION 
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1. OVERVIEW OF CANCER DURING CHILDHOOD AND ADOLESCENCE 
The term childhood cancer usually comprises all cancers arising in individuals before the 
age of 15 years
1
. Histologically, childhood tumors are very variable and are classified into twelve 
major groups
1
 (Figure 1), further divided into 47 diagnostic subgroups according to the 
International Classification of Childhood Cancer
2
.  
                     
Figure 1. Composition of tumor types across childhood age groups
1
.   
In childhood populations of Europe, North America and other developed regions of the 
world, cancer incidence rates are around 140 per million. Cancer incidence in the developing 
countries is less well known, because there have been too few efficient population-based cancer 
registries. In some developing countries, where the children comprise 40–50% of the population, 
the proportion of childhood cancers represents 3–10% of the total, whereas in the developed 
countries, it is less than 1%. Mortality patterns also differ. Cancer accounts for some 4–5% of 
childhood deaths in developed countries, (where it is the second-leading cause of death among 
children aged 1–14), and less than 1% in developing countries, where deaths from infectious 
diseases are much more prominent
1
.   
Cancer in adolescents comprises all cases occurring in individuals aged 15 to 19 years. In 
the populations of Caucasian descent, the most common cancers are lymphomas and carcinomas. 
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Other frequent cancer groups are central nervous system (CNS) tumors, germ cell tumors and 
sarcomas of bone and soft tissues, with slightly different ranks in males and females
1
 (Figure 2). 
             
Figure 2. Composition of tumor types across adolescents
1
.   
Adolescence is the age of predominant occurrence of a few specific tumor types. Bone 
tumors (both osteosarcoma and Ewing tumor) usually present the first age-specific peak in 
adolescents overall and in males (in females the first peak of the two types of bone tumors occurs 
in the age group 10–14).  
Survival probability has considerably changed within the past 30 years. Clinical research 
by cooperating groups of pediatric oncology centers has progressively increased the long-term 
survival rate from <20% before 1975 to >70-80% depending on the specific disease, in the new 
millennium
3
.  
International cooperation contributes to quality assurance because the majority of 
children with an oncologic disease are treated according to standard protocols. Reference centers 
therefore fulfill the important function of controlling, providing a second opinion and assessing 
the data of each child periodically
3
.  
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2. OVERVIEW OF LEUKEMIA DURING CHILDHOOD AND ADOLESCENCE  
The acute leukemias of childhood and adolescence are rare diseases than collectively 
represent around 30% of malignancies in children aged less than 14 years and 10% in those aged 
15 to 19.  
Leukemias can be classified as acute and chronic. Acute leukemia is characterized by 
clonal expansion of immature hematopoietic or lymphoid precursors, whereas chronic leukemias 
are characterized by expansion of mature marrow elements. This second group is very rare in 
children.  
The acute leukemias are classified according to the predominant cell lineages involved, 
primarily either lymphoblastic or myelogenous. Approximately 80% of childhood acute 
leukemias are lymphoblastic (ALL) and 15% are myelogenous (AML). The remainder are 
difficult to characterize as either ALL or AML and are sometimes classified as undifferentiated 
(acute undifferentiated leukemia)
4
.  
2.1 Acute lymphoblastic leukemia in children and adolescents  
ALL is the most frequent cancer type in children. Thirty-eight out of one million children 
are newly diagnosed with ALL annually. It is more frequent in boys than in girls (2:1 ratio) with 
a peak incidence between 2 and 5 years of age. The incidence in white children is twice as high 
as in non-white children.  
 The history and symptoms reflect the degree of bone marrow infiltration by leukemic 
cells and the extramedullary involvement of the disease. The disease can affect almost any organ. 
The duration of symptoms may be days to several weeks, and occasionally months.  
Abnormal laboratory findings are commonly seen at the time of presentation. The 
number of red blood cells (RBC), platelets and white blood cells (WBC) may vary depending on 
the degree of bone marrow involvement. Associated electrolyte disturbances are frequently 
observed as a reflect of the compromise of organ function due to infiltrating blast cells. An 
appropriate management of these alterations is crucial at the very beginning of the diagnosis and 
treatment, as it will be discussed later.  
The diagnosis of ALL is based most of the times on the findings from the bone marrow. 
Nevertheless, sometimes the diagnosis can be established by means of the results obtained from 
blood or other biological samples.   
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The leukemic characterization and classification is made based on the morphology (FAB 
classification
5
), cytochemistry, immunology, flow cytometry, biochemistry, cytogenetic and 
molecular aspects of the malignant cells. Based on the patterns of reactivity with a panel of 
lineage-associated antibodies, ALL has been sub classified into three broad categories: mature B-
cell ALL, B-progenitor ALL and T-progenitor ALL. In some instances, individual leukemic cells 
simultaneously express both lymphoid and myeloid surface antigens. These leukemias have been 
referred to as mixed lineage or biphenotypic leukemia. The immunophenotypic subsets are 
associated with distinctive clinical and laboratory features
3,4
.    
2.2 Treatment of acute lymphoblastic leukemia  
With current regimens for the treatment of childhood ALL, complete remission is 
achieved in more than 95 per cent of patients and the five year survival rate exceeds 90% in the 
developed countries
6
. This is true despite the fact that, with few exceptions, the drugs used for 
the treatment of ALL today were available by the late 1960s
7–9
. This improvement in outcome 
has been largely achieved as a result of international collaborative efforts through clinical trials 
and study groups
6
. 
The rate of success in the treatment of ALL has increased steadily since the 1960s
4,10
. 
Before 1947, when Farber and co-workers attained the first complete remission in a child with 
ALL, the median duration of survival from the time of diagnosis was 2 months. During the 1950s 
drugs such as 6-mercaptopurine (6-MP), methotrexate (MTX) and corticosteroids were found to 
be active in leukemia-bearing mice and subsequently in human leukemias. Some of the first 
controlled trials were conducted at that time, consisting of single-agent antileukemic 
chemotherapy protocols. Active drugs introduced in the 1960s and 1970s included the 
anthracyclines (doxorubicin and daunorubicin), asparaginase and the epipodophyllotoxines 
(etoposide [VP-16] and teniposide [VM-26]).  
To identify treatment components responsible for improved treatment outcome, the 
Childhood ALL Collaborative Group was formed in 1994 to systematically review and analyze 
results from relevant randomized trials. Analysis of data from four clinical trials that enrolled 
patients between 1972 and 1984 showed that anthracyclines reduced hematologic relapse but 
failed to improve event-free survival, partly because of the increased induction failures and 
deaths in remission
11
. Meta-analysis of trials started between 1965 and 1998 showed that the 
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addition of vincristine plus prednisone or prednisolone pulses during post-remission therapy 
improved event-free survival; the lack of improvement with vincristine and dexamethasone 
pulses in the more recent trials was attributed to the greater intensity of the early therapy
12
. Meta-
analysis of three trials that enrolled patients between 1992 and 2002 suggested that thioguanine 
improved event-free survival compared with mercaptopurine for males younger tan age 10 years, 
but its lack of effect on survival and association with a high risk of veno-occlusive disease 
(VOD) of the liver made mercaptopurine the standard thiopurine of choice
13
. Meta-analysis of 47 
trials of CNS-directed therapy conducted between 1970 and 1999 showed that CNS radiotherapy 
can generally be replaced by intrathecal therapy, and triple intrathecal therapy should be used 
with effective systemic therapy such as intravenous high-dose methotrexate to realize its full 
benefit of CNS control without the hazard of increased systemic relapse
14
. 
Besides this, significant efforts have been made to harmonize definitions in ALL, so that 
investigators around the world could use the same terminology. In this sense, participants in The 
Ponte di Legno group meeting in 1995 agreed to use similar criteria to present the treatment 
outcome so that results could be compared among various clinical trials to identify effective 
treatment strategies for specific subsets of ALL
15,16
.  
Regarding the biology of ALL in specific group of patients, big advances have been 
made in the last few years. Some examples are depicted in table 1
6
:  
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Table 1. Clinical research findings from selected collaborative studies 
Subgroup of 
ALL 
Years 
Study 
Number 
Study 
Groups 
Number 
Patients 
Major Findings Reference 
11q23 
rearranged 
1983-
1995 
11 497 
Prognosis was particularly dismal in infants; allogeneic transplantation did not improve 
outcome in patients with t(4;11) ALL. Poor early response to prednisone or age younger than 
3 months conferred a particularly dismal prognosis among infants with t(4;11). 
17,18 
Hypodiploid 
1986 
1996 
11 139 Prognosis was very poor, especially among patients with fewer than 44 chromosomes. 19 
Hypodiploid 
2008 
2013 
2 126 
Genome profiling and sequencing identifies distinct genetic alterations in subtypes of 
hypodiploid ALL. Near-haploid patients have Ras pathway mutations and IKZF3 mutations; 
low-hypodiploid patients have IKZF2 alterations and TP53 mutations, many of which are 
inherited. 
20 
Ph positive 
1986 
1996 
10 326 
Presenting age, leukocyte counts, and response to initial treatment with glucocorticoids and 
intrathecal methotrexate affected treatment outcome; matched-related transplantation 
improved outcome. 
21 
Ph positive 
1995 
2005 
10 610 Both matched-related and matched-unrelated transplantation improved treatment outcome. 22 
Ph positive 
2004 
2009 
10 178 
Imatinib combined with intensive chemotherapy was well tolerated and might improve 
outcome. 
23 
Ph-like 
2008 
2009 
2 221 
Genetic alteration of IKZF1 was associated with high levels of minimal residual disease and a 
very poor outcome. 
24 
Ph-like 
2008 
2009 
2 297 
These cases were associated with a high frequency of deletions in genes involved in B-cell 
development, resistance to asparaginase and daunorubicin, and unfavorable outcome. 
25 
Ph-like 2014 5 264 
More than 90% of the patients had kinase-activating alterations, some of which were amenable 
to inhibition with tyrosine kinase inhibitors such as imatinib or dasatinib. 
26 
Early T-cell 
precursor 
1992 
2006 
2 30 
These patients had distinctive immunophenotype (CD1a, CD8, or CD5 weak with stem-cell or 
myeloid markers) and high risk of remission induction failure or hematologic relapse. 
27 
Down 
syndrome 
1995 
2004 
16 653 
Compared with other patients, these patients have lower event-free survival as a result of 
increased relapse hazard and treatment-related mortality. Younger age and leukocyte count 
<10 x 109/L at diagnosis and the presence of high hyperdiploidy and ETV6-RUNX1 are 
favorable prognostic factors. 
28 
Induction 
failure 
1985 
2000 
14 1041 
Patients with induction failure are highly heterogeneous. Although allogeneic transplantation 
improved outcome for T-cell ALL, chemotherapy should be the treatment of choice for B-
ALL without other adverse features. 
29 
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Summarizing, the following factors have been identified to have an impact in outcome:   
- The development of complex chemotherapeutic regimens designed to achieve clonal 
eradication.  
- The development of cell kinetic studies that have been important in the design of 
timed sequential use of cyto-toxic drugs.  
- Biology studies that have permitted to identify particular molecular and genetic 
alterations enabling physicians to identify patients at higher risk of relapse and 
therefore adapting therapy according.  
- The recognition of the central nervous system as a sanctuary site that has permitted to 
adapt therapy evolving from craniospinal radiotherapy to systemic and intrathecal 
chemotherapy. 
- The improvements in supportive care.  
- Clarification of risk groups. Classical classification into standard, intermediate and 
high-risk groups is based on age, white blood cell counts at diagnosis, extent of 
disease (CNS or testicular involvement), response to chemotherapy after pre-phase 
and at the end of induction and biological findings.   
In general, current treatment regimens for patients with newly diagnosed ALL include 
four phases: 
- Remission induction: Designed to rapidly destroy measurable leukemic cells and 
minimize residual leukemic burden (i.e. the total number of leukemic cells in the 
body). 
- CNS-directed therapy: Used to address the issue of pharmacological sanctuary sites 
(i.e. areas of the body, such as the brain and spinal cord, that are not well penetrated 
by conventional doses of most antileukemic drugs). 
- The intensification/consolidation phase: Designed to further reduce the total body 
leukemia cell burden and address issues of antileukemic drug resistance. Such 
treatment usually consists of higher doses of the same drugs used during induction or 
of high doses of different drugs. 
- The maintenance/continuation phase: Considered to eradicate the residual 
leukemic cell burden and avoid relapse.  
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Attempts to boost cure rates further with the use of hematopoietic stem cell 
transplantation (HSCT) have improved the outcome for some, but not all, subtypes of ALL, 
suggesting that intensification of existing treatments is unlikely to rise cure rates substantially 
and will instead increase treatment related toxicity and the risk of such life-threatening late 
sequelae as second cancers.  
2.3 Complications of acute lymphoblastic leukemia treatment   
At the time of diagnosis, the major clinical problems arise from metabolic disturbances 
secondary to leukemia cell lysis, disrupted hematopoiesis leading to abnormal peripheral blood 
counts, and leukemic infiltration of non-hematopoietic organs. Initiation of chemotherapy may 
exacerbate these issues and lead to additional problems, including myelosuppression, increased 
risk of infections and mucosal toxicity.  
Complications of treatment will be described in this section with more detail as they are 
the subject of this study
4,30
: 
- Metabolic complications: When effective chemotherapy was first employed in acute 
leukemia, rapid lysis of leukemic cells often resulted in serious and occasionally fatal 
metabolic disturbances (hyperkalemia, hyperuricemia, hyperphosphatemia and 
hypocalcemia). This is particularly worrying in situations with high burden of disease 
(e.g. white cell count exceeds 100x10
9
/l (10 to 20 percent of acute leukemia)).  The 
introductions of allopurinol, and more recently recombinant urate oxidase 
(rasburicase), together with a skill fluid electrolyte therapy, have done much to solve 
this problem
4,30
.  
- Anterior mediastinal mass: Leukemic infiltration of the thymus gland appears as an 
anterior mediastinal mass on chest radiography. It is observed in about 10 percent of 
patients with newly diagnosed ALL and is nearly always associated with the T-cell 
immunophenotype. Leukemic infiltration of the mediastinal structures may cause life-
threatening tracheobronchial or cardiovascular compression leading to a superior 
vena cava syndrome (SVC). Pleural effusion may also be associated. Prompt 
initiation of systemic chemotherapy (such as corticosteroids) is necessary to handle 
such emergencies and rarely emergency radiation therapy may be necessary
4,30
.  
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- Anemia and thrombocytopenia: Thrombocytopenia, in association with anemia, is a 
common presenting feature of ALL; however, active bleeding is a relatively unusual 
feature at the time of diagnosis. Any active hemorrhage associated with a platelet 
count less than 100x10
9
/l should be treated with platelet transfusion. Similarly, 
symptomatic anemia should be treated by transfusion of packed red blood cells. 
Stabilization of these two parameters should take no longer than 12 to 24 hours and 
should therefore not delay the start of antileukemic therapy
4,30
.  
- Coagulation abnormalities: Disseminated intravascular coagulation (DIC) is rarely 
observed in patients with ALL at diagnosis. It is most often seen in T-cell ALL as a 
result of thromboplastic substances released from the blasts as well as in patients with 
the uncommon t(17;19) translocation associated with the B-progenitor 
immunophenotype. L-asparaginase can induce a coagulopathy by inhibition of protein 
synthesis of clot forming and clot inhibitory proteins.  CNS and peripheral thrombosis 
and hemorrhage have been observed in 1 to 2 percent of patients receiving 
asparaginase therapy
4,30
.  
- Infection: Infection due to granulocytopenia is an important early complication of 
ALL, observed at the time of diagnosis and during therapy. Most infections are 
presumed to be bacterial, but specific etiologic agents often are not identified. 
Cultures should be obtained promptly, and the patients should immediately be given 
broad-spectrum intravenous antibiotics with activity against bowel and respiratory 
agents. Documented episodes of bacteremia have been reported in 15 to 30 percent of 
children receiving chemotherapy for ALL. As chemotherapy regimens have become 
more intensive, fungal disease, including invasive infections of Candida and 
Aspergillus species, has been increasingly observed during the initial treatment of 
leukemia. Viral infections, including varicella complicated by pneumonitis, hepatitis, 
or cerebritis can be particularly devastating. It became a major problem, especially 
with prednisone therapy, and many children died of severe disseminated varicella, 
while others had treatment interrupted for long periods with consequent risk of 
relapse. Pneumocystis jirovecii can cause a severe, often fatal, interstitial 
pneumonitis. The incidence of P. Jirovecii increases with the degree and duration of 
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immunosuppression and thus is usually observed during the later phases of ALL. 
Prophylaxis with trimethroprim-sulfamethoxazol markedly reduces its incidence
4,30
.  
- Typhlitis: This is neutropenic enterocolitis. It most commonly occurs in the caecum 
and typically follows a prolonged course of neutropenia, resulting in benign mucosal 
ulceration, bacterial invasion and bowel perforation and peritonitis. Management 
includes bowel rest and administration of intravenous fluids and broad-spectrum 
antibiotics. Surgery is usually not indicated except for the rare occurrence of 
perforation or uncontrolled bleeding
4,30
.  
- Acute neurologic toxicity: Seizures and other acute neurologic events have been 
observed in up to 20 percent of children with ALL. Cranial irradiation, intrathecal 
chemotherapy and high doses of systemic methotrexate, have been associated with 
acute neurotoxicity. Peripheral and autonomic neuropathy associated with vincristine 
is often seen in children receiving therapy for ALL
4,30
.  
- Cardiac sequelae: Echocardiographic abnormalities, in particular increased after 
load and decreased contractility, are common late effects of anthracycline therapy. 
The severity of cardiac dysfunction is correlated with higher cumulative doses of 
anthracycline and higher doses rate. Patients treated at a young age, females and those 
with Down syndrome appear to be more vulnerable to anthracycline-related cardiac 
toxicity
4,30
.  
- Hematopoietic stem cell transplantation (HSCT) related complications: HSCT 
has been used as part of the multimodal approach for the treatment of children with 
ALL. Although is mainly used in the context of relapsed ALL, HSCT has been 
considered in first complete remission in very selected groups of patients such as 
those harboring t(9;21) or high levels of minimal residual disease at the end of 
induction among others. Infectious complications constitute the major cause of 
morbidity and mortality in pediatric and adult patients given HSCT
31,32
. The 
incidence and the severity of infections strongly correlate with the use of 
immunosuppressive therapy and the time of neutrophil and immune reconstitution 
following HSCT. The risk of infection is higher in patients after allogeneic than 
autologous HSCT, in those with graft versus host disease (GVHD), and with delayed 
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immune reconstitution, especially following haploidentical and cord blood HSCT. 
Other complications include GVHD per se, veno-occlusive disease and specific organ 
toxicities (liver, kidney or lung). Outcome of patients undergoing HSCT has notably 
improved during the last years by a more precise selection of potential candidates 
along with a notably improvement in supporting measures adopted by the transplant 
units
33
.  
- Second malignant neoplasms (SMN): Second malignant neoplasms including 
malignant gliomas, AML and carcinomas of the parotid and thyroid glands, have been 
reported in survivors of ALL. Risk factors for the development of secondary AML 
include treatment with epipodophyllotoxines and alkylating agents 
4,34,35
. Secondary 
solid tumors have been observed in patients who received cranial or craniospinal 
irradiation (CSI), especially those receiving higher doses (1800 to 2400 cGy). Long-
term cumulative incidence rates of secondary neoplasms range between 1 and 3 per 
cent
4,36
.  
- Central venous catheters related complications: Indwelling central venous 
catheters (CVC) have been in use for the last three decades and have revolutionized 
the care of children with cancer and those requiring long-term access for medications 
and blood products. Central venous device–related complications have been 
extensively described in the literature. They can be approximately divided by thirds 
among infectious events, venous thrombosis, and mechanical events and up to 40 per 
cent of children with CVC will experience any of these complications
37–39
. 
- Other toxicities: Asparaginase is associated with pancreatitis in 5 to 10 percent of 
patients and allergic reactions in up to one third. Complications due to corticosteroids 
include hypertension, hyperglycemia, avascular necrosis, mood and behavioral 
problems and an increased incidence of bone fractures
4,30
. Inadvertent intrathecal 
administration has been reported with fatal outcome
40
 so strict guidelines are to be 
implemented in ALL protocols to prevent such an unfortunate event
41
.   
2.4 Treatment related deaths in children with acute lymphoblastic leukemia: A perspective 
Impressive advances in the management of childhood ALL in recent decades have 
resulted in constantly increasing survival rates of children and adolescents with ALL as 
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described above. A major drawback of this success history is the fact, that in most frontline 
multicenter trials of childhood ALL, up to 5% of children die due to toxic side effects of 
antileukemic treatment
8,42
. Besides that, some patients still die before any anticancer therapy can 
be started, suggesting a more aggressive behavior of the disease that also relates to the supportive 
care of children with leukemia given at this very early stage.  
The majority of treatment related deaths (TRD) occur during recurring and prolonged 
episodes of neutropenia and lymphopenia caused by cytotoxic and immunosuppressive drugs or 
by the leukemia itself inhibiting bone marrow recovery during induction therapy. The rest of 
TRD relate to specific drug toxicities or supportive care complications, other than infections: 
chemotherapy causes immunosuppression; high-dose steroids cause immunosuppression as well 
as metabolic disturbances and the children often suffer from suboptimal nutrition; indwelling 
catheters, repeated admissions and the frequent and widespread use of antibiotics increases the 
risk of infections; the malignant disease itself may lead to hemorrhages, thrombosis, need of 
transfusions and tumor lysis complications before or after the initiation of therapy
8,43
; some 
drugs have specific toxicities that have been recognized as cause of death both during active 
treatment or after it (e.g. asparaginase induced pancreatitis, anthracycline related cardiotoxicity); 
radiotherapy has potential acute and delayed side effects adding toxicity to conventional 
concurrent chemotherapy
44,45
; in the recent years, HSCT has been implemented in first line 
therapies for children with special ALL features aiming to overcome the limitations of 
conventional chemotherapy but also adding specific toxicities in this group of patients
46
.  
Therefore, infections, bleeding or thrombosis, tumor burden complications and therapy 
induced organ toxicities are the most common causes of TRD. To summarize, four major factors 
influence the risk of these and other severe toxicities
42
: 
- The leukemia itself (e.g. the tumor burden and specific organ involvement). 
- Intensity of treatment. 
- The supportive care (including specific guidelines and physician and patient 
compliance to these). 
- Host factors (including inherited genetic polymorphisms that influence drug 
disposition and immune function).  
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A description of TRD reported by other groups
7–9,42,43,47–65
 is shown in Appendix 1. In 
general, death rates occurring before remission (i.e. before any anticancer therapy is started or 
during induction) range between 0.3 and 3 per cent, while those occurring after first complete 
remission range between 1.5 and 5.3 per cent. A progressive reduction in TRD has been 
demonstrated by the majority of the groups along the years, reflecting a more accurate selection 
of patients by risk stratification factors and subsequently more directed therapy, an improvement 
in the supportive care measures and a learning process by a progressive implementation of 
protocols in the different cancer centers, among others.  
Collaborative study groups have identified some factors that may put children at a higher 
risk of TRD. Age less than one year or more than ten, high leukocyte count at diagnosis 
(>100x10
9
/L), female gender, T cell-immunophenotype and constitutional trisomy 21 are already 
reported
7,42,43
. Patients undergoing HSCT in first CR have been also considered as more prone to 
experience toxic deaths than those who receive conventional chemotherapy
42
.  
Most of these studies come from high-income countries where the degree of development 
and the availability of resources are much higher. For this reason, other groups have focused in 
the analysis of TRD in low-income countries. Unfortunately in these countries, the outstanding 
figures achieved in Europe, North America or some Asian countries are far less obtained. 
Potential reasons for different survival rates include a higher rate of relapse, more abandonment 
of treatment, and higher rates of TRD, even when similar or modified European or North 
American protocols are used. TRD rates in low-income countries using these protocols vary 
between 10 to 20 per cent
66–68
. It has been hypothesized that underlying population biological 
features as well as more advanced stage at presentation may change the underlying relationship 
between clinical parameters and TRD
69
. On the other hand, other investigators have found that 
socioeconomic factors like low income and lower parental education are bigger contributors to 
TRD than biological features
70
.  
Minor changes in chemotherapeutic treatment composition and scheduling have been 
repeatedly reported to have an impact on survival rates but also on treatment-related toxicity and 
mortality. Liang et al found that L-asparaginase used in the induction was associated to a higher 
degree of toxicity and toxic deaths when compared to an anthracycline based regimen
64
. 
Belgaumi et al reported that the addition of daunomycin to a dexamethasone based induction 
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regimen lead to a significant increase in the toxicity rates in children with B-precursor ALL
71
. 
These experiences highlight the difficulties of balancing the risk for fatal-related complications 
against the benefits that a different approach may have on the disease outcome.  
The results presented here reflect the accumulated experience of the EORTC-CLG over 
40 years in children ALL trials. This study will focus on the incidence, pattern and causes of 
death as first event and its predisposing factors for all eligible children enrolled in four 
consecutive trials.  
3. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER 
(EORTC) 
The European Organization for Research and Treatment of Cancer (EORTC) was 
founded as an international organization under Belgian law in 1962 by eminent oncologist 
working in the main cancer research institutes of the European Union (EU) countries and 
Switzerland. It was named the ‘Groupe Européen de Chimiothérapie Anticancéreuse’ and 
became EORTC in 1968 (www.eortc.org).   
3.1 EORTC aims and mission  
The aims of the EORTC are to develop, conduct, coordinate, and stimulate translational 
and clinical research in Europe to improve the management of cancer and related problems by 
increasing survival but also patient quality of life. Extensive and comprehensive research in this 
wide field is often beyond the means of individual European hospitals and can be best 
accomplished through the multidisciplinary multinational efforts of basic scientists and 
clinicians. 
The ultimate goal of the EORTC is to improve the standard of cancer treatment through 
the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy 
that are already in use and also through the development of new drugs and other innovative 
approaches. This is accomplished mainly by conducting large, multicenter, prospective, 
randomized, phase III clinical trials. In this way, the EORTC facilitates the passage of 
experimental discoveries into state of the art treatments. 
Through translational and clinical research, the EORTC offers an integrated approach to 
drug development, drug evaluation programs and medical practices. 
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EORTC Headquarters, a unique pan European clinical research infrastructure, is based in 
Brussels, Belgium, from where its various activities are coordinated and run. The EORTC is both 
multinational and multidisciplinary, and the EORTC Network comprises over 300 hospitals and 
cancer centers in over 30 countries, which include some 2,500 collaborators from all disciplines 
involved in cancer treatment and research. 
The 180 members of the EORTC Headquarters staff handle some 6,500 new patients 
enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open 
to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 
patients. 
Intergroup collaboration is also promoted to face current challenges of clinical trials 
aiming at targeted therapies. 
3.2 EORTC Children’s Leukemia group  
 The EORTC Children’s Leukemia Group (CLG) is one of the 21 cooperative groups 
working within the structure of the EORTC. The CLG is part of the offspring of the EORTC 
Hemopathies Working Party which in 1978 split into a pediatric and to an adult branch.  
At that time, the Berlin-Frankfurt-Munster (BFM) designed by H. Riehm for acute 
lymphoblastic leukemia appeared much more efficacious than all others and the CLG decided to 
adapt that treatment strategy for its own clinical trials. 
Since then, the group has actively worked in the development of clinical trials in the field 
of malignant blood diseases in children including ALL, acute myeloid leukemia (AML), 
myelodysplastic syndromes (MDS) and lymphomas.  
Some of the most relevant findings in the EORT-CLG trials are depicted in table 2, which 
exemplary the philosophy of this group, its contributions in the field of pediatric ALL and how 
different questions have been answered over time.  
Currently the group is constituted by 24 centers spread over three countries: Belgium, 
France and Portugal.  
The aims of the group are:  
- To improve the treatment of leukemia and related malignancies (lymphomas, MDS) 
by means of clinical trials.  
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- To promote the study of these diseases with regard to their epidemiology and the 
long-term sequelae of treatment.  
- To promote the clinical application, on a large number of patients, of new biologic 
techniques.
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Table 2. Summary of the most relevant findings in the EORTC-CLG trials 
Name of 
study 
Years 
Study 
Patients 
enrolled (n) 
Patients Major Findings Ref 
58741 
1971 
1978 
217 
Children 
and adult 
with ALL 
in first CR 
A) 1st Randomization between 1 year polychemotherapy (P) or methotrexate (M) based consolidation 
Consolidation P was more toxic than consolidation M. No differences in disease free interval o survival duration 
B) 2nd Randomization between 4 year chemotherapy (C) or immunotherapy (I) based maintenance 
Immunotherapy maintenance showed a superiority regarding chemotherapy maintenance  
72 
58831 
58832 
1983 
1989 
780 
Children 
with ALL 
A) Patients with SR-ALL were randomized to receive cyclophosphamide (CPM) (1 g/m2 days 1 and 29 phase 
IB): Absence of CPM had no impact on outcome: 10 years DFS rates ±1 s.e. 71% ± 3.3% and 70% ± 3.7% with and 
without  
B) Medium and HR patients were randomized to receive cranial radiation after protocol II containing HD-
MTX: HD-MTX alone was as effective as HD-MTX followed by cranial radiotherapy in terms of DFS, isolated CNS 
relapse-free interval and CNS relapse-free interval 
44 
58881 
1989 
1998 
2078 
Children 
with ALL 
A) Patients were randomized to receive high doses cytarabine (1g/m2) during interval therapy: the combination 
of cytarabine at high doses with methotrexate at high doses during interval therapy did not improve prognosis 
B) Patients were randomize to test the advantage of adding monthly intravenous 6-mercaptopurine (1 g/m2) to 
conventional maintenance:  The addition of 6-mercaptopurine iv during maintenance increased the risk of late 
relapse 
C) Patients were randomized to evaluate the efficacy and the toxicity of Erwinia asparaginase vs E. coli 
asparaginase: E. coli asparaginase was more toxic but has a higher efficacy than Erwinia asparaginase. EFS rates at 5 
years were 74.0% ± 2.4% in the E. coli group vs 61.1% ± 2.7% in the Erwiniase group. Survival rates at 5 years were 
83.2% ± 2.0% in the E. Coli group vs 76.8% ± 2.4% in the Erwiniase group. 
44 
58881 
1989 
1998 
178 
Children 
with ALL 
The presence or absence and level of residual leukemia were significantly correlated with the risk of early relapse at 
each of the times studied (P<0.001). Residual leukemia after induction of a remission is a powerful prognostic factor 
in childhood ALL.  
73 
58881 
58951 
1989 
2008 
134 
Children 
with T-
ALL 
NOTCH+ (NOTCH1 and/or FBXW7 mutated)) patients showed a better early response to chemotherapy as compared 
with NOTCH- patients. 
5-year EFS of 73% and 70% (P=0.82), and 5-year OS of 82% and 79% (P=0.62) for NOTCH+ and NOTCTH-. 
74 
58951 
1998 
2008 
1947 
Children 
with ALL 
A) Patients were randomized to dexamethasone (6 mg/m2/day) to prednisolone (60 mg/m2/day) in induction 
therapy: The 8-year event-free survival rate was 81.5% in the dexamethasone arm and 81.2% in the prednisolone 
arm; the 8-year overall survival rates were 87.2% and 89.0% respectively. Incidence of G3-4 toxicities was similar. 
Dexamethasone decreased the 8-year central nervous system relapse incidence by 1.6%. 
75 
58951 
1998 
2008 
1223 
Children 
with ALL 
Patients with IKZF1(del) had a lower 8-year event-free survival (EFS, 67.7% versus 86.5% (p<0.001). IKZF1(del) 
increased risk only in the high hyperdiploid ALLs and in 'B-other' ALLs, that is, lacking classifying genetic lesions.  
76 
ALL: Acute lymphoblastic leukemia; CNS: Central nervous system; CPM: Cyclophosphamide; CR: Complete remission; DFS: Disease free 
survival; EFS: Event free survival; HD-MTX: High doses methotrexate; HR: High-risk; OS: Overall survival.  
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II. HYPOTHESIS AND OBJECTIVES 
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1. HYPOTHESIS  
Over the last decades we have assisted to a substantial increase in survival rates of 
children and adolescents with acute lymphoblastic leukemia (ALL). This improvement has been 
largely achieved as a result of the optimization in the use of existing antileukemic agents and the 
progressive introduction of new agents, better risk-group stratification, improvement in the 
knowledge of leukemia biology and supportive care in contemporary clinical trials. However, a 
number of children, who might otherwise be cured, still tragically die before they can be started 
on any anti leukemic treatment or from complications of the treatment itself.  
Therefore, is of paramount importance to identify what factors may put some patients at 
risk of dying from treatment related complications. That could be achieved by an analysis of the 
long-term results of big cooperative groups using similar approaches along an expanded period 
of time. The Children’s Leukemia Group from the European Organization for Research and 
Treatment of Cancer (EORTC-CLG), with a vast experience in the development of international 
collaborative protocols in childhood ALL, is in the position to face this challenge. 
 
Changes in the strategies for patients with ALL over the last decades, such as 
modifications in the dose intensity, risk stratification and the use of bone marrow 
transplantation in selected cases might have had an impact in the incidence and type of 
treatment related deaths in children with newly diagnosed ALL.  
The pattern of infectious and non-infectious complications may have evolved over 
time with the introduction of novel antimicrobial agents and improvement in supportive 
care.  
We propose to analyze the impact of the different first line treatment protocols 
developed by the EORT-CLG on the type and number of treatment related deaths over the 
last forty years. We believe that the results obtained from this study will help us to increase 
and improve our understanding about treatment related toxicities. These results may help 
us in the future to adapt and individualize ALL therapies in order to minimize their 
undesirable side effects while maximizing their benefits.  
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2. OBJECTIVES 
2.1 Primary objective 
- To assess the types and causes of treatment related deaths in children with newly diagnosed 
ALL treated according to the first line EORTC-CLG ALL protocols 58741 – 58831/2, 58881 
and 58951 from 1971 to 2008. 
2.2 Secondary objectives 
- To define the incidence and causes of treatment related deaths in the four trials grouped in 
two categories: early death (death before first complete remission) and death in first complete 
remission. 
- To assess whether the treatment era carries an impact in the incidence of treatment related 
deaths.   
- To identify risk factors of increased likelihood of treatment related deaths in children with 
ALL. 
- To compare the incidence and type of treatment related deaths of the EORTC-CLG ALL 
protocols with the results reported by other collaborative groups.   
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3. OBJETIVOS 
3.1 Objetivo primario 
- Describir los tipos y causas de mortalidad relacionada con el tratamiento en niños con 
leucemia linfoblástica aguda de nuevo diagnóstico tratados en los protocolos de primera línea 
del grupo EORTC-CLG 58741, 58831/2, 58881 y 58951 desde 1971 a 2008.  
3.2 Objetivos secundarios 
- Definir la incidencia y causas de muerte relacionadas con el tratamiento en los cuatro 
ensayos clínicos agrupados en dos categorías: Muerte precoz o muerte antes de la primera 
remisión completa y Muerte en primera remisión completa.  
- Averiguar si la era de tratamiento impacta en la incidencia de muertes relacionadas con el 
tratamiento.  
- Identificar factores de riesgo para fallecer de muerte tóxica en pacientes pediátricos con 
LLA.  
- Comparar la incidencia, el tipo y la causa de mortalidad relacionada con el tratamiento de los 
protocolos EORTC-CLG con los resultados publicados por otros grupos colaborativos.  
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III. PATIENTS AND METHODS 
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1. PATIENTS AND METHODS 
1.1 Data collection and evaluation of results  
All the data were collected, processed and analyzed at the EORTC data center in 
Brussels.  
Data for this study was obtained from three different sources: 
- Electronic databases for each of the corresponding trials that contain all the coded 
information about patients. Data extraction was made by means of two-computer software: Vista 
Update and Vista Stat.  
- Patient´s files that contain the entire corresponding patient case report forms (CRFs). 
- Queries to sites when data considered essential for this study could be retrieved neither 
from the electronic database nor from the patient´s files.  
1.2 Selection of patients 
The criteria to include patients in this study were: 
- Age < 18 years at the time of diagnosis. 
- Diagnosis of ‘de novo’ ALL not previously treated except for the reasons specified in 
each single protocol.  
- To be eligible according to the inclusion/exclusion criteria specified in each of the 
EORTC ALL-CLG protocols.  
- For those who completed induction, available data about response evaluation.  
Patients who committed any sort of violation foresaw by the protocol along treatment and 
were therefore not kept in the trial for treatment purposes anymore, were kept nevertheless for 
the follow up and survival analysis purposes.  
1.3 Study group definitions  
Patients considered to be the subject of this study were included in two groups (Figure 3): 
- Early death (ED) included (Also named death before first complete remission):   
o Death before treatment (DBT): Patients who died after having been registered 
into the trial and before any anticancer therapy was initiated. 
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o Death during prephase/induction/consolidation: Patients who died after having 
been registered into the trial and before achieving a first complete remission 
following pre-phase and induction/consolidation therapies.  
- Death in first complete remission (DCR): Patients who died in first CR for other 
reasons than ALL during or after having completed first line ALL-CLG therapies. 
Patients who died of hematopoietic stem cell transplantation (HSCT) related toxicity 
performed in first CR, were included in this group and considered as cases of 
transplant related mortality (TRM). 
 
 
Figure 3. Study group definitions flowchart 
 
The causes of death were grouped as: 
- Tumor burden related deaths:  Included tumor lysis syndrome (TLS) and 
leukostasis with compromised organ function due to infiltrating blast cells (e.g. 
mediastinal mass).  
- Infections: Within this group, five major sub-groups were defined 
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o Bacterial / Viral / Fungal / Pneumocystis jirovecii / Others or unknown. 
- Bleeding or thrombosis related deaths: All hemorrhages, including those associated 
to leukostasis (e.g. intracerebral infiltration of leukemic blasts and intracerebral 
bleeding) were included in this group. Bleeding and thrombosis episodes were 
described as separate events for further clarification despite begin considered within 
the same group for the purposes of the analysis. 
- Organ toxicity not induced by infection (e.g. anthracycline induced cardiotoxicity, 
asparaginase induced pancreatitis).  
- Transplant related mortality (TRM): TRM has been defined as any cause of death 
in patients who underwent HSCT in first remission that could be directly attributed to 
the procedure itself.  The ultimate cause of death associated to transplant (e.g. graft 
versus host disease, hemorrhages) was described. Infections leading to death after 
transplant were included within this group. EBV driven post-transplant 
lymphoproliferative disorder (PTLD) has been included within this group. 
- Secondary malignant neoplasms (SMN): SMNs were defined as any malignancies 
having occurred after initial ALL and distinct from it whatever the remission status of 
the patient was. SMNs were not prospectively recorded in trials 58741, 58831/2 and 
58881. SMNs were categorized following standard international recognized 
classifications for oncological diseases in children
2
.  
- ALL progression: In patients who died before remission and for which the 
investigators could not address any of the other causes described here.  
- Others or uncertain causes: 
o Others in the group of Early Death included non-infectious neurological 
insults (stroke, cerebral edema, brain hernia, and encephalopathy), adult 
respiratory distress syndrome (ARDS), veno-occlusive disease (VOD), 
iatrogenic and unknown causes. 
o Others in the group of Death in Complete Remission included ARDS, 
aspiration, cardiac arrhythmias, sudden death, traffic accidents, suicide, 
iatrogenic and unknown causes. 
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For the purposes of this study, ‘histiocytic disorders’77 including 
hemophagocytic lymphohistiocytosis (HLH), macrophagic activation 
syndrome (MAS) and other systemic histiocytosis were not considered within 
the group of secondary malignancies and analyzed aside. If they were the 
cause of death, they were included in this group of others. 
1.4 National Cancer Institute (NCI) group definitions  
Patients were initially classified according to the specific risk criteria defined in each 
protocol. In order to homogenize groups under the same risk criteria and to compare with the 
results reported by other groups, patients were also classified according to the NCI risk criteria
78
 
for children with ALL in: 
- Standard group: Those aged between ≥1 and <10 years or with an initial WBC 
<50x10
9
. 
- High-risk group: Those aged <1 or ≥10 years or with an initial WBC ≥50x109. 
1.5 Age/Time definitions 
 Age at the time of recruitment was calculated based on a 365.25 day-year period as 
follows: 
- Start date was date of birth. 
- End date was the minimum value among date of registration, date of diagnostic bone 
marrow (BM) or peripheral blood (PB) and date of start any antileukemic therapy 
(prephase or induction). 
- Conversion between days and years was made by dividing the number of days 
(difference between start and end dates) by a factor of 365.25 according to the 
EORTC statistics guidelines.  
- For protocol 58741, age was calculated using date of birth as the start date, and date 
of starting consolidation as the end date because only patients who achieved a CR 
after induction (and therefore able to proceed to the consolidation) were to be 
included in the protocol.  
Any other calculations involving dates were made based on these same premises. 
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1.6 Disease definitions  
- Acute lymphoblastic leukemia (ALL): Any disease associated with the presence of 
≥ 25% of lymphoblasts in at least one bone marrow aspirate. 
- Non-Hodgkin Lymphoma (NHL): Any neoplastic proliferation within the lymphoid 
cell lineage with less than 25% lymphoblasts in the bone marrow. 
The diagnosis for ALL/NHL was based on bone marrow aspirates by means of 
cytology, cytochemistry.   
- Central nervous system (CNS) involvement: The definitions used here are based on 
international accepted definitions. Apart from the CNS status there are also CNS 
involvement definitions (taking into account other involvements). Recommendations 
were done in order to assure that any lumbar punction was done under a stable 
haemostatic condition and an experienced physician did that.     
o Initial CNS status (Cerebrospinal fluid findings(CSF) at Day 1) 
 For non-traumatic punctures, CNS status is defined as follows: 
 CNS 1: nontraumatic puncture, ≤ 5 WBC/μl CSF without 
leukemic cells on cytospin. 
 CNS 2 (Surreptitious): nontraumatic puncture, ≤ 5 WBC/μl 
CSF with identifiable leukemic cells on cytospin. 
 CNS 3: nontraumatic puncture, > 5 WBC/μl CSF with 
identifiable leukemic cells on cytospin. 
 For traumatic lumbar punctures, CNS status is defined as follows: 
A traumatic lumbar puncture (TLP) is defined as 10 or more 
erythrocytes/μl CSF or as CSF macroscopically contaminated with 
blood. 
 TLP +: traumatic lumbar puncture with leukemic cells on 
cytospin. 
 TLP -: traumatic lumbar puncture without leukemic cells on 
cytospin  
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o ‘Late’ CNS status (beyond the 1st IT injection)  
 For patients with initial CNS 2 at Day 1: 
 “Late CNS 1”:  Patients with initial CNS 2 at day 1 becoming 
CNS 1 or TLP - at the second lumbar puncture (mostly Day 4 
of prephase) 
 “Late CNS 3”:  Patients with initial CNS 2 at day 1 remaining 
CNS 2 or becoming CNS 3 or TLP + at the second lumbar 
puncture at the second lumbar puncture (mostly Day 4 of 
prephase) 
 Patients with initial TLP + at Day 1: 
  ‘TLP+ Late CNS 1’: Patients with initial TLP+ becoming 
CNS 1 or TLP- at the second lumbar punction (mostly Day 4 of 
prephase) 
 ‘TLP+ Late CNS 3’: Patients with initial TLP+ remaining 
TLP+ or becoming CNS2 or CNS3 at the second lumbar 
puncture (mostly Day 4 of prephase)  
o Definitions of CNS disease: 
 CNS involvement:  
 CNS 3 status (All CNS status including ‘Late’ CNS 3) 
 Intracerebral or meningeal leukemic (proven or probably) mass 
seen on the MRI or CT scans 
 Cranial nerve palsy (irrespective of CSF or imaging findings) 
 Surreptitious (CNS 2): As defined above  
 Dubious: In case of hemorrhagic spinal tap, CNS involvement is 
called dubious when the following three criteria are met: 
 > 5 leukocytes/mm3 and  
 > 50% leukemic cells on cytospin 
 Ratio erythrocytes / leukocytes >10. 
- ALL morphology classification: Was made according to the French-American-
British morphology classification (FAB)
5
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- NHL morphology classification: Was made according to the Revised European-
American classification of lymphoid neoplasms (REAL)
79
. 
1.7 Response criteria 
- Complete remission (CR): 
o Disappearance of all symptoms and of all physical and radiological signs 
related to the leukemia or the NHL. 
o < 5% blasts in the bone marrow with either normal cellularity or moderately 
reduced cellularity with signs of recovering myelopoiesis and 
thrombocytopoiesis in the peripheral blood. 
o CSF: No blasts. 
- Good partial response (GPR): 
o Disappearance of all clinical, imaging and cytological signs of lymphoma or 
of leukemia except in one tumor site with persistence of a residual mass, the 
main diameter of which must not exceed 30% of the initial diameter. 
- Partial response (PR): 
o In ALL: Any response less than CR, with 5.1%-25% blasts in the bone 
marrow at completion of induction. 
o In T-lineage ALL: even if the number of blasts in the bone marrow is < 5%, 
there is a partial response in case of a residual mass, the main diameter of 
which, exceeds 30% of the initial diameter. 
o In NHL: any response less than GPR at completion of induction. 
- Resistance: 
o In ALL: Blasts in the bone marrow > 25% at completion of induction or PR at 
completion of induction and failure to achieve a CR at completion of 
consolidation. 
o In NHL: No response (no CR nor GPR) after induction or progression from 
GPR after consolidation or failure to achieve CR/GPR after consolidation. 
- Bone marrow relapse: 
o Reappearance of more than 20% leukemic blasts cells in the BM. 
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o In case of leukemic blasts between 5% and 20% a control with more than 20% 
was necessary to ascertain the diagnosis of relapse. 
- Extra-medullary relapse: 
o Reappearance of leukemic blasts or lymphoma cells in any extra-medullary 
tissue. 
1.8 Treatment guidelines and follow-up 
For all trials a detailed written protocol was provided to all investigators and participating 
centers.  
Standard supportive care guidelines including management of hyperleukocytosis or bulky 
disease were provided in each protocol. Institutional guidelines for supportive care where applied 
individually in each participant center at physicians’ discretion.  
Recommendations for specific parts of trial such as HSCT were provided including 
selection criteria for transplant, selection of donors, conditioning chemotherapy and prevention 
of GVHD. Only reference centers for autologous or allogeneic transplantation were allowed to 
perform such procedure.  
Specific Pneumocystis jirovecii prophylaxis was recommended in all trials except for the 
58741.  
Strict rules were implemented at the end of each phase of the treatment to proceed 
further.   
In order to avoid the inadvertent administration of IT injection of Vincristine, one of the 
most common errors reported by other groups
80
, the day of the administration of any IT 
chemotherapy did not coincide with the day of administration of IV Vincristine since protocol 
58951.  
Follow up monitoring was performed by sending out questionnaires from participating 
centers on a yearly or bi-yearly basis. In case any other event occurred meanwhile, the 
corresponding questionnaire was filled up and sent. 
1.9 Ethical considerations and patient informed consent 
The corresponding Institutional Review Board and Ethics Committee at each site 
approved the different clinical trials described in this study.  
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All patients, parents or legal guardians were informed of the aims of the different 
EORTC ALL-CLG trials, the possible adverse events (AE), the procedures and possible hazards 
to which he/she was exposed, and the mechanism of treatment allocation. 
They were informed as to the strict confidentiality of their patient data, but that their 
medical records could be reviewed for trial purposes by authorized individuals other than their 
treating physician. Data was properly anonymized.  
Written informed consent was obtained from parents or legal guardians of all patients 
included in the EORTC ALL-CLG trials described in this study before they were registered at 
the EORTC Data Center. 
That was done in accordance with the national and the local regulatory requirements in 
practice at each time period.  
1.10 Statistical analysis 
Definitions: 
- Follow up was calculated using the date of diagnosis as the starting date and the date 
of last follow-up (date of death or last day known to be alive) as the ending date. If 
the date of diagnosis was not available, the minimum date among date of registry or 
date of start treatment was used instead.  
- Time to death was calculated using the date of diagnosis as the starting date and date 
of death as the end date. If the date of diagnosis was not available, the minimum date 
among date of registry or date of start treatment was used instead.  
- Time to relapse was calculated using the date when a first CR was achieved after 
induction or consolidation as the starting date and the date of first relapse as the end 
date. 
- Time to death in first CR was calculated using the date when the first CR was 
achieved after induction or consolidation as the starting date and the date of death in 
first CR as the end date. 
- Relapse free survival (RFS) was calculated from the date of CR until the date of first 
relapse or in case no event occurred, until the day of last follow-up; patients who did 
not reach CR either after the induction IA or the consolidation IB or IB’ were 
considered as events at time 0. 
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- Event free survival (EFS) was calculated from the date of CR until the date of first 
relapse or until death in CR, or in case no event occurred, until the day of last follow-
up; patients who did not reach CR either after the induction IA or the consolidation 
IB or IB’ were considered as events at time 0.  
- Overall survival (OS) was defined as the time from diagnosis to death of any cause or 
last follow-up if they remained alive.  
Statistical procedures: 
- Probabilities of survival (pEFS and pOS) were estimated using the Kaplan-Meier 
method.  
- Patients’ baseline characteristics were summarized as number (percentage) of patients 
for categorical variables and median (range) for continuous variables. Differences in 
clinical variables were studied by χ2 test or Fisher exact test for categorical data. 
Mean quantitative variable differences were compared using Student's t test. The 
assumption of normality was tested by the Shapiro-Wilk test. Levene's test was 
calculated to compare the equality of variances. If the data failed the normality test, 
thus the Wilcoxon signed rank sum test was performed. All p values were two-sided. 
P values were considered statistically significant when they were <0.05.  
- For the analysis of risk factors for death before remission and death in complete 
remission a multivariate analysis via logistic regression analysis was performed.  
- Calculations of risk factors in first remission was done by excluding patients who did 
not reach complete remission, as they were not at risk of dying in complete remission 
and censoring patients who relapsed at the time of these events. 
- In order to identify the risk factors for early death, the following baseline 
characteristics were compared between those who died before remission and those 
who did not, excluding all patients from trial 58741, because they were included in 
the trial once in remission, and the 58951 because data for this analysis was not 
available. Variables included in this analysis were: age at diagnosis, gender, WBC at 
diagnosis, immunophenotype, protocol, NCI risk and CNS involvement 
- In order to identify the risk factors for dying in first complete remission, the 
following baseline characteristics were compared between those who died in 
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remission and those who did not, excluding all patients who did not achieve a first CR 
after induction: protocol, age at diagnosis, gender, WBC at diagnosis, 
immunophenotype, NCI risk, CNS involvement and having been transplanted in first 
CR. Data from the 58951 trial was not used for this analysis because it was not 
available. Trials 58831/58832 and the 58881 were grouped for analysis of risks in 
remission because the 58741 notably differed from the two others both in the period 
in which was performed and in the background treatment.  
- Statistical analyses were performed using SPPS 21® software. 
1.11 Literature search strategy and bibliography 
Literature review was performed using ‘leukemia’, ‘treatment’,  ‘complications’ and 
‘death’ as MeSH search terms in PubMed. Search was limited using the advanced search 
function for articles published in ‘all child’ (0-18 years) and ‘young adult’ (19-24) and whose 
language was English, French, German or Spanish. No other restrictions were used. To identify 
additional publications, search was performed in EMBASE and The Cochrane Library, 
references from articles, review articles, reference pediatric oncology textbooks and 
communications to congresses or non-published data. 
2. PROTOCOLS  
2.1 Protocol 58741 
Description 
This study was undertaken in 1971. Based on previous evidence, the trial aimed to 
compare in a first step two different consolidation treatments for ALL patients who had already 
achieved a complete remission at the end of the induction therapy. In a second step, the trial 
compared two different approaches at the time of maintenance, chemotherapy or immunotherapy 
based.  
Objectives of the trial 
- To compare the effectiveness of two consolidations treatments in CR after induction 
of remission with vincristine (VCR) - prednisone (plus daunorubicin if necessary). 
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- To assess the effectiveness of immunotherapy in patients in complete remission after 
induction and consolidation treatment of ALL. 
Eligibility criteria 
Inclusion criteria: 
- Patients aged between one and fifty years. 
- Newly diagnosis of ALL induced in CR according to the protocol. 
Exclusion criteria: 
- Patients over 50 years of age. 
- Patients whose induction treatment had been initiated elsewhere for more than 2 
weeks or had received cytostatic drugs other than 6-Mercaptopurine (6-MP), 
corticosteroids, vincristine or daunorubicin. 
- Patients with leukemic transformation of a lymphoma showing initially no blood or 
marrow transformation. 
- Those who did not achieve a CR at the end of induction. 
Randomization 
- All randomizations took place at the EORTC data center in Brussels. In this particular 
trial randomizations were obtained by telephone or telex.  
- At the time of randomization for consolidation, patients younger or older than 21 
years were randomized separately in the different participating centers.  
- At the time of randomization for maintenance treatment, patients assigned for 
consolidations P or M were randomized separately.  
The patients eligible for the present study were randomly assigned to one of the two 
consolidations regimens, Polychemotherapy (P) or Methotrexate based (M), and 1 year later to 
maintenance by chemotherapy (C) or by immunotherapy (I).  
Treatments 
- Induction to remission treatment: 
Induction therapy consisted of daily oral prednisolone (40mg/m
2
) and weekly intravenous 
injections of VCR (2mg/m
2
) for 4 weeks. If after 3 VCR injections, the bone marrow still 
contained 6%-15% blasts or 16%-25% blasts, the induction was prolonged to, respectively, 5 or 
6 weeks. If after 3 injections of VCR, the marrow still contained >25% blasts, the induction was 
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prolonged to 6 weeks, and 2 weekly injections of daunorubicin 60mg/m
2
 were added. If CR was 
not achieved within 8 weeks, the patient did not enter the trial. CR was defined as the absence of 
blasts in the blood, the absence of marrow aplasia, the presence of less than 5% blasts in the bone 
marrow, and the absence of leukemic infiltration on examination.  
No prophylactic treatment of Pneumocystis carinii was given.  
The reinduction therapy given to the relapsing patient was not standardized, since it was 
anticipated, and this was indeed the case, that relapse would occur during the administration of a 
variety of drugs.  
- Consolidation treatment: 
Here the term ‘consolidation’ will be used for a one-year therapy phase, despite in 
general this term has been used for a 1-12 week period of intensive treatment after remission 
induction.  
Consolidation P (P for polychemotherapy) consisted of an 8 successive phases of 
chemotherapy given within a period of 12 or 13 months maximum. The first 4 phases given in 6 
months were repeated during the next 6 months. Phases 1 and 5 (4 weeks) consisted of L-
Asparaginase 150.000 IU/m
2
 given IV once a week and 6-MP, 70 mg/m
2
/day orally in 2 or 3 
doses. Central nervous system (CNS) prophylaxis was administered during phase 1. Phases 2 and 
6 (8 weeks) consisted of prednisone (PDN) 40mg/m
2
/day orally in 3 or 4 doses, and 6-MP 
70mg/m
2
/day orally in 2 or 3 doses. Phases 3 and 7 (8 weeks) consisted of bis-chlorethyl-
nitrosureum (BCNU), 50mg/m
2
 once a month IV for phase 3 and 100mg/m
2
 once a month IV for 
phase 7, and cyclophosphamide (CPM), 70 mg/m
2
/day orally for 8 weeks. Phases 4 and 8 (6 
weeks) consisted of methotrexate (MTX), 15-20 mg/m IM or orally, twice a week, and VCR 
1mg/m IV once a week.  
Consolidation M (M because methotrexate was the major agent) consisted in 7 successive 
phases of chemotherapy given within a period of 12 or maximum 13 months. The 7 phases were 
identical and consisted of 30 days intermittent MTX followed by 21 days of reinforcement with 
PDN and VCR. MTX was given at 15mg/m
2
 IV bolus injection during 3, 4 or 5 consecutive 
days, depending on the tolerance. Three sequences of 3, 4 or 5 days separated by at least 5 days 
of therapy had to be given over a period of 1 month. Reinduction was repeated after every 30 
days of intermittent MTX: VCR 2mg/m
2 
IV at days 1, 8 and 15, and prednisone, 40 mg/m
2
/day 
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orally at days 1-15 and then decreased progressively on days 16 and 17. MTX was restarted at 
day 21 of reinduction.  
The doses were reduced in case of toxicity. The L-Asparaginase injections were spaced 
when fibrinogen fell below 50mg/dl and were reduced to 40.000 IU/m
2
/week or discontinued 
according to severity of transaminase, amylase, glucose or CNS abnormalities. For 
hematological toxicity, when WBC was >3000/µl and platelets >100.000/µl all drugs could be 
given at 100% of the dose. Below 1.000 WBC/µl and 50.000 platelets/µl, all therapy was 
stopped.  Between these thresholds, adjustments of the doses were recommended: with WBC 
between 2.000 and 3.000/l and/or platelets between 50.000 and 100.000/l, the dose of MTX, 6-
MP, CPM and BCNU was reduced by 50%. Between 1.000 and 2.000 WBC/µl MTX, 6-MP and 
CPM were stopped, with Asparaginase, VCR and BCNU (first cycle) being reduced to 50% of 
the original dose. When, for consolidation M, WBC was 2.000-3.000/µl, only 3 days of MTX 
were give, but when WBC was below 2.000/µl, MTX was delayed until WBC reached 2.000/µl. 
- Prophylaxis of CNS relapses: 
Prophylactic therapy of CNS leukemia was given to all patients immediately after CR 
was achieved, during the begging of consolidation P or M. Before July 1973, patients received 
12 monthly intrathecal injections of MTX (5mg/m
2
) and cytarabine (10mg/m
2
) and craniospinal 
irradiation, 1.500 rads to the skull and 1.000 rads to the spine. After that date, based on published 
promising results by Aur et al
81
, the regimen was changed to 2.400 rads cranial irradiation 
combined with 5 intrathecal injections of MTX (12mg/m
2
) given over a 16 day period. 
- Maintenance treatment: 
The patients who were still in continuous CR after 1 year of consolidation were further 
randomized, separately for each consolidation arm, to receive either maintenance chemotherapy 
or immunotherapy for a period of 4 year.  
Maintenance chemotherapy consisted of daily 6-MP (90mg/m
2
) and weekly oral or 
intramuscular MTX (15/m
2
). These drugs were stopped for 21 days when reinforcement was 
given: prednisone (40mg/m
2
 orally on days 1-5) and VCR (1.5 mg/m
2
 IV on days 1, 8 and 15). 
These reinforcements were given every 3 months the first year, every 4 months the second year, 
and every 6 months thereafter.  
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Patients on immunotherapy received a combination of a) 2ml of fresh fluid Bacillus 
Calmette-Guerin (BCG) (From the Institute Pasteur, Brussels) spread over a 20 x 5 cm 
scarification on one leg. The preparation contained 8 x 10
7
 viable units/ml and was administered 
twice weekly for 6 months and once a week thereafter; b) allogeneic non irradiated leukemic 
blasts, 4 x 10
7
 blasts injected intradermally once a week for the first 3 months and then once a 
month. The blast cells were obtained from one or several leukemic donors before treatment and 
cryopreserved at -196ºC in the presence of 10% dimethylsulfoxide (DMSO). DMSO was not 
washed out prior to the administration to the patient.  
Both types of maintenance treatment were stopped after 4 years, i.e. 5 years from the 
beginning of consolidation.  
A representative schema of the trial is shown in Figure 4.  
Treatment details are depicted in table 3.  
 
 
 
 
 
 
 
 
Figure 4. Trial 58741 schema 
    
 
70 
IV: s PO: Per os; ID: Intradermal 
a 
Prednisone (PDN) and Vincristine (VCR) were to be prolonged up to 8 weeks depending on the 
response observed in the BM at 4 and 6 weeks respectively. Daunorubicin was added at week 4 of 
treatment in case >25% blasts were observed in the BM.  
b 
CNS prophylaxis was administered during phase I of P consolidation and during first course of M 
consolidation and consisted of 2.400 rads cranial irradiation combined with 5 intrathecal injections of 
Methotrexate (MTX) (12mg/m
2
) given over a 16 day period. 
c 
Three courses of MTX were given over a period of 30 days followed by a 21 days reinduction period of 
VCR and PDN. On day 21 a second course of MTX was started followed by its corresponding 
reinduction. This sequence was repeated 7 times over a 12 to 13 months period.  
d 
Maintenance chemotherapy consisted on daily 6-Mercaptopurine (6-MP) and weekly MTX. These drugs 
were stopped when reinforcement with VCR and PDN were given. Reinforcement was administered 
every 3 months the first year, every 4 months the second year, and every 6 months thereafter. 
Table 3 - EORTC-CLG 58741: Treatment protocol for all patients 
Treatment phase/drug Dose Days Given 
Induction 
- Prednisonea 
- Vincristine 
- Daunorubicin 
 
140mg/m/day
2 
2mg/m
2 
60mg/m
2
 
 
1-28  
8,15,22,29  
36,43 
P Consolidation 
Phase I/V (Weeks 1 and 5)
b
 
- L-Asparaginase (IV) 
- 6-Mercaptopurine 
Phase II/VI (Weeks 2 and 7) 
- Prednisone 
- 6-Mercaptopurine 
Phase III/VII (Weeks 3 and 7) 
- BCNU (IV) 
- Cyclophosphamide (PO) 
Phase IV/VIIII (Weeks 4 and 8) 
- Methotrexate (PO) 
- Vincristine 
 
 
150.000 IU/m
2 
70mg/m
2 
 
40mg/m
2 
70mg/m
2 
 
50mg/m
2
  
70mg/m
2 
 
15-20mg/m
2 
1mg/m
2 
 
 
8,15,22,29  
1-28  
 
1-42 
1-42 
 
 
1-42 
 
1,8,15,22,29,36,43,50,57,64,71,78 
8,15,22,29,36,43 
M consolidation 
- Methotrexate (Weeks 1-4)c 
- Vincristine (Weeks 5-9) 
- Prednisone (Weeks 5-9) 
 
15mg/m
2 
2mg/m
2 
40mg/m
2 
 
1, 11, 21 
1,8,15 
1-15 
C Maintenance  
- 6-Mercaptopurined 
- Methotrexate (PO) 
- Vincristine 
- Prednisone 
 
90mg/m
2 
15mg/m
2 
1.5mg/m
2 
40mg/m
2 
 
Once a day 
Once a week 
1, 8, 15 
1-15 
I Maintenance  
- Bacillus Calmette-Guerin 
 
- Allogenic blasts (ID) 
 
2ml(8x10
7
IU/ml) 
 
4 x 10
7 
blasts 
 
Twice weekly for first 6 months 
and once a week afterwards 
Once a week for first 3 months and 
once a month afterwards 
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2.2 Protocols 58831/58832 
Description  
From 1983 to 1989, all children with ALL and NHL under the age of 18 years of age 
were included in one of the two studies: CLG-EORTC 58831 for standard risk patients and 
58832 for medium and high-risk patients. These trials were based on BFM-like protocols, in 
which the treatment stratifications relied on three initial factors: the number of circulating blasts, 
the size of the liver and of the spleen below the costal margin. Risk factor (RF) calculation was 
carried out according to Langerman
82
 (RF = 0.2 x log
10
 (blasts/mm
3
 + 1) + 0.06 x cm 
hepatomegaly + 0.04 x cm splenomegaly). The protocol 58831 for standard risk (SR) ALL was 
designed for patients with a RF below 1.2, whereas medium (MR) (RF between 1.2–1.69) and 
high-risk (HR) ALL patients (RF >1.7) were treated according to the more intensive protocol 
58832. 
Objectives of the trial 58831 
- To investigate if the BMF regimen remains equally efficient after deletion of 
cyclophosphamide from the initial intensive phase of treatment. 
- To evaluate the possible improvements in short term and long term toxicity after 
deletion of cyclophosphamide.  
Eligibility criteria 58831 
Inclusion criteria: 
- All patients less than 18 years of age with newly diagnosed (non-B) ALL with 
standard risk (SR) characteristics, i.e. with a risk factor (RF) < 1.2, who achieve a CR 
at completion of induction therapy (IA). 
Exclusion criteria: 
- Patients with B-cell ALL, as identified by the presence of surface immunoglobulins 
on the leukemic blasts. 
- Previously treated patients, unless the treatment was limited to corticoids and/or 
vincristine, was shorter than duration of 8 days, and if the diagnosis of SR ALL can 
could be established with the available clinical and cytological data. 
- Patients with NHL, which subsequently developed into leukemia.  
- Patients with NHL and bone marrow invasion. 
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- Patients with severe encephalopathy, severe heart disease or trisomy 21. 
- Patients with initial involvement of the CNS. 
- Patients who did not achieve CR within 35 days of induction therapy. These patients 
were eligible for protocol 58883.  
Objectives of the trial 58832 
- To investigate whether subclinical leukemic involvement of the CNS could be 
equally eradicated by high dose methotrexate alone as by high dose methotrexate 
followed by radiotherapy to the cerebral meninges in ALL children with medium and 
high-risk characteristics. To answer this question, the therapeutic protocol provided 
high doses methotrexate (500mg/m
2
) given four times concomitantly with intrathecal 
methotrexate to all patients. Subsequently, the patients were randomized to receive or 
not to receive radiotherapy to the brain.  
Eligibility criteria 58832 
Inclusion criteria: 
- All patients less than 18 years of age with newly diagnosed (non B) ALL with 
medium and high-risk characteristics who achieved CR at completion of protocol I 
phase B and remained in CR at completion of reinduction protocol II.  
- Patients with initial SR characteristics who did not achieve CR at completion of 
protocol I, phase A but did achieve CR at completion of protocol I, phase B and 
remained in CR up to the time of randomization (end of protocol II).  
Exclusion criteria: 
- Patients with B-cell ALL, as identified by the presence of surface immunoglobulins 
on the leukemic blasts. 
- Previously treated patients, unless the treatment was limited to corticoids and/or 
vincristine, was shorter than duration of 8 days, and if the diagnosis of MR and HR 
ALL can could be established with the available clinical and cytological data. 
- Patients with NHL, which subsequently develops into leukemia.  
- Patients with NHL and bone marrow invasion. 
- Patients with severe encephalopathy, severe heart disease or trisomy 21. 
- Patients with initial involvement of the CNS. 
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- Patients who did not achieve CR within completion of protocol I, phase B. 
Randomization 
All randomizations took place at the EORTC data center in Brussels. In this particular 
trial randomizations were obtained by telephone or telex.  
Patients in the 58831 trial were randomized at the time of phase I according to center. 
Patients in the 58832 trial were randomized during protocol II phase b according to center 
and to category of risk (MR and HR respectively).  
Treatments 
Treatment details for both protocols are here described: 
Induction therapy (protocol IA) consisted of 4-weekly vincristine and daunorubicin, daily 
prednisolone for 4 weeks and daily i.v. infusion of asparaginase for 21 days. This was followed 
by a 4-week early consolidation (protocol IB) that included daily 6-mercaptopurine for 28 days 
and Cytarabine for 4 consecutive days each week. Patients with standard risk ALL were 
randomized to receive or not cyclophosphamide (1 g/m2 on days 1 and 29 of protocol IB). All 
medium and high-risk children received this alkylating agent. After completion of IB, the 
interval therapy was applied consisting of an 8-week course of 6-mercaptopurine p.o. and four 
administrations of high-dose methotrexate injections, 500 mg/m2 for standard risk patients and 
2500 mg/m2 for medium and high-risk patients. Finally, standard risk patients (protocol 58831) 
received a 1-month late intensification treatment that included dexamethasone for 14 days, two 
doses of doxorubicin and vincristine and four doses of asparaginase followed by cytarabine (two 
cycles as in consolidation) and 6-thioguanine. For medium and high-risk patients (trial 58832) 
this late intensification lasted 6 instead of four weeks (protocol IIA and IIB) and was the same as 
trial 58881.  For standard risk patients, a total of six IT methotrexate injections were scheduled 
during these phases of treatment and, for median and high-risk patients, seven IT injections. 
Maintenance therapy was pursued with 6-mercaptopurine daily and oral methotrexate weekly, 
without IT treatment, for duration of 2 years from the start of induction therapy. Medium and 
high-risk patients were randomized into two groups, for receiving or not prophylactic cranial 
radiation after the completion of protocol II and before the start of maintenance therapy. 
Children above 2 years of age received 24 Gy, the dose was reduced for younger patients (20 Gy 
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between 1 and 2 years of age). Patients with CNS manifestations at diagnosis were not eligible in 
trial 58831/58832. 
Evaluation of response was made at the end of Induction (IA) and end of Consolidation 
(Protocol IB). Patients who did not achieve a CR at the end of IA were meant to continue into 
IB. Patients who either achieved a CR at the end of IA or IB were considered responders to 
therapy and allocated to the corresponding trial as specified in the inclusion/exclusion criteria.  
Patients with high-risk features could be considered for transplantation in first remission. 
The decision to proceed to transplantation was based on the investigator criteria at each center. 
For the purposes of this study, only patients having achieved a first complete remission after 
protocol Ia or Ib and having been decided to receive a transplant were included in the analysis of 
toxic deaths. 
Representative schemas of the trial are shown in Figures 5 and 6.  
Treatment details are depicted in tables 4 and 5.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Trial 58831 schema 
Figure 6. Trial 58832 schema 
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Table 4 - EORTC-CLG 58831: Treatment protocol for standard risk patients (SR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV) 
- Methotrexate (IT) 
Protocol IB 
- Cyclophosphamide according 
to randomization 
- Cytarabine 
- 6-Mercaptopurine 
- Methotrexate (IT) 
 
 
60mg/m
2 
1.5mg/m
2 
30mg/m
2
 
5000 IU/m
2
  
12mg (age-dependent) 
 
1g/m
2
 
 
75mg/m
2
 
60mg/m
2 
12mg (age-dependent) 
 
 
1-28 
1,8,15,22 
1,8,15,22 
1-21 
1 
 
36,63 
 
38-41, 45-48, 52-55, 59-62 
36-63 
39 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate 
- Methotrexate  (IT) 
 
25mg/m
2
 
500mg/m
2
 
12mg (age-dependent) 
 
1-56 
8,22,36,50 
8,22,36,50 
Reinduction: Protocol II 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV) 
- Cytarabine 
- 6-Tioguanine  
 
10mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2
 
75mg/m
2
 
60mg/m
2
 
 
1-14 
1,8 
1,8 
1,4,8,11 
17-20, 24-27 
15-28 
Maintenance 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
IT: Intrathecal; IV: Intravenous; PO: Per os 
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Table 5 - EORTC-CLG 58832: Treatment protocol for medium (MR) and high-risk (HR) 
patients  
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV) 
- Methotrexate (IT) 
Protocol IB 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- Methotrexate (IT) 
 
 
60mg/m
2 
1.5mg/m
2 
30mg/m
2
 
5000 IU/m
2
  
12mg (age-dependent) 
 
1g/m
2
 
75mg/m
2
 
60mg/m
2 
12mg (age-dependent) 
 
 
1-28 
1,8,15,22 
1,8,15,22 
1-21 
1 
 
36,63 
38-41, 45-48, 52-55, 59-62 
36-63 
39 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate 
- Methotrexate  (IT) 
 
25mg/m
2
 
2.5g/m
2
 
12mg (age-dependent) 
 
1-56 
8,22,36,50 
8,22,36,50 
Reinduction:  
Protocol IIA 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV) 
Protocol IIB 
- Cyclophosphamide 
- Cytarabine 
- 6-Tioguanine  
 
 
10mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2 
 
1g/m
2 
75mg/m
2
 
60mg/m
2
 
 
 
1-28 
1,8, 15, 22 
1,8, 15, 22 
1,4,8,11 
 
29 
31-34, 38-41 
29-42 
Maintenance
a 
- 6-Mercaptopurine 
- Methotrexate 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
IT: Intrathecal; IV: Intravenous; PO: Per os 
a 
Medium and high-risk patients were randomized into two groups, for receiving or not 
prophylactic cranial radiation after the completion of protocol II and before the start of 
maintenance therapy. 
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2.3 Protocol 58881 
Description  
From 1989 to 1998 patients with ALL were included in the 58881 protocol. Based on 
previous evidence obtained from preceding EORTC trials and other groups, the CLG decided to 
run this randomized trial to test the efficacy of two different asparaginase formulation in front 
line therapy, the value of the addition of high doses cytarabine to the interval therapy and the 
value of alternation intravenous and oral administration of 6-mercaptopurine when compared to 
exclusive administration alone during maintenance.  
Objectives  
- To test the relative efficacy and toxicity of two different Asparaginase formulations  
(Erwinia Vs. E. Coli) in front line therapy in children with ALL and NHL 
- To test whether the addition of high-dose cytarabine to interval chemotherapy 
improved the disease-free survival and the central nervous system-free interval in 
patients with increased risk non B-cell ALL, and in patients with stage III or stage IV 
non-B NHL. 
- To test whether alternation of intravenous and oral administration of 6-
mercaptopurine as compared to exclusive oral administration of this drug, during 
maintenance, improved the disease-free survival and the central nervous system free 
interval, in all patients with non-B cell ALL and non-B cell NHL (excluding very 
high-risk patients). 
Eligibility criteria  
Inclusion criteria: 
- All patients less than 18 years of age, with non B-cell ALL or with non B-cell NHL 
(any stage). 
Exclusion criteria: 
- Patients previously treated, unless the treatment consisted of corticoids only and did 
not exceed 7 days in duration, and clinical as well as hematologic data were available 
allowing for correct staging of the patients with B-cell ALL or B-cell NHL. 
B-cell ALL was defined by L3 morphology in the FAB classification and by the 
presence of immunoglobulins on the membrane or in the cytoplasm of at least 20% of 
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the leukemic blasts or by the presence of translocations specific for B-cell neoplasias, 
i.e. t (2;8), t (8;14) or t (8;22). All ALL with a less mature immunophenotype within 
the B-cell lineage, including those with cytoplasmic µ-chains and L1 or L2 
morphology (i.e. pre-B-cell ALL), were eligible. The very rare cases of ALL with L1 
or L2 morphology and immunoglobulins on the membrane were eligible for this 
study. In patients with NHL where the immunophenotype was not available, the 
diagnosis of B-cell NHL could be established on cytological and histological criteria, 
according to the Kiel classification
83
. 
Eligibility criteria for the randomized trial pertaining Asparaginase Therapy  
Inclusion criteria: 
- All patients less than 18 years of age, with non B-cell ALL or with non B-cell NHL 
(any stage). 
Exclusion criteria: 
- Patients previously treated, unless the treatment consisted of corticoids only and did 
not exceed 7 days in duration, and clinical as well as hematologic data were available 
allowing for correct staging of the patients with B-cell ALL or B-cell NHL. 
Eligibility criteria for the randomized trial pertaining to Interval Therapy 
Inclusion criteria: 
- All patients with increased risk non-B ALL (non-T with an risk factor > 0.8 and all T 
ALL, excluding very high-risk patients) or with stage III or stage IV non-B NHL, 
who achieved CR by the end of protocol Ia (induction) and remained in CR after 
completion of protocol Ib (consolidation). 
Exclusion criteria:  
- Low risk non-B non-T ALL patients, i.e. with R.F. < 0.8. 
- Stage I or stage II NHL. 
- Patients not in first CR. 
- Very high-risk patients. 
- Patients with non-equivocal or overt initial involvement of the CNS. 
Eligibility criteria for the randomized trial pertaining to Maintenance Therapy 
Inclusion criteria: 
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- All patients, with non B-cell ALL of any R.F. (excluding very high-risk patients only) 
or with non B-cell NHL of any stage, who achieved CR by the end of protocol Ia 
(induction) and remained in first CR after completion of protocol II (reinduction).   
Exclusion criteria: 
- Patients not in first CR. 
- Very high-risk patients. 
- Patients with non-equivocal or overt initial involvement of the CNS. 
Eligibility criteria in the pilot study for Very High-risk Patients 
Inclusion criteria: 
- All patients with non B-cell ALL or non B-cell NHL, with any one of the following 
very high-risk features: 
o Bad response to prednisolone (or prednisone) prephase therapy (i.e. with the 
persistence of more than 1,000/mm3 leukemic blasts in the peripheral blood 
after 7 days of prephase therapy). 
o Absence of complete remission after completion of induction (by the end of 
protocol Ia). This failure to achieve CR had to be established by a bone 
marrow examination at day 42, before the start of Ib.  
o Undifferentiated immunophenotype, i.e., negativity for B (including CD19, 
CD20, CD24) and T-cell markers and for CALLA (CD10) and for myeloid 
markers (acute undifferentiated leukemia or AUL).  
o Cytogenetic abnormalities: t (9;22) or t (4;11) translocation, or nearhaploidy. 
Randomization 
This process was done centrally (EORTC Data Center, Brussels) by telephone through 
the Euro-Code network.  
For the first question, randomization was stratified according to center, disease (leukemia 
versus lymphoma), risk factor (< 0.8, 0.8-1.19, ≥1.2), and immunophenotype (B versus T 
lineage) for leukemia patients, and by Murphy stage (stage I-II versus III-IV) for lymphoma 
patients. Randomization was not stratified by the presence of t(9;22).  
Subsequent randomizations were stratified according to treatment arm and initial risk 
factor or Murphy stage. 
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Treatments 
Patients were initially randomized to Erwinia-asparaginase (Erwiniase, Ipsen, 
Maidenhead, United Kingdom) or E coli–asparaginase (Paronal, Medac, Hamburg, Germany for 
the Belgian centers, or Kidrolase, Bellon, Montrouge, France for the French and Portuguese 
centers, both produced by Kyowa Hakko, Tokyo, Japan). Physicians had to switch to the other 
asparaginase in case of allergy grade 1 or higher. In case of pancreatitis or thrombosis, 
asparaginase was eliminated from the treatment. This comparison was carried out between 
November 1990 and October 1993 
All patients received the same induction regimen with the exception of Asparaginase 
during the study period. After that, and in view of the differences between the two Asparaginase 
groups, all patients received E. Coli unless otherwise contraindicated
84
. 
After completion of this treatment, patients who had more than 1000 blasts/mm
3
 of blood 
at the end of the first week of prednisolone treatment, those who did not achieve complete 
remission, and those with a t(4;11) or t(9;22) translocation were considered to have a very high-
risk of relapse and so were classed in a very high-risk (VHR) group. The remaining patients 
considered as standard risk of relapse (low and intermediate risk according to Langerman
82
 (RF 
= 0.2 x log10 (blasts/mm
3
 + 1) + 0.06 x cm hepatomegaly + 0.04 x cm splenomegaly) as in the 
58831/2 trials) received the same treatment with a consolidation (protocol IB), an interval 
therapy and a protocol II.  
The second question investigated the value of high doses of cytarabine (1 g/m
2
, twice, at 
a 12 h interval) combined with high doses of methotrexate during the interval therapy. Only 
patients with no VHR feature, either with B cell phenotype and a RF 0.8, or those with T cell 
lineage were eligible for this second randomization, which was carried out between September 
1989 and January 1996.  
A total of 10 IT methotrexate injections were scheduled during the intensive phases of 
treatment, but no IT was planned during maintenance. Cranial radiation was systematically 
omitted even for patients with CNS manifestations at diagnosis (5 blasts/mm
3
 in CSF: CNS-3 
status). The latter patients received two additional IT injections during induction and two during 
consolidation, and one IT injection, combined with high-dose methotrexate, every 3 months, 
during maintenance. So, patients with CNS involvement at diagnosis received a total of 20 IT 
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methotrexate injections. The presence of CNS blast cells with fewer than five leukocytes per 
micro liter was considered as surreptitious (CNS-2 status). In case of traumatic spinal tap with 
blood admixture and the impossibility of deciding between blood contamination and probable 
involvement, it was considered as dubious. Further to the publication of the prognostic 
significance of low leukemic cells in the CNS
85
 almost 40% of study population with 
surreptitious or dubious CNS involvement were treated the same as those with overt CNS 
involvement. VHR patients received an intensified treatment for 1 year consisting of an 
intensified consolidation IB, a ‘VANDA’ course, an interval therapy followed by two series of 
three chemotherapeutic courses (R1, R2, and R3) according to the BFM relapse protocol
86
 which 
relied on rotational high dose pulses of chemotherapy. This VHR treatment contained alkylating 
agents (cyclophosphamide in consolidation and ifosfamide in R2 bloc). The cumulative 
anthracycline dose/m
2 
was 220 mg daunorubicin and 16 mg mitoxantrone. The CNS directed 
chemotherapy included a total of 16 IT methotrexate injections, six of which were triple, with 
cytarabine and steroids, scheduled during this first year of intensified treatment and also 10 
courses of high-dose methotrexate. For those with CNS leukemia at diagnosis, IT methotrexate 
was pursued during maintenance every 3 months (a total of 20 IT injections were given during 
the overall treatment). Cranial radiotherapy was not planned.  
For VHR patients who have an HLA-identical donor, with a negative mixed lymphocyte 
culture, bone marrow transplantation in first complete remission was an alternative to the VHR 
protocol. VHR patients having received the Ia and the Ib protocol, whether in CR or in PR or 
with progressive disease, with a genotypically identical HLA donor were considered potential 
candidates for transplantation. The decision to proceed to transplantation was based on the 
investigator criteria at each center. For the purposes of this study, only VHR patients having 
achieved a first complete remission after protocol Ia or Ib and having been decided to receive a 
transplant were included in the analysis of toxic deaths.  
The third randomization was made to test the advantage of adding monthly intravenous 
6-mercaptopurine (1 g/m
2
) to conventional maintenance therapy with daily oral 6-
mercaptopurine (initial dose 50 mg/m
2
) adjusted to maintain the leukocytes between 2000 and 
3000/mm
3
 and methotrexate 20 mg/m
2
 once a week. All patients in complete remission after 
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protocol II or after the last R3 bloc for those qualified as VHR, were eligible for this third 
question, which included patients between November 1990 and November 1996. 
For all patients, the total duration of treatment was two years.  
Representative schemas of the trial are shown in Figures 7 and 8.  
Treatment details are depicted in tables 6 and 7.  
 
 
 
 
 
           
 
 
 
          
 
 
 
 
 
 
Figure 7. Trial 58881 schema 
Figure 8. Trial 58881 schema VHR 
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Table 6 - EORTC-CLG 58881: Treatment protocol for standard risk patients (SR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV)a 
- Methotrexate (IT) 
Protocol IB 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- Methotrexate (IT) 
 
 
60mg/m
2 
1.5mg/m
2
 
30mg/m
2
 
10000IU/m
2
 
12mg (age dependent) 
 
1g/m
2
 
75mg/m
2
 
60mg/m
2 
12mg (age dependent) 
 
 
1-28 
8,15,22,29 
8,15,22,29 
12,15,18,22,25,29,35,38 
1,8,22,38,52 
 
36,63 
38-41, 45-48, 52-55, 59-62 
36-63 
39 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Methotrexate  (IT)  
- Cytarabine (according to 
randomization
 b
) 
 
25mg/m
2
 
5g/m
2
 
12mg (age dependent) 
1g/m
2 
(twice 12-h 
interval) 
 
1-56 
8,22,36,50 
9,23,37,51 
 
9,23,37,51 
Reinduction: Protocol II 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV) 
- Methotrexate (IT) 
- Cyclophosphamide 
- Cytarabine 
- 6-Tioguanine   
 
10mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2
 
12mg (age dependent) 
1g/m
2
 
75mg/m
2
 
60mg/m
2
 
 
1-21 
8,15,22,29 
8,15,22,29 
8,11,15,18 
38 
36 
38-41, 45-48 
36-49 
Maintenance
c 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
IT: Intrathecal; IV: Intravenous; PO: Per os 
a 
Patients, regardless of their risk group, were randomly assigned to receive E. Coli asparaginase 
or Erwinia asparaginase at equal doses.  
b 
Patients in CR, with an initial RF >0.8 or with a T-lineage ALL and without VHR features, 
were eligible for this randomization. 
c 
Patients in CR after protocol II or after the last R3 bloc for those qualified as VHR were eligible 
for the third randomization to test the advantage of adding monthly intravenous 6-
mercaptopurine (1 g/m
2
) to conventional maintenance therapy.  
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Table 7 - EORTC-CLG 58881: Treatment protocol for very high-risk patients (VHR)  
Treatment phase/drug Dose Days Given 
Protocol IB 
- Cyclophosphamide  
- Methotrexate  
- Cytarabine 
- Asparaginase 
- 6-Mercaptopurine 
- Methotrexate (IT) 
 
1g/m
2 
5g/m 
1g/m
2
 
25000 IU/m
2 
25mg/m
2 
12mg (age dependent) 
 
43,85 
43,57,71 
50,51,64,65,78,79 
44,51,58,65,72,79 
43-84 
44,58,72 
VANDA 
- Dexamethasone 
- Cytarabine 
- Mitoxantrone 
- Etoposide 
- Asparaginase 
- Methotrexate (IT) 
 
20mg/m
2
 
2g/m
2
 
8mg/m
2
 
150mg/m
2
 
10000mg/m
2
 
12mg (age dependent) 
 
1-5 
1,2 
3,4 
3,4,5 
7,9,11,13 
5 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Methotrexate  (IT)  
- Cytarabine 
 
25mg/m
2
 
5g/m
2
 
12mg (age dependent) 
1g/m
2
 (12-h interval) 
 
1-42 
8,22,36 
9,23,37 
9,23,37 
Block R1 
- Dexamethasone 
- 6-Mercaptopurine 
- Vincristine 
- Methotrexate 
- Cytarabine 
- Asparaginase 
- MTX/Cytarabine/PDN (IT) 
 
20mg/m
2
 
100mg/m
2
 
1.5mg/m
2
 
5mg/m
2
 
2mg/m
2
 
25000 IU/m
2
 
12mg/30mg/10mg 
 
1-5 
1-5 
1,6 
1 
5 
6 
1 
Block R2 
- Dexamethasone 
- 6-Thioguanine 
- Vindesine 
- Methotrexate 
- Ifosfamide 
- Daunorubicin 
- Asparaginase  
- MTX/Cytarabine/PDN (IT) 
 
20mg/m
2
 
100mg/m
2
 
3mg/m
2
 
5mg/m
2
 
400mg/m
2
 
50mg/m
2
 
25000mg/m
2
 
12mg/30mg/10mg 
 
1-5 
1-5 
1 
1 
1-5 
5 
6 
1 
Block R3 
- Dexamethasone  
- Cytarabine 
- Etoposide  
- Asparaginase 
- MTX/Cytarabine/PDN (IT) 
 
20mg/m
2
 
2g/m
2
 
150mg/m
2
 
25000IU/m
2
 
12mg/30mg/10mg 
 
1-5 
1,2 
3,4,5 
6 
5 
Maintenance
c 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
c 
Patients in CR after protocol II or after the last R3 bloc for those qualified as VHR were eligible for the third 
randomization to test the advantage of adding monthly intravenous 6-mercaptopurine (1 g/m
2
) to conventional 
maintenance therapy.  
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2.4 Protocol 58951 
Description  
From 1998 to 2008 patients with ALL were included in the 58951 protocol. Based on 
previous evidence obtained from preceding EORTC trials and other groups, the CLG decided to 
run this randomized trial to test the efficacy of dexamethasone vs prednisolone administered 
during induction regarding the EFS and survival in children with ALL and with lymphoblastic 
NHL and to assess the value of the increase of the number of administrations of L-Asparaginase 
during consolidation (protocol I) and during late intensification (protocol II) and the value of 
pulse of vincristine and prednisone during maintenance in average risk patients.  
Objectives of the trial 
- To assess the value of dexamethasone vs prednisolone administered during induction 
regarding the EFS and Survival in children with ALL and with lymphoblastic NHL. 
- To assess the value of the increase of the number of administrations of L-
Asparaginase during consolidation (protocol I) and during late intensification 
(protocol II) regarding the EFS and Survival in children without VHR features.  
- To asses the value of pulse of vincristine and prednisone during maintenance in 
average risk patients.  
Eligibility criteria 
Inclusion criteria:  
- Age less than 18 years.  
- Previously untreated.  
- Acute lymphoblastic leukemia of FAB L1 or L2 morphology whatever the immuno-
phenotype or precursor B- and precursor T-lymphoblastic non-Hodgkin lymphoma.  
Exclusion criteria:  
- Acute lymphoblastic leukemia of FAB L3 morphology. 
- Diffuse large cell B-cell lymphoma, Burkitt’s lymphoma and high-grade B-cell 
lymphoma Burkitt like, according tot the REAL classification. 
Eligibility criteria for the randomized trial pertaining to the corticoid question 
Inclusion criteria: 
- Fulfill all the inclusion and exclusion criteria mentioned before.  
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- Having been signed the informed consent before day 1 of the pre-phase or at the 
beginning or protocol IA.   
Eligibility criteria for the randomized trial pertaining to the asparaginase question 
Inclusion criteria: 
- Achievement of complete remission or good partial response (GPR) for T-ALL 
between day 28 and day 42 of protocol I. 
- Absence of VHR features. 
- Absence of severe toxicity possibly related to asparaginase.  
Eligibility criteria for the randomized trial pertaining to the pulses question 
Inclusion criteria: 
- Average risk patients 
- Continuous complete remission at the time of maintenance.  
Randomization 
- This process was done centrally (EORTC Data Center, Brussels) by telephone or 
internet.  
Risk groups 
Very low risk (VLR) 
1. ALL of B-cell lineage  
2. and leukocyte count < 10x109/l 
3. and DNA index (DI) > 1.16 and < 1.50, and chromosome number 51-66 or DI 
> 1.16 and < 1.50, and chromosome number is unknown or chromosome 
number 51-66, and DI is not assessed 
4. and good response to the prephase 
5. and absence of t(9;22) / BCR-ABL, of t(4;11) / MLL-AF4, of 11q23 / MLL 
rearrangement and of AUL 
6. and absence of CNS and gonadal involvement 
 
Average risk (AR) 
1. ALL with good response to the prephase who are neither VLR nor VHR 
2. VLR ALL with CNS involvement (CSF+ or CSF +/-) 
3. B lymphoblastic NHL stage III and IV without any VHR feature 
4. T lymphoblastic NHL 
 
AR patients are sub stratified in: 
AR1:  
- B-cell lineage ALL with < 100x109/l 
- surreptitious or hemorrhagic CSF becoming CSF negative at D4 of prephase 
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- precursor B lymphoblastic NHL stage III and IV 
- precursor T lymphoblastic NHL stage I and II 
AR2:  
- B-cell lineage ALL with > 100x109/l 
- T-cell lineage ALL whatever the leukocyte count 
- patients with overt or non-equivocal CNS involvement at D0 or any CSF 
involvement at D4 
- gonadal involvement 
- precursor T lymphoblastic NHL stage III and IV 
 
Very high risk (VHR) 
1. Poor response to the prephase (i.e. ≥ 1x109/l blasts in peripheral blood after 
completion of the prephase) 
2. or t(9;22) or bcr/abl 
3. or t(4;11) / MLL-AF4 
4. or 11q23 / MLL rearrangement 
5. or near-haploidy (< 34 chromosomes or D.I. < 0.7) 
6. or hypodiploid (35-40 chromosomes or D. I. > 0.7 and < 0.8) 
7. or AUL 
8. or for B-lineage ALL: failure to achieve CR after completion of protocol IA. 
9. or for T-lineage ALL: failure to achieve CR or good partial response after 
completion ofprotocol IA 
10. or minimal residual disease (MRD) > 10-2 (more than 1,000 blasts / 100,000 
mononuclear BM cells) at evaluation of IA (on day 35) 
Treatment 
 The protocol was a Berlin-Frankfurt-Munster (BFM)-like protocol, without cranial or 
local irradiation. Concerning the randomization dexamethasone versus prednisolone, the patients 
could be randomly assigned either before the beginning of the prephase (day 1), or at the 
beginning of protocol IA (day 8), at the investigator’s discretion. In the latter case, prednisolone 
was used throughout the prophase. 
All patients had to receive dexamethasone (6 mg/m
2
/day) or prednisolone (60 
mg/m
2
/day), orally, in two divided doses throughout prephase (day 1 to day 7) and induction 
therapy (day 8 to day 35, including a tapering down period of 8 days). During protocol IIA, all 
patients received dexamethasone 6 mg/m
2
. 
If they had an HLA identical donor, all very high-risk patients were eligible for 
hematopoietic stem cell transplantation except those whose only very high-risk criterion was a 
poor corticosteroid response on day 8, without T-cell immunophenotype or early precursor B-
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ALL or white blood cell count ≥100×109/L. Otherwise, the patients continued chemotherapy for 
a total treatment duration of 2 years. 
Non VHR patients achieving acomplete remission or good partial response for T-ALL 
between day 28 and day 42 of protocol I were eligible for the second randomization: 
a) Arm S=Short: no asparaginase during Ib and 4 injections of asparaginase during IIA 
b) Arm L=Long: 8 injections of asparaginase during Ib and 8 during IIA 
Average risk patients were eligible for the third randomization at the time of maintenance 
to receive or not pulses with vincristine and prednisone. Maintenance was prolonged for up to 2 
years.  
Representative schemas of the trial are shown in Figures 9 and 10.  
Treatment details are depicted in tables 8, 9, 10 and 11.  
 
 
 
 
 
 
 
 
 
 
Figure 9. Trial 58951 schema 
Figure 10. Trial 58951 VHR schema 
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Table 8 - EORTC-CLG 58951: Treatment protocol for very low risk (SR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
or Dexametasone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV/IM) 
- Triple intrathecal chemo 
Protocol IB 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- Triple intrathecal chemo 
- Asparaginase (IV/IM) 
(According to randomization) 
 
 
60mg/m
2 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000IU/m
2
 
Age dependent 
 
1g/m
2
 
75mg/m
2
 
60mg/m
2 
Age dependent 
0 or 5000UI/
2
 
 
 
8-28 
8-28 
8,15,22,29 
8,15 
12,15,18,22,25,29,32,35 
12, 15 
 
36,63 
38-41, 45-48, 52-55, 59-62 
36-63 
38, 52 
38, 41, 45, 48, 52, 55, 59, 
62 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Triple intrathecal chemo 
 
25mg/m
2
 
5g/m
2
 
Age dependent 
 
1-56 
8,22,36,50 
9,23,37,51 
Reinduction: Protocol II 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV/IM) 
- Asparaginase (IV/IM) 
(According to randomization) 
- Triple intrathecal chemo 
- Cytarabine 
- 6-Tioguanine   
 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2 
10000-5000 IU/m
2 
Age dependent 
75mg/m
2
 
60mg/m
2
 
 
1-21 
8,15,22,29 
8,15 
8,11,15,18 
8,11,15,18, 22, 25, 29, 32 
38 
38-41, 45-48 
36-49 
Maintenance
 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
IT: Intrathecal; IM: Intramuscular; IV: Intravenous; PO: Per os 
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Table 9- EORTC-CLG 58951: Treatment protocol for average risk-1 (AR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
or Dexametasone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV/IM) 
- Triple intrathecal chemo 
Protocol IB 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- Triple intrathecal chemo 
- Asparaginase (IV/IM) 
(According to randomization) 
 
 
60mg/m
2 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000IU/m
2
 
Age dependent 
 
1g/m
2
 
75mg/m
2
 
60mg/m
2 
Age dependent 
0 or 5000UI/
2
 
 
 
8-28 
8-28 
8,15,22,29 
8,15, 22, 29 
12,15,18,22,25,29,32,35 
12, 15 
 
36,63 
38-41, 45-48, 52-55, 59-62 
36-63 
38, 52 
38, 41, 45, 48, 52, 55, 59, 
62 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Triple intrathecal chemo 
 
25mg/m
2
 
5g/m
2
 
Age dependent 
 
1-56 
8,22,36,50 
9,23,37,51 
Reinduction: Protocol II 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV/IM) 
- Asparaginase (IV/IM) 
(According to randomization) 
- Cyclophosphamide 
- Triple intrathecal chemo 
- Cytarabine 
- 6-Tioguanine   
 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2 
10000-5000 IU/m
2 
Age dependent 
1g/m
2
 
Age dependent 
75mg/m
2
 
60mg/m
2
 
 
1-21 
8,15,22,29 
8,15, 22, 29 
8,11,15,18 
8,11,15,18, 22, 25, 29, 32 
 
36 
38 
38-41, 45-48 
36-49 
Maintenance
 a 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
- Triple intrathecal chemo 
 
50mg/m
2 
20mg/m
2 
Age dependent 
 
Daily 
Weekly  
Every 70 days (6 times) 
IT: Intrathecal; IM: Intramuscular; IV: Intravenous; PO: Per os 
a 
Average risk patients were eligible for the third randomization at the time of maintenance to 
receive or not pulses with vincristine and prednisone 
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Table 10- EORTC-CLG 58951: Treatment protocol for average risk-2 (AR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
or Dexametasone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV/IM) 
- HD-MTX 
- Cyclophosphamide  
- Triple intrathecal chemo 
Protocol IB 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- Triple intrathecal chemo 
- Asparaginase (IV/IM) 
(According to randomization) 
 
 
60mg/m
2 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000IU/m
2 
5g/m
2 
1g/m
2
 
Age dependent 
 
1g/m
2
 
75mg/m
2
 
60mg/m
2 
Age dependent 
0 or 5000UI/
2
 
 
 
8-28 
8-28 
8,15,22,29 
15, 22, 29 
12,15,18,22,25,29,32,35 
8 
9 
12, 15 
 
36,63 
38-41, 45-48, 52-55, 59-62 
36-63 
38, 52 
38, 41, 45, 48, 52, 55, 59, 
62 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Triple intrathecal chemo 
 
25mg/m
2
 
5g/m
2
 
Age dependent 
 
1-56 
8,22,36,50 
9,23,37,51 
Reinduction: Protocol II 
- Dexamethasone 
- Vincristine 
- Doxorubicin  
- Asparaginase (IV/IM) 
- Asparaginase (IV/IM) 
(According to randomization) 
- Cyclophosphamide 
- Triple intrathecal chemo 
- Cytarabine 
- 6-Tioguanine   
 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000 IU/m
2 
10000-5000 IU/m
2 
Age dependent 
1g/m
2
 
Age dependent 
75mg/m
2
 
60mg/m
2
 
 
1-21 
8,15,22,29 
8,15, 22, 29 
8,11,15,18 
8,11,15,18, 22, 25, 29, 32 
 
36 
38 
38-41, 45-48 
36-49 
Maintenance
a 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
- Triple intrathecal chemo 
- HD-MTX 
- Asparaginase 
 
50mg/m
2 
20mg/m
2 
Age dependent 
5g/m
2 
25000 IU/m
2 
 
Daily 
Weekly  
Every 70 days (6 times) 
Every 70 days (6 times) 
Every 70 days (6 times) 
IT: Intrathecal; IM: Intramuscular; IV: Intravenous; PO: Per os 
a 
Average risk patients were eligible for the third randomization at the time of maintenance to receive or not pulses 
with vincristine and prednisone 
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Table 11- EORTC-CLG 58951: Treatment protocol for very high risk (VHR) 
Treatment phase/drug Dose Days Given 
Induction-Consolidation 
Protocol IA 
- Prednisolone 
or Dexametasone 
- Vincristine 
- Daunorubicin 
- Asparaginase (IV/IM) 
- HD-MTX 
- Cyclophosphamide  
- Triple intrathecal chemo 
Protocol IB 
- Dexamethasone 
- Vincristine 
- HD-MTX 
- Cyclophosphamide  
- Cytarabine 
- 6-Mercaptopurine 
- 6-Tioguanine 
- Triple intrathecal chemo 
- Daunorubicin 
- Vindesine 
- Asparaginase (IV/IM)  
 
 
60mg/m
2 
6mg/m
2
 
1.5mg/m
2
 
30mg/m
2
 
10000IU/m
2 
5g/m
2 
1g/m
2
 
Age dependent 
 
10mg/m
2 
1.5mg/m
2 
5g/m
2 
500mg/m
2
 
2g/m
2
/12h 
100mg/m
2 
100mg/m
2 
Age dependent 
50mg/m
2 
3mg/m
2
 
10000UI/
2
 
 
 
8-28 
8-28 
8,15,22,29 
15, 22, 29 
12,15,18,22,25,29,32,35 
8 
9 
12, 15 
 
36-40, 50-54 
36, 41 
36, 50 
52, 53 
40 
36-40 
50-54 
37, 51 
54 
50 
41, 43, 45, 55, 57, 59 
VANDA 
- Dexamethasone 
- Cytarabine 
- Mitoxantrone 
- Etoposide 
- Asparaginase 
- Methotrexate (IT) 
 
20mg/m
2
 
2g/m
2
 
8mg/m
2
 
150mg/m
2
 
10000mg/m
2
 
12mg (age dependent) 
 
1-5 
1,2 
3,4 
3,4,5 
7,9,11,13 
5 
Interval Therapy 
- 6-Mercaptopurine  
- Methotrexate (24 h infusion) 
- Triple intrathecal chemo 
 
25mg/m
2
 
5g/m
2
 
Age dependent 
 
1-42 
8,22,36 
9,23,37 
Block R1 
- Dexamethasone 
- 6-Mercaptopurine 
- Vincristine 
- Methotrexate 
- Cytarabine 
- Asparaginase 
- MTX/Cytarabine/PDN (IT) 
 
20mg/m
2
 
100mg/m
2
 
1.5mg/m
2
 
5mg/m
2
 
2mg/m
2
 
25000 IU/m
2
 
12mg/30mg/10mg 
 
1-5 
1-5 
1,6 
1 
5 
6 
1 
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Block R2 
- Dexamethasone 
- 6-Thioguanine 
- Vindesine 
- Methotrexate 
- Ifosfamide 
- Daunorubicin 
- Asparaginase  
- Triple intrathecal chemo 
 
 
20mg/m
2
 
100mg/m
2
 
3mg/m
2
 
5mg/m
2
 
400mg/m
2
 
50mg/m
2
 
25000mg/m
2
 
Age dependent 
 
 
1-5 
1-5 
1 
1 
1-5 
5 
6 
1 
Block R3 
- Dexamethasone  
- Cytarabine 
- Etoposide  
- Asparaginase 
- Triple intrathecal chemo 
 
20mg/m
2
 
2g/m
2
 
150mg/m
2
 
25000IU/m
2
 
Age dependent 
 
1-5 
1,2 
3,4,5 
6 
5 
Maintenance
 
- 6-Mercaptopurine (PO) 
- Methotrexate (PO) 
 
50mg/m
2 
20mg/m
2
 
 
Daily 
Weekly  
IT: Intrathecal; IM: Intramuscular; IV: Intravenous; PO: Per os 
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IV. RESULTS 
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1. RESULTS 
The following diagram represents the number of patients initially eligible for this study, 
those who were excluded and those finally included (Figure 11): 
 
 
1.1 Protocol 58741 
The trial was opened for recruitment in May 1971 and the last patient was entered in 
December 1978. 
224 patients were initially recruited for this study.   
10 patients were considered ineligible for the analysis according to the eligibility criteria 
specified in the protocol: Inadequate stage or histopathology at diagnosis (2), treatment never 
started (1), missing forms due to institutional difficulties (4), treatment stopped for more than 2 
months (1), other protocol violations (2).  
32 patients were not included for the analysis because they were ≥ 18 years at the time of 
diagnosis. 
2 patients were ≥ 18 years at the time of diagnosis and also fulfilled any of the exclusion 
criteria. 
Figure 11. Consort diagram eligible patients 
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2 patients were aged less than one year at the time of diagnosis but became older than one 
at the time of consolidation and therefore could be considered as eligible for the trial. These two 
patients were considered older than one year for the purposes of the analysis.  
In the end, 40 patients were not included. That yielded 184 patients considered fully 
evaluable for the final analysis.  
The numbers of patients randomized to each question proposed by the trial are described 
here:  
- All 184 patients were randomized for the consolidation question to receive a 
polychemotherapy (P) (n=95, 51,6%) or a methotrexate (M) (n=89, 48,4%) based 
treatment. 
- 110 patients were randomized for the maintenance question to receive chemotherapy 
(C) (n=54, 49,1%) or an immunotherapy (I) (n=56, 50,9%) based treatment. That was 
due to the fact that 51 patients relapsed during consolidation and 10 patients died in 
CR during this phase. Besides that, 5 patients refused further treatment, 5 violated the 
protocol during this phase, and in 3 patients the responsible physicians decided not to 
continue with the treatment due to excessive experienced toxicity. Nevertheless these 
patients were followed up and included in the survival analysis in order to comply 
with the intention to treat principle.    
Baseline and demographic features of the 184 selected patients are depicted in table 12. 
Immunophenotype was not available for this trial.  
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Table 12- Baseline and demographical features of the 184 patients (%) - 58741 Trial 
Gender  
 Male 
 Female 
 
109 (59) 
75 (41) 
Median age at diagnosis (Years) 5 (1-18) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
11 (5.9) 
89 (48.1) 
48 (26) 
36 (20) 
ALL immunophenotype  Not available in this trial 
Risk groups Not available in this trial 
NCI risk group 
 
 Standard 
 High-risk 
 
119 (64.7) 
65 (35.3) 
CNS involvement
 
 Not involved 
 Involved 
 
177 (96.2) 
7 (3.8) 
WBC groups at diagnosis (x10
9
/l) 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
88 (47.6) 
30 (16.3) 
40 (21.6) 
13 (7) 
13 (7) 
CNS: Central nervous system; NCI: National Cancer Institute; WBC: White blood cells. No 
immunophenotype data were available for this study.   
 
Median follow up for the whole population was 9.4 years (0.2-17.3). 
Median follow up for those patients who were still alive at last evaluation was 12.8 years 
(2.7-17). Last entry for one patient was 16 months after having started maintenance therapy. He 
was alive at that time and censored as alive at last follow up (2.7 years of follow up). If we omit 
this patient, median follow up for those patients who were still alive at last evaluation was 12.8 
years (9.2-17). 
Outcome of patients is depicted in table 13. At the time of the last evaluation 78 patients 
were still alive and in continual CR.   
The EFS rate (±1 s.e.) was 77% ± 3.2% at 1 year, 44% ± 3.7% at 5 years and 43% ± 3.7% 
at 10 years.  
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The OS rates (±1 s.e.) were 88% ± 2.4% at 1 year, 55% ± 3.7% at 5 years and 49% ± 
3.7% at 10 years. 
Table 13 - Outcome of the 184 patients (%) - 58741 Trial 
Continuous CR
a
 78 (42.2) 
Death in first CR 15 (8.1) 
Relapse 91 (49.5) 
Type of relapse 
 BM only 
 CNS only 
 Gonads only 
 CNS combinedb 
 Othersc 
 
56 (30.4) 
18 (9.8) 
6 (3.3) 
8 (4.3) 
3 (1.6) 
BM: Bone marrow; CNS: Central nervous system; CR: Complete remission 
a 
Continuous CR: Includes only patients who remain in first CR after protocol first line therapy  
b 
CNS combined included: 7 CNS and BM relapses and 1 CNS, BM and testicular relapse 
c 
Others included: 2 combined BM and testicular relapses and 1 mediastinal relapse 
 
91 patients experienced relapse. Median time to relapse was 15.7 months (0.9-123.6).  
Of those 92 patients who experienced relapse, 79 eventually died. 12 of those 92 patients 
are still alive and in CR after subsequent treatment lines.   
Median time to death for the whole population was 28 months (2.5-151.6).  
A total of 15 patients died in first CR. 10 patients died during consolidation, 4 during 
maintenance and 1 after having completed treatment. Clinical features and causes of death for 
these patients according to the different randomized treatments are depicted in table 14. 
Median time to death for those patients who died in first CR was 7.8 months (2.5-151.6). 
Most frequent cause of death among those who died in first CR was infection (11 
patients, 73.3%). Four patients died of Pneumocystis jirovecii infection, three during 
consolidation and two during maintenance. Four other patients died of disseminated varicella, 
representing all viral causes of death, two during consolidation and two during maintenance. E. 
Coli and Klebsiella were responsible in two other cases.  In one patient, the infective organism 
could not be identified.  
 In three patients chemotherapy induced hepatic toxicity was the last cause of death, two 
during consolidation and one in maintenance.  
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One patient died of an unspecified brain tumor 12.5 years (151.6 months) after first 
diagnosis of ALL and 8 years after having completed all treatment respectively, including CNS 
irradiation. No toxic deaths happened during the immunotherapy maintenance phase.  
Those 13 patients who did not proceed to the maintenance randomization due to toxicity, 
physicians’ decision or protocol violation were still alive and in CR at last follow-up.  
Table 14 - Clinical features and causes of death of the 15 patients who died in first complete 
remission (%) - 58741 Trial 
Gender  
 Male 
 Female 
 
9 (59.8) 
6 (40.2) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
3 (20) 
10 (67.6) 
1 (6.7) 
1 (6.7) 
ALL immunophenotype  Not available in this trial 
Risk groups Not available in this trial 
NCI risk group 
 
 Standard 
 High-risk 
 
12  (79.9) 
3 (20.1) 
Death period 
 P consolidation 
 M consolidation 
 P maintenance 
 M maintenance 
 Post – treatment  
 
6 (40) 
4 (26.7) 
4 (26.7) 
0 (0) 
1 (6.7) 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Unknown  
 Bleeding/Thrombosis 
 Organ toxicity  
 Transplant related mortality 
 Secondary neoplasms 
 Others 
 
11 (73.3) 
2 
4 
0 
4 
1 
0 
3 (20) 
0 
1 (6.7) 
0 
NCI: National Cancer Institute 
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1.2 Protocols 58831/58832 
These trials were opened for recruitment in July 1983 and the last patient was entered in 
June 1989. 
Patients included in both studies will be presented together in this section.  
788 patients were initially included in these trials. 
8 patients had the diagnosis of NHL and therefore excluded from this analysis.  
780 patients had the diagnosis of ALL. Among them, 735 were eligible for the evaluation 
of the induction response, whereas 45 were considered as ineligible: CNS involvement (7), 
suspicious CNS involvement in addition to other ineligibility criteria (2), unknown RF (2), 
response to treatment not evaluable (3), other reasons (31). Among the 735 eligible and 
evaluable patients, 11 were considered a posteriori by the study coordinator as having CNS 
involvement and 8 as a dubious or surreptitious involvement. However, they were included by 
the local investigators and therefore included in the analysis in order to comply with the intention 
to treat principle.   
The numbers of patients randomized to each question proposed by the trial are described 
here:  
- A total of 383 standard risk patients were randomized into two groups, to receive (n=192) 
or not  (n=191) cyclophosphamide during IB.  
- For medium and high-risk patients, a total of 183 patients were randomized into two 
groups, to receive high-doses methotrexate alone (n=90) or high doses methotrexate 
followed by cranial radiotherapy (n=93). The groups were well balanced regarding 
several initial features.  
Baseline and demographic features of the 735 selected patients are depicted in table 15. 
332 patients received any sort of pre-phase therapy before induction treatment. That was 
permitted by the protocol as long as it did not last for more than 8 days and treatment was limited 
to corticoids and/or vincristine. That was the case in all these patients. The reasons for prephase 
in this group were: leukocytosis (110), bulky disease (22), both (63) and others (137). 289 
patients received exclusively steroids and 43 a combination of steroids and vincristine.  
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Table 15 - Baseline and demographical features of the 735 patients – 58831/58332 Trial 
Gender 
 Male 
 Female                                                        
 
397 (54) 
338 (46) 
Median age at diagnosis (Years) 4.7 (0.1-17.7) 
Age groups at diagnosis (Years) 
 < 1 
 1  
 2 -5  
 6 - 9 
 ≥ 10 
 
23 (3.1) 
64 (8.7) 
368 (50.1) 
152 (20.7) 
128 (17.4) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
547 (74.4) 
94 (12.8) 
94 (12.8) 
Risk groups  
 SR 
 MR/HR 
 
463 (63) 
267 (36.3) 
NCI Risk group
a 
 Standard 
 High-risk 
 
484 (65.9) 
250 (34.1) 
CNS involvementb  
 Unknown 
 No (CNS-1) 
 Dubious 
 CNS-2 
 CNS-3 
 
0 (0) 
  716 (97.4) 
  8 (1.1) 
0 (0) 
  11 (1.5) 
WBC groups at diagnosis (x10
9
/l)
a 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
326 (44.4) 
161 (21.9) 
170 (23.1) 
48 (6.5) 
29 (3.9) 
CNS: Central nervous system; HR: High-risk; MR: Medium Risk; NCI: National Cancer 
Institute; SR: Standard risk; WBC: White blood cells 
a
 One patient with an unknown WBC at diagnosis has not been included in the table 
b
 19 patients were found a posteriori to have CNS involvement despite the trial was designed for 
patients without CNS involvement at diagnosis.  
 
A total of 707 (96.2%) patients achieved complete remission after induction.  
28 patients did not achieve a CR at the end of induction/consolidation or died before the 
response to treatment could be evaluated.  
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The EFS rate (±1 s.e.) was 92% ± 1.0% at 1 year, 70% ± 1.7% at 5 years, 68% ± 1.8% at 
10 years and the estimated OS rates (±1 s.e.) were 94% ± 0.9% at 1 year, 80% ± 1.5% at 5 years 
and 77% ± 1.6% at 10 years.  
Outcome of patients is depicted in table 16.  
Table 16- Outcome of the 735 patients (%) – 58831/58332 Trial 
No CR after induction/consolidationa 
 Induction failure 
 Early death 
28 (3.8) 
12 (1.6) 
16 (2.2) 
Continuous CRb 480 (65.3) 
Death in first CR 9 (1.2) 
Relapse 217 (29.6) 
Type of relapse 
 BM only 
 CNS only 
 Gonads only 
 CNS combinedc 
 Othersd 
 
112 (15.3) 
42 (5.7) 
8 (1.1) 
31 (4.2) 
24 (3.2) 
BM: Bone marrow; CNS: Central nervous system CR: Complete remission;  
a
 Including the 16 patients who died before they could be evaluated for response after 
induction/consolidation 
b 
Continuous CR: Includes only patients who remain in first CR after protocol first line therapy  
c 
CNS combined included: 27 combined CNS and BM, 2 CNS and gonadal and 2 CNS, BM and 
gonadal.  
d 
Others included: 14 combined BM and gonadal, 2 BM and mediastinal, 1 BM and bone, 2 BM 
and ganglionar, 1 testicular and ocular, 1 ganglionar, 1 bone and 1 ocular relapse. In 2 cases the 
data 
 
12 out of these 28 patients not achieving a CR after induction could be evaluated. In 4 
patients no evidence of response was observed and they were considered as absolutely resistant 
at the end of the consolidation. In 6 patients the best response achieved was a partial response 
(PR) at the end of consolidation. 1 patient persisted in hypoplasia for more than four weeks after 
having completed the consolidation and 1 patient presented still extra medullary disease at the 
end of the consolidation; therefore, both patients were considered no responders to 
induction/consolidation therapy. 2 of these patients continued therapy according to protocol but 
considered as failures and the other 10 underwent second line therapies according to responsible 
physicians’ decisions including 3 allogenic and 2 autologous transplants. At last follow up 5 
patients were still alive in CR.  
    
 
105 
16 out of these 28 patients died before having obtained a conclusive response to induction 
therapy and were considered as having died before a first CR was achieved.  
Two patients died before starting any anticancer therapy in the context of very-high WBC 
(475 and 489 x10
9
/l).  One patient died before leukapheresis could be started and died of DIC 
and one other died once leukapheresis was started but he did not respond and died of multi-organ 
failure. 
During induction 9 patients died before they could be evaluated for response and 5 other 
patients were found to have hypoplastic bone marrow after induction and died before proceeding 
to consolidation. 6 of these 14 patients were given any sort of pre-phase treatment (4 due to 
leukocytosis, 1 due to leukocytosis and bulky disease and 1 for other reason). Clinical features 
and causes of death for these patients are pictured in table 17. 
Most frequent type of death in this group of 16 patients was infection (11 patients, 
68.8%). Bacterial organisms represented the majority of infectious related deaths, mainly 
Streptococcus pyogenes (4) and Pseudomonas (3); one patient died of a septic shock of probably 
urinary origin by E. Coli and Klebsiella. In second place fungal organisms, two pulmonary and 
one cerebral aspergillosis. Five patients died of bleeding complications, mainly intracranial 
hemorrhage (3) and DIC (2). In one of the patients with cerebral hemorrhage there was a 
pulmonary aspergillosis associated and in one patient with DIC there was a sepsis by 
Streptococcus pyogenes associated. One patient with a pulmonary aspergillosis experienced also 
necrotizing enterocolitis (‘other’ in table). One patient with congenital undifferentiated ALL 
presented with very high WBC (960 x10
9
/l). He died on day 48 after having completed IA but 
whose response could not be evaluated and was considered of having died of disease in the 
absence of any other reasonable cause of death.  
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NCI: National Cancer Institute 
a  
One patient died of a sepsis of urinary origin by E. Coli and Klebsiella 
 
b 
One patient died of pulmonary aspergillosis and cerebral hemorrhage; another one died of Streptococcus pyogenes 
sepsis and DIC. These 2 patients have been categorized in the infection group and bleeding group. One patient died 
of DIC in the context of hyperleukocytosis and he has been categorized in the group of bleeding and tumor burden.  
c 
One patient died of necrotizing enterocolitis and had pulmonary aspergillosis  
Table 17- Clinical features and causes of death of the 16 patients who died before getting 
into complete remission (Early Deaths) (%) - 58831/2 Trials  
Gender  
 Male 
 Female 
 
6 (37.5) 
10 (62.5) 
Time period of death  
 Death before treatment 
 Death during pre-phase 
 Death during induction 
 
2 (12%) 
0 (0%) 
9 (88%) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
1 (6.3) 
1 (6.3) 
7 (44.1) 
3 (18.9) 
4 (25.2) 
WBC groups at diagnosis (x10
9
/l) 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
9 (55.8) 
2 (12.6) 
1 (6.3) 
1 (6.3) 
3 (18.9) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
12 (75.8) 
2 (12.6) 
2 (12.6) 
NCI Risk group
 
 Standard 
 High-risk 
 
8 (50) 
8 (50) 
Cause of death
 
 Tumour burden  
 Infection 
 Bacteriala 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Others 
 Bleeding/Thrombosisb  
 ALL progression 
 Othersc 
 
2 (10) 
11 (55) 
8 
0 
3  
0 
0 
5/0 (25) 
1 (5) 
1 (5) 
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Nine patients received an HSCT in first CR as consolidation therapy between September 
1986 and November 1989. 8 patients had an allogeneic HSCT while only one had an autologous. 
3 of these patients died afterwards. 2 patients receiving an allograft died of causes related to the 
transplant as described below and the patient receiving the auto graft relapsed in the marrow 
eleven months later and subsequently died of disease. 
Nine patients died in first CR at some point during treatment. Median time to death for 
this group of patients was 0.7 years (0.2-2.2). These patients are displayed in table 18. 
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Table 18 - Clinical features and causes of death of the 9 patients who died in first complete 
remission (%) – 58831/2 Trials 
Gender  
 Male 
 Female 
 
7 (77.8) 
2 (22.2) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
1 (11.1) 
6 (66.6) 
0 (0) 
2 (22.2) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
5 (55.5) 
2 (22.2) 
2 (22.2) 
Risk groups  
 Standard Risk 
 Medium Risk 
 High-Risk 
 
5 (55.5) 
3 (33.3) 
1 (11.1) 
NCI Risk group
 
 Standard 
 High-risk 
 
6 (66.6) 
3 (33.4) 
Death period 
 Interval therapy 
 Protocol II 
 HSCT 
 Maintenance 
 Post – treatment  
 
2 (22.2) 
1 (11.1) 
2 (22.2) 
4 (44.4) 
0 (0) 
 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Others 
 Bleeding/Thrombosis 
 Organ toxicity  
 Transplant related  
 Secondary neoplasms 
 Others 
 
 
4 (44.4) 
0 
3 
1 
0 
0 
0 (0) 
0 (0) 
2 (22.3) 
0 (0) 
3 (33.3) 
HSCT: Hematopoietic stem cell transplantation; NCI: National Cancer Institute; WBC: White 
blood cell(s) 
 
    
 
109 
Most frequent cause of death among these 9 patients was infection (4 patients, 44.4%). 
Viral infections accounted for the majority of events (3), two measles induced pneumopathy and 
one ECHO virus 6 encephalopathy and pneumopathy. All of them occurred during maintenance. 
Pulmonary aspergillosis resulted in death in one patient during Protocol II.  
Two of these patients died after having received an allogenic transplant in first CR 
meaning for a TRM of 22.2% (2 cases of TRM in 9 patients who received a graft in first CR).  
The first one was found to be positive for the Philadelphia chromosome at the end of the 
consolidation. For that reason, this patient was decided to receive a matched related allogeneic 
transplant after consolidation therapy. He died two months after transplant of conditioning 
regimen related toxicity.  
The second patient received the interval and protocol therapies according to trial 
directions. He underwent a matched related allogeneic transplant after protocol II and died one 
month later of a capillary leak syndrome related to the conditioning regimen and cyclosporine 
toxicity.  
Three patients form the category of others.  
Two patients died of malignant systemic histiocytosis during treatment, one after interval 
therapy and one during maintenance. Presentation was similar in both cases with malaise, fevers, 
anemia, and splenomegaly. One patient presented also bone, bone marrow and pleural invasion 
of histiocytes.  No evidence of leukemic cells was found in any of the biological samples tested 
and infectious causes were thoroughly ruled out. Progression of the disease was extremely quick 
in first case. Second patient received a course of COPAD chemotherapy and achieved a CR but 
died of cardiac arrest days after the start of salvage treatment.  
Only one patient died of a non-toxic cause. Last cause of death was assumed by the 
investigators to be a supraventricular tachycardia (SVT) related to the manipulation of the central 
venous catheter (CVC) during a flushing procedure. Autopsy was inconclusive suggesting the 
possibility of fat emboli. 
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1.3 Protocol 58881 
This trial was opened for registration in January 1989 and the last patient was entered in 
November 1998.  
2216 patients were initially included in this trial.  
2077 had the diagnosis of ALL while 139 had the diagnosis of NHL and therefore not 
included in this study.  
12 out of the 2077 ALL patients could not be evaluated for response due to lack of 
information (3), protocol violation (1), and treatment refusal (1) or other reasons (7). That 
yielded 2065 patients fully evaluable for this study. 
The numbers of patients randomized to each question proposed by the trial are described 
here:  
- 653 ALL children were randomized to receive Escherichia Coli asparaginase or Erwinia 
asparaginase 
- 593 patients were randomized to two groups to test the value of cytarabine in interval 
therapy 
- 820 patients were randomized into two groups for maintenance therapy without or with 
i.v. Mercaptopurine.  
Baseline and demographic features of the 2065 selected patients are depicted in table 19. 
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Table 19 - Baseline and demographical features of the 2065 patients (%) – 58881 Trial 
Sex  
 Male 
 Female                                                        
 
1163 (56.3) 
902 (43.7) 
Median age at diagnosis (Years)  4 (0-17) 
Age groups at diagnosis (Years) 
 < 1 
 1  
 2 -5  
 6 - 9 
 ≥ 10 
 
60 (2.9) 
 160 (7.7) 
 1079 (52.3) 
 405 (19.6) 
 361 (17.5) 
Immunophenotype 
 B-Lineage 
 T-Lineage                                           
 
1766 (85.5) 
299 (14.5) 
NCI Risk group a
 
 Standard 
 High-risk 
 
1305 (63.2) 
759 (36.8) 
CNS involvement  
 Unknown 
 No (CNS-1) 
 Dubious 
 CNS-2 
 CNS-3 
 
18 (0.9) 
  1889 (91.5) 
  53 (2.6) 
  51 (2.5) 
  54 (2.6) 
WBC groups at diagnosis (x109/l)a 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
915 (44.3) 
 384 (18.6) 
469 (22.7) 
167 (8.1) 
128 (6.2) 
CNS: Central nervous system; NCI: National Cancer Institute; WBC: White blood cell(s) 
a
 One patient with an unknown WBC at diagnosis, has not been included in the table.  
 
32 ALL patients were Down syndrome.  
Median follow up for the whole population was 7.4 years (0-18.2). 
Median follow up for those patients who were still alive at last evaluation was 8.3 years 
(1.3-18.2). 
2019 (97.7%) patients achieved a CR at the end of induction/consolidation. 
46 patients (1.8%) did not achieve a CR at the end of induction/consolidation or died 
before the response to treatment could be evaluated.  
Outcome of patients is shown in table 20. 
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Table 20 - Outcome of the 2065 patients (%) – 58881 Trial 
No CR after induction/consolidation
 a
 
 Induction failure 
 Early death 
46 (2.2) 
27 (1.3) 
19 (0.9) 
Continuous CR
 b
 1443 (69.9) 
Death in first CR 64 (3.1) 
Relapse 510 (24.7) 
Type of relapse 
 BM only 
 CNS only 
 Gonads only 
 CNS combined 
 Others 
 
299 (14.5) 
71 (3.4) 
24 (1.2) 
77 (3.7) 
39 (1.9) 
BM: Bone marrow; CNS: Central nervous system; CR: Complete remission  
a
 Including the 19 patients who died who died before they could be evaluated for response after 
induction  
b 
Continuous CR: Includes only patients who remain in first CR after protocol first line therapy  
 
The overall EFS rate (±1 s.e.) was 94% ± 0.5% at 1 year, 75% ± 1% at 5 years, 73.3% ± 
1% at 8 years and 73% ± 1.1% at 10 years and the estimated survival rates were 96% ± 0.4% at 1 
year, 84% ± 0.8% at 5 years and 81% ± 0.9% at 10 years. 
83 patients received a HSCT in first CR. Of those patients 79 had an allogeneic HSCT 
while 4 had an autologous.  
Donor type for those who received an allo-HSCT was: matched sibling donor (MSD) 
(52), matched unrelated donor (MURD) (17), haploidentical (4), mismatched related donor 
(MMRD) (3), mismatched unrelated donor (MMURD) (1), cord blood (CB) (1) and not known 
in one patient.  
20 ALL patients developed a secondary neoplasm during or after treatment, 16 in first 
CR, 2 in second CR and 2 in partial remission. They could be split among: acute myeloid 
leukemia (AML) (9), bone/soft tissues sarcomas (3), Hodgkin lymphoma (2), papillary thyroid 
carcinoma (2), B-Cell NHL (1), renal PNET (1), cutaneous histiocytosis (1) and peritoneal 
carcinomatosis (1).  
19 patients died before getting into complete remission. These patients’ characteristics 
are displayed in table 21. 
Most frequent type of death among these 19 patients was infection (10 patients, 52.6%). 
Bacterial organisms represented the majority of infectious related deaths, mainly Streptococcus 
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(3) and Pseudomonas (3), followed by fungal organisms (one pulmonary aspergillosis with 
associated sepsis by pseudomona), and others unknown but presumably bacterial (3). One of 
these patients was found to have an interstitial pneumonia. Despite all efforts made to identify 
the cause the patient died in the context of respiratory failure but the organism could not be 
identified.  
Five patients died before any treatment could be initiated: 1 sepsis by Streptococus, 1 
ARDS, 1 multi-organ failure in the context of a very high WBC (1.250 x10
9
/l) and associated 
Streptococcus infection that did not respond to leukapheresis, 1 cerebral hemorrhage with high 
WBC count (580 x10
9
/l) and 1 patient was considered to have died of progressive ALL before 
any anticancer therapy could be started 
During induction, intracranial hemorrhage was responsible for death in 2 patients; one 
with a very high WBC count (600 x10
9
/l). Two patients died of gastrointestinal bleeding during 
induction. Two other patients died in the context of an adult respiratory distress syndrome 
(ADRS) and veno-occlusive disease (VOD).  
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Table 21- Clinical features and causes of death of the 19 patients who died before getting into 
complete remission (Early Deaths) (%) - 58881 
Gender  
 Male 
 Female 
 
8 (42.1) 
11 (57.9) 
Time period of death  
 Death before treatment 
 Death during pre-phase 
 Death during induction 
 
5 (26.3) 
5 (26.3) 
9 (47.4) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
7 (37.1) 
2 (10.6) 
4 (21.2) 
1 (5.3) 
5 (26.5) 
WBC groups at diagnosis (x10
9
/l) 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
7 (37.1) 
0 (0) 
2 (10.6) 
4 (21.2) 
6 (31.8) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
17 (89.4) 
2 (10.6) 
0 (0) 
NCI Risk group
 
 Standard 
 High-risk 
 
4 (21.2) 
15 (78.8) 
Cause of death
 
 Tumour burden a 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Unknown 
 Bleeding/Thrombosis  
 ALL progression 
 Others c 
 
1 (5) 
10 (50) 
6 
0 
1 
0 
3 
5/0 (25) 
1 (5) 
3 (15) 
NCI: National Cancer Institute; WBC: White blood cell(s) 
a   
One patient died of leukostasis related complications and Streptococcus sepsis. He has been 
categorized in the tumour burden group and in the infection group.  
c
  Others: 2 ARDS (one during pre-phase, one in induction) and 1 VOD.  
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A total of 64 patients died in CR and they are presented in table 22. 
Infection was the most frequent cause of death in these 64 patients when considering also 
the infections leading to death after bone marrow transplant (21 during chemotherapy and 11 
after HSCT respectively, 50%).   
For those who did not undergo a bone marrow transplant, bacterial organisms represented 
the majority of infectious related deaths with no specific predominant organism: E. Coli (1), 
Lysteria monocytogenes (1), Mycoplasma pneumoniae (1), Enterobacter (1), Staphylococus 
epidermidis, and three bacterial organisms but not confirmed the specie.  
Viruses were responsible for death in four cases, two measles induced pneumopathy, one 
secondary hemophagocytic lymphohistiocytosis (HLH) driven by EBV and one Influenza B 
induced myocardiopathy. Three events happened during maintenance and one during R2 block. 
Aspergillus was the most frequent fungal organism responsible for death in first CR (4) followed 
by Candida (2), mostly during consolidation therapy and one fungal infection but not confirmed 
the specie.  
Two patients died of pulmonary embolism (PE). In one case it was related to the CVC 
recently inserted during phase IIA in a patient with congenital stenosis of pulmonary arteries but 
the autopsy confirmed that the embolism was not related to the cardiac abnormality. The other 
patient died of PE suspected of being of fungal origin but with un-identified organism.  
Six patients were grouped in the category of death of organ toxicity. The assessment of 
relationship was made by the local investigators: one of anthracycline cardiac related toxicity 
(cumulative doses of Daunurubicin 120mg/m
2 
and Doxorubicin 120mg/m
2
), one of toxic 
epidermal toxicity (Lyell’s syndrome), one of undefined hepatic toxicity and one of pancreatitis 
related to native E. Coli Asparaginase. One patient died of renal toxicity related to MTX and 
Enterobacter Cloacae sepsis and one of myocardiopathy related to anthracycline toxicity and 
Influenza B infection. This later patient was treated in the very high-risk group and had already 
received 220mg/m
2
 of Daunorubicin and 16mg/m
2
 of Mitoxantrone.  
Six patients died of other causes: one undefined pulmonary disease in a patient with 
ataxia telangiectasia syndrome, one undefined neurological/cardiological disease, one primary 
HLH, one macrophage activation syndrome (MAS), one patient that experienced a cardiac arrest 
when was inserted a CVC in the context of a Candida sepsis and one sudden death at home. 
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Autopsy was not performed in this patient with unclear causes although last evaluation was 
normal. Five events happened while on treatment.  
22 patients died of causes directly related to the bone marrow transplant procedure itself 
accounting for a TRM of 26.5% (22 cases of TRM in 83 patients who received a graft in first 
CR). In 12 cases the transplant was performed from a MSD, in 6 cases from a MURD, in 2 cases 
from a haploidentical donor, in 1 from a MMURD and in 1 from a mismatched CB donor.  
Causes of death in this group could be split among: infection (11), GVHD (7), 
intracranial hemorrhages (2) and others (2). 
Infection was the most frequent cause of death in patients receiving a transplant. Fungal 
infections were the most common causes of death after graft, responsible in 5 cases (4 
Aspergillus and one Candida). Viruses, including a post-transplant limphoproliferative disorder-
EBV mediated, one disseminated HSV and one Papillomavirus related leukoencephalopathy, 
were responsible for 3 deaths. Toxoplasmosis involving the brain and the lung was the cause of 
death in 2 patients respectively.  In one patient the cause of death was a septic episode but the 
germ could not be identified.   
Acute GVHD was the cause in 3 patients while chronic was in 4 patients. 4 of these 
patients had received the cells from a matched sibling donor while 3 from a MUD. 
Intracranial hemorrhages were responsible of death in 2 patients.  
Finally, one patient died of an undefined lung insufficiency and other developed an 
ARDS, the causes of which could not be identified.  
11 ALL patients who achieved CR after first line therapy and developed a second 
neoplasm died of this second malignancy (10) or related toxicity (1). That was the case in one 
patient who developed a secondary AML and died days after of the bone marrow transplant 
while in CR for the AML due to conditioning regimen related toxicity. Only one patient who 
developed AML had received epipodophyllotoxins in first line.  
Therefore, AML was responsible for death in 7 patients while the other 4 died from 
Ewing sarcoma, adult type sarcoma, peritoneal carcinomatosis and pulmonary epithelioma with 
cerebral involvement.  
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Table 22 - Clinical features and causes of death of the 64 patients who died in first complete 
remission (%) – 58881 Trial 
Gender  
 Male 
 Female 
 
36 (56.3) 
28 (33.7) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
1 (1.6) 
3 (4.7) 
19 (29.7.2) 
15 (23.4) 
26 (40.6) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 
49 (76.6) 
15 (23.4) 
NCI Risk group
 
 Standard 
 High-risk 
 
23 (35.9) 
41 (64.1) 
Death period 
 Consolidation 
 Interval therapy 
 Protocol II 
 Blocs 
 HSCT 
 Maintenance 
 Post – treatment  
 
9 (14.1) 
3 (4.7) 
10 (15.6) 
2 (3.1) 
22 (34.4) 
10 (15.6) 
8 (12.5) 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal a 
 Pneumocystis jirovecii 
 Others 
 Bleeding/Thrombosis b 
 Organ toxicity c  
 Transplant related  
 Secondary neoplasms 
 Others 
 
19 (30.9) 
8 
4 
7 
0 
0 
0/2 (2.9) 
6 (8.7) 
22 (32.3) 
11 (16) 
6 (8.8) 
NCI: National Cancer Institute; HSCT: Hematopoietic stem cell transplantation 
a 
One patient died of combined infection of S. Aureus and Candida sepsis 
b 
One patient experienced PE related to a undefined fungal infection 
c 
One patient died of Grade IV renal toxicity related to MTX and Enterobacter Cloacae sepsis 
and one patient died of a myocardiopathy related to anthracyclines and Influenza B infection. 
They have been categorized in the group of infection and therapy induced toxicity.  
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1.4 Protocol 58951 
This trial was opened for registration in December 1998 and August 2008.  
1947 patients with newly diagnosed ALL were enrolled in the EORTC 58951 trial. Nine 
were considered ineligible (6 had been already treated with steroids and 3 because they had 
another disease rather than ALL). 
At the time of finishing collecting the data for this cohort (Year 2012), data was not 
mature enough and therefore the analysis of outcome and risk factors regarding toxic deaths in 
this population was not possible, as it has been done for previous protocols.  
Therefore, only a descriptive analysis of toxic deaths for this trial will be performed.  
98 patients underwent bone marrow transplantation in first complete remission.  
14 patients died before achieving a first complete remission (0.7%) and 35 in first 
complete remission (1.8%). 
Clinical features and causes of death for these patients are presented in tables 23 and 24. 
In those who died before getting into remission, most frequent type of death was 
infection (13 patients, 92.8%). Bacterial organisms were represented by: Enterobacter cloacae 
(3), Streptococus B (2), Proteus (2), Staphylococus haemoliticus (1), Pseudomonas (2), E. Coli 
(3). In three cases there were two bacterial agents that were considered cause of infection leading 
to death. There were 3 patients who died from pulmonary invasive aspergillosis. One patient died 
of a gastrointestinal bleeding. In this patient a pulmonary co-infection by Pseudomonas was 
evidenced.  
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Table 23- Clinical features and causes of death of the 14 patients who died before getting into 
complete remission (Early Deaths)  (%) - 58951 
Gender  
 Male 
 Female 
 
5 (35.7) 
9 (66.3) 
Time period of death  
 Death before treatment 
 Death during pre-phase 
 Death during induction 
 
0 (0) 
0 (0) 
14 (100) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
0 (0) 
5 (35.7) 
5 (35.7) 
4 (28.5) 
WBC groups at diagnosis (x10
9
/l) 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
4 (28.5) 
4 (28.5) 
6 (43) 
0 (0) 
0 (0) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
10 (75) 
4 (25) 
0 
NCI Risk group
 
 Standard 
 High-risk 
 
10 (71.4) 
4 (28.6) 
Cause of death
 
 Tumour burden  
 Infection 
 Bacterial a 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Others 
 Bleeding/Thrombosis  
 ALL progression 
 Others 
 
0 (0) 
13 (92.8) 
13 
0 
3 
0 
0 
1/0 (7.2) 
0 (0) 
0 (0) 
NCI: National Cancer Institute; WBC: White blood cell(s) 
a
 Three patients experienced a combined bacterial infection 
 
A total of 35 patients died in first complete remission. They are presented in table 24.  
Infection was the most frequent cause of death in these patients when considering also the 
infections leading to death after bone marrow transplantation (16 patients during chemotherapy, 
and 4 in transplant patients).   
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Among those who received conventional chemotherapy, bacterial organisms represented 
the majority of infectious related deaths with no specific predominant microorganism: E. Coli 
(2), Proteus (1), Streptotocus (1), Pseudomona (1) and Enterococus (1). One patient developed a 
macrophage activation syndrome (MAS) related to Flavimonas Oryzihabitans. Two patients died 
of a sepsis of unknown origin (one of them with associated pulmonary hemorrhage and 
thrombosis).  
Viruses were responsible in 2 cases (2 during chemo and 2 during HSCT). In those 
treated with chemo there were one VHB infection and one varicella pneumonia. 
4 patients had fungal infections, 3 Aspergillus and 1 Candida, all in patients getting 
chemotherapy, during phases of intensive therapy (Protocol II and VANDA).  
One patient in this trial died of a Pneumocistiss Jiroveciii lung infection. This patient was 
under prophylaxis for this germ, but despite this he developed this infection. This patient was 
treated with high doses  but the infection progressed and finally died.  
One patient had diffuse pulmonary and gastrointestinal hemorrhage.  
In the group of others, two patient developed and ARDS, two MAS of unknown origin, 
one systemic vasulitis, one cardiomyopathy not related to anthracyclines and one accident after 
finishing treatment. One patient had a cardiogenic shock; the autopsy suggested that it may had 
been related to a viral infection but it could not finally confirmed.  
Transplant related mortality in this cohort was lower than in the previous trial: 7 out of 98 
patients transplanted in first remission died (TRM=7,1%). Among those patients who were 
transplanted: 
- 4 died of infection: 1 PTLD-EBV driven, 1 systemic adenovirus with fulminant hepatitis 
and multi-organ failure (MOF), 1 VZV encephalitis and one bacterial infection non 
identified.   
- 2 died of graft-versus host disease (1 acute and one chronic) 
- 1 died of MOF of un-identified origin  
3 patients developed a secondary malignancy leading to death: 2 AML, 1 
meduloblastoma. One AML and the medulloblastoma occurred during maintenance therapy.  
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Table 24 - Clinical features and causes of death of the 35 patients who died in first complete 
remission (%) – 58951 Trial 
Gender  
 Male 
 Female 
 
21 (60) 
14 (40) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
2 (5.7) 
13 (37.1) 
6 (17.1) 
14 (40) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 
27 (77.1) 
8 (22.9) 
NCI Risk group
 
 Standard 
 High-risk 
 
14 (40) 
21 (60) 
Death period 
 Consolidation 
 Interval therapy 
 Protocol II 
 Blocs 
 VANDA 
 HSCT 
 Maintenance 
 Post – treatment 
 
5 (14.3) 
1 (2.9) 
7 (20) 
3 (8.6) 
6 (17.1) 
7 (20) 
4 (11.4) 
2 (5.7) 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Unknown  
 Bleeding/Thrombosis a 
 Organ toxicity 
 Transplant related  
 Secondary neoplasms 
 Others 
 
16 (44.4) 
7 
2 
4 
1 
2 
1/1 (5.5) 
0 (0) 
7 (19.4) 
3 (8.3) 
8 (22.2) 
NCI: National Cancer Institute; HSCT: Hematopoietic stem cell transplantation 
a
 One patient had sepsis of unknown origin and associated pulmonary thrombosis and 
hemorrhage and he has been included in the group of infection and thrombosis.  
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1.5 Summary of results 
A significant reduction of all treatment related deaths has been observed between the 
58741 protocol (8.1%) and the three other trials (3.4%, 3.9% and 2.5% respectively) (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
On average, the rate of toxic deaths in all four trials is 4.5%. If we exclude the 58741 trial 
that has the highest rate of toxicity and was performed early in the decade of the 70´s, the rate is 
3.3%.  
A detailed summary of infective and non-infective treatment related deaths by category, 
protocol and phase of protocol in Appendix 2. 
 
Figure 12. Percentage of treatment related deaths by category 
Early death 
58831/2 Vs 58881: # χ2=1296.9; df=1; p=<0.001 
58831/2 Vs 58951: ## χ2=1434.1; df=1; p=<0.001 
Death in complete remission 
58741 Vs 58831/2: * χ2=393; df=1; p=<0.001 
58741 Vs 58881: ** χ2=556.1; df=1; p=<0.001 
58741 Vs 58951: *** χ2=417.1; df=1; p=<0.001 
All treatment related deaths 
58741 Vs 58831/2: + χ2=243.9; df=1; p=<0.001 
58741 Vs 58881: ++ χ2=658.9; df=1; p=<0.001 
58741 Vs 58951: +++ χ2=944.5; df=1; p=<0.001 
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1.5.1 Early death 
49 patients died before remission out of 4732 patients at risk (1% of all patients) (Patients 
from protocol 58741 are not included in this section because this trial only included patients once 
in remission). 
A progressive significant reduction of deaths before remission has been observed in the 
last three protocols (58831/2, 58881 and 58951; 2.2%, 0.9% and 0.7% respectively) (Figure 12).  
Table 25 – Risk factors during induction in the 58831/2 and 58881 trials 
FACTORS Total Observed Expected P-value Odds 
ratio 
95% Confidence 
Interval 
GENDER    0.013
*
 2.92 1.26-6.80 
- Female 1240 21 15.5    
- Male 1559 14 19.5    
AGE (Years)    0.035 1.47 1.04-2.10 
- < 1 83 8 1    
- ≥ 1 and < 2 224 3 2.8    
- ≥ 2 and < 6 1447 11 18.1    
- ≥ 6 and < 10 557 4 7    
- ≥ 10  488 9 6.1    
WBC (x10
9
/l)    0.098 1.43 0.94-2.19 
- < 10 1240 16 15.1    
- ≥ 10 and < 25 545 2 6.6    
- ≥ 25 and < 100 639 3 7.8    
- ≥ 100 and < 250 215 5 2.6    
- ≥ 250  157 8 1.9    
NCI Risk Group    0.001 5.25 1.99-13.79 
- High  1008 23 12.6    
- Standard 1789 12 22.4    
CNS Involvement    0.059 3.21 0.96-10.77 
- Yes 177 4 1.8    
- No 2604 24 26.2    
IMMUNOPHENOTYPE    0.866 0.89 0.24-3.34 
- T 393 4 4.9    
- B 2313 29 29.1    
PROTOCOL    0.000 4.69 2.10-10.45 
- 58831/2 735 16 9.2    
- 58881 2065 19 25.8    
 
CNS: Central nervous system; NCI: National Cancer Institute; WBC: White blood cells 
* In grey tone background variables that achieved statistical significance (p<0.05) 
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In the multivariate analysis age, female gender, NCI-High Risk and those having been 
treated in the 58831/2 protocols were variables significantly associated with an increased risk of 
dying before remission (Table 25).  
Regarding age, patients aged less than one year had an odds ratio of 9.7 (95% CI 4.5-
20.7, p=0.000) of dying before remission compared with all other groups.   
A table summarizing the clinical features and causes of death before remission across all 
trials is presented below (Table 26).   
Before remission, most frequent type of death was infection (n=34, 62.9%). Among 
infections, bacterial (n=27, 73%) and fungal organisms (n=7, 19%) represented the most frequent 
causes (Figure 13). Bacterial organisms are mostly represented by Streptococcus (n=9, 26%) and 
Pseudomonas (n=7, 21%) while Aspergillus was the only fungal infective organism (n=7, 20%) 
(Figure 14) (Appendix 2, Table A). 
Before remission, bleeding disorders were the second most frequent type of death (n=11, 
20.4%), mainly intracranial hemorrhages (n=6) and gastrointestinal hemorrhages (n=3). DIC was 
mostly observed in patients with high WBC at diagnosis and often in the context of an associated 
infection (n=2). The incidence of tumor burden related deaths has been low across the years 
when compared with the rest of causes (n=3, 5.6%) (Figure 15)  (Appendix 2, Table B).  In the 
last trial, the 58951, non-infective deaths have practically disappeared (n=1; 7.2%). 
In the last 58951 trial, there were not patients dying before anti-leukemia treatment could 
be initiated while there were 7 in the previous trials dying in this period.  
One patient dying from necrotizing enterocolitis and pulmonary aspergillosis in trial 
58831/2 and 2 patients with ARDS and 1 VOD in the 58881 represent the category of other 
causes (n=4).  
 
 
Figures 13-14. Types of infective deaths before remission and by organism 
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Figure 15. Non-Infective deaths before remission 
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Table 26- Clinical features and causes of death of all the patients who died before getting into 
complete remission (Early Death) (%)  
PROTOCOL 58831/2 58881 58951 TOTAL 
Total 16 (32.7) 19 (38.8) 14 (28.5) 49 (100) 
Gender  
 Male 
 Female 
 
6 (37.5) 
10 (62.5) 
 
8 (42.1) 
11 (57.9) 
 
5 (35.7) 
9 (66.3) 
 
19 (38.8) 
30 (61.2) 
Time period of death  
 Death before treatment 
 Death during pre-phase 
 Death during induction 
 
2 (12) 
0 (0) 
14 (88) 
 
5 (26.3) 
5 (26.3) 
9 (47.4) 
 
0 (0) 
0 (0) 
14 (100) 
 
7 (14.2) 
5 (10.2) 
37 (75.6) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
1 (6.3) 
1 (6.3) 
7 (44.1) 
3 (18.9) 
4 (25.2) 
 
7 (37.1) 
2 (10.6) 
4 (21.2) 
1 (5.3) 
5 (26.5) 
 
0 (0) 
0 (0) 
5 (35.7) 
5 (35.7) 
4 (28.5) 
 
8 (16.3) 
3 (6.1) 
16 (32.6) 
9 (18.4) 
13 (26.5) 
WBC groups at diagnosis (x10
9
/l) 
 < 10 
 < 25 
 < 100 
 < 250 
 ≥ 250 
 
9 (55.8) 
2 (12.6) 
1 (6.3) 
1 (6.3) 
3 (18.9) 
 
7 (37.1) 
0 (0) 
2 (10.6) 
4 (21.2) 
6 (31.8) 
 
4 (28.5) 
4 (28.5) 
6 (43) 
0 (0) 
0 (0) 
 
20 (40.8%) 
6 (12.2) 
9 (18.4) 
5 (10.2) 
9 (18.4) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Not available 
 
12 (75.8) 
2 (12.6) 
2 (12.6) 
 
17 (89.4) 
2 (10.6) 
0 (0) 
 
10 (75) 
4 (25) 
0 
 
39 (79.6) 
8 (16.3) 
2 (4.1) 
NCI Risk group
 
 Standard 
 High-risk 
 
8 (50) 
8 (50) 
 
4 (21.2) 
15 (78.8) 
 
10 (71.4) 
4 (28.6) 
 
22 (44.9) 
27 (55.1) 
Cause of death
 
 Tumour burden  
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Unknown 
 Bleeding/Thrombosis  
 ALL progression 
 Others 
 
2 (10) 
11 (55) 
8 
0 
3  
0 
0 
5/0 (25) 
1 (5) 
1 (5) 
 
1 (5) 
10 (50) 
6 
0 
1 
0 
3 
5/0 (25) 
1 (5) 
3 (15) 
 
0 (0) 
13 (92.8) 
13 
0 
3 
0 
0 
1/0 (7.2) 
0 (0) 
0 (0) 
 
3 (5.6) 
34 (62.9) 
27 
0 
7  
0 
3 
11/0 (20.4) 
2 (3.7) 
4 (7.4)  
NCI: National Cancer Institute; WBC: White blood cell(s) 
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1.5.2 Death in first complete remission 
123 patients died in complete remission. 
A significant reduction of death rates in first complete remission was especially evident 
between the 58741 protocol (8.1%) and all three others (1.2%, 3% and 1.8% respectively) 
(Figure 12).  On average, the rate of toxic deaths in remission in all four trials was 3.5%. If we 
exclude the 58741 trial that was conducted early in the 70´s, the rate was 2%.  
Table 27 – Risk factors in remission in the 58741 and 58831/2-58881 trials 
FACTORS Total Observed Expected P-value Odds 
ratio 
95% Confidence 
Interval 
GENDER    0.851 0.95 0.56-1.60 
- Female 1282 36 38.8    
- Male 1627 52 49.2    
AGE (Years)    0.022
*
 0.709 0.53-0.95 
- < 1 72 1 2.2    
- ≥ 1 and < 2 229 7 6.9    
- ≥ 2 and < 6 1512 35 45.7    
- ≥ 6 and < 10 590 16 17.8    
- ≥ 10  506 29 15.3    
WBC (x10
9
/l)    0.618 1.068 0.82-1.38 
- < 10 1304 27 39.5    
- ≥ 10 and < 25 565 17 17.1    
- ≥ 25 and < 100 669 28 20.2    
- ≥ 100 and < 250 220 11 6.7    
- ≥ 250  150 5 4.5    
NCI Risk Group    0.324 1.43 0.79-2.91 
- High  1026 47 31    
- Standard 1882 41 57    
CNS Involvement    0.459 0.65 0.22-2.01 
- Yes 173 4 5.2    
- No 2726 83 81.8    
IMMUNOPHENOTYPE    0.698 1.15 0.58-2.28 
- T 377 17 10.2    
- B 2313 54 60.8    
HSCT in first remission    0.000 17.07 9.02-32.30 
- Yes 92 24 2.8    
- No 2817 64 85.2    
PROTOCOL    0.000 3.22 1.81-5.74 
- 58741 184 15 5.6    
- 58831/2-58881 2725 73 82.4    
 
CNS: Central nervous system; HSCT: Hematopoietic stem cell transplantation; NCI: National Cancer Institute; 
WBC: White blood cell(s) 
* In grey tone background variables that achieved statistical significance (p<0.05) 
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In the multivariate analysis age, having been transplanted in first remission and having 
been treated in the 58741 trial were significantly associated with an increased risk of dying in 
remission (Table 27).  
Regarding age, patients aged >10 years were at a significant increased risk of death in 
remission when compared with all other groups together (p=0.000; OR 2.45; 95% CI 1.51-3.80). 
Patients above ten years represented 33% of deaths in remission in trials 58741 to 58881.  
A table summarizing the clinical features and causes of death in remission across all trials 
is presented below (Table 28).  
Infection was the most frequent cause of death in first CR both on conventional 
chemotherapy and after HSCT. For those who died of infection receiving conventional 
chemotherapy in first CR, bacterial infections are the most frequent cause of death (n=18; 36%) 
(Figure 16). Second and third causes are virus (n=13; 26%) and fungus (n=12; 24%), though the 
pattern of infective organisms has notably changed (Appendix 2, table A). 
In the trial 58741 (1970-1980) four patients deceased due to Pneumocystis jirovecii 
infections. Since the introduction of systematic Pneumocystis jirovecii prophylaxis in the early 
80´s for protocol 58831/2 and subsequent trials, no related death to this organism has been 
reported so far until the 58951 trial where one fatal case has been reported. In trial 58741, four 
patients experienced fatal varicella infections; fatal varicella infections have not been reported 
during trials 58831/2, 58881 but one case of varicella pneumonia has been described in 58951. 
On the other hand, in trials 58831/2 and 58881 measles induced pneumopathy has been as the 
most frequent viral organism (n=4). All these cases happened between 1998 and 1991, 3 were 
boys and 1 girl. Aspergillus remains the most common fungal organism death responsible in first 
CR (n=8).  
Transplant related mortality was high in trials 58831/2 and 58881 (22% and 26% 
respectively) and became notably lower in the last trial, the 58951 (7%). 31 patients died from 
HSCT related toxicities (Figure 17). For those who undergo HSCT in first CR, infections 
represent the most frequent type of death (n=15, 48.8%) (Figure 18). Among infections virus are 
the most common organisms (40%) followed by fungal infections (33.3%), mainly represented 
by Aspergillus, and in third place are parasites, both cases by Toxoplasma (13.3%) (Figure 19). 
Infective deaths were not reported after HSCT in trial 58831/2, probably due to the global low 
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number of transplants performed in first CR at that time. Second most frequent cause remains 
GVHD, followed by hemorrhages, non-specific multiorgan failure (MOF) or related conditioning 
regimen toxicity (Table 29).   
Secondary malignant neoplasms represent an important part of deaths in first CR 
(11.9%), mainly due to secondary AML and bone/soft tissue sarcomas. By protocol, one patient 
in the 58741 died of an unspecified brain tumor, eleven patients in the 58881 protocol died of 
secondary neoplasms (7 AML, one Ewing sarcoma, one adult type sarcoma, one peritoneal 
carcinomatosis and one pulmonary epithelioma with cerebral metastasis) and 3 in the 58951 (2 
AML, 1 medulloblastoma) 
Organ toxicity related toxic deaths are very heterogeneous (n=9, 7.1%). In the 57841 trial 
three patients died of chemotherapy induced hepatic toxicity. In the 58881 there were two cases 
of anthracyclines related cardiomyopathy (one of them maybe precipitated by an Influenza B 
infection), one case of toxic epidermal necrolysis (Lyell's syndrome), one acute pancreatitis 
related to asparaginase, one due to hepatic toxicity that could not be linked to an underlying 
infection, and one grade IV renal toxicity related to methotrexate and sepsis by Enterobacter 
Cloacae. The local investigators made the assessment of relationship between chemotherapy and 
death.  
Two cases of pulmonary embolism have been reported, one suspected to be of fungal 
origin and the other one the other one linked to the insertion of a central venous catheter (CVC). 
One patient in the 58951 trial died of a sepsis of unknown origin, with associated pulmonary 
hemorrhage and thrombosis. 
Seven patients developed a histiocytic disorder and were represented by two cases of 
malignant systemic histiocytosis in protocol 58831/2, one case of primary HLH and one 
macrophage activation syndrome (MAS) both in protocol 58881 and three in the 58951, one of 
which was suspected to be related to a Flavimonas orzyhabitans infection.  
In two cases, iatrogenia could be considered as the cause of death. First case was a patient 
who experienced a supraventricular tachycardia while manipulation of the central venous 
catheter (CVC) during a flushing procedure. Autopsy suggested that death could be related to fat 
emboli. The second case experienced a pulmonary embolism days after the insertion of a CVC in 
a child with congenital stenosis of the pulmonary artery. Autopsy did not confirm that this 
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episode could be related to the cardiac abnormality and the cause of death was assumed to be 
related to the foreign body. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 16 and 17. Infective and non-infective deaths in remission 
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Table 28- Clinical features and causes of death of all the patients who died in complete remission (%) 
PROTOCOL 58741 58831/2 58881 58951 TOTAL 
Total 15 (12.2) 9 (7.3) 64 (52) 35 (28.5) 123 (100) 
Gender  
 Male 
 Female 
 
9 (59.8) 
6 (40.2) 
 
7 (77.8) 
2 (22.2) 
 
36 (56.3) 
28 (33.7) 
 
21 (60) 
14 (40) 
 
73 (56.9) 
50 (43.1) 
Age groups at diagnosis (Years) 
 < 1 
 1 
 2 -5 
 6 - 9 
 ≥ 10 
 
0 (0) 
3 (20) 
10 (67.6) 
1 (6.7) 
1 (6.7) 
 
0 (0) 
1 (11.1) 
6 (66.6) 
0 (0) 
2 (22.2) 
 
1 (1.6) 
3 (4.7) 
19 (29.7) 
15 (23.4) 
26 (40.6) 
 
0 (0) 
2 (5.7) 
13 (37.1) 
6 (17.1) 
14 (40) 
 
1 (0.8) 
9 (7.3) 
48 (39.1) 
22 (17.9) 
43 (35) 
ALL immunophenotype  
 B-Lineage 
 T-Lineage 
 Unknown/NA 
 
Not available 
Not available 
15 (100) 
 
5 (55.5) 
2 (22.2) 
2 (22.2) 
 
49 (76.6) 
15 (23.4) 
0 (0) 
 
27 (77.1) 
8 (22.9)  
(0) 
 
81 (65.9) 
25 (20.3) 
17 (13.8) 
NCI Risk group
 
 Standard 
 High-risk 
 
12  (79.9) 
3 (20.1) 
 
6 (66.6) 
3 (33.4) 
 
23 (35.9) 
41 (64.1) 
 
14 (40) 
21 (60) 
 
55 (44.7) 
68 (55.3) 
Death period 
 Consolidation 
 Interval therapy 
 Protocol II 
 Blocs 
 VANDA 
 HSCT 
 Maintenance 
 Post – treatment 
 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
Not comparable 
 
0 (0) 
2 (22.2) 
1 (11.1) 
0 (0) 
0 (0) 
2 (22.2) 
4 (44.4) 
0 (0) 
 
9 (14.1) 
3 (4.7) 
10 (15.6) 
2 (3.1) 
0 (0) 
22 (34.4) 
10 (15.6) 
8 (12.5) 
 
     
5 (14.3) 
1 (2.9) 
7 (20) 
3 (8.6) 
6 (17.1) 
7 (20) 
4 (11.4) 
2 (5.7) 
 
 
14 (11.4) 
6 (4.9) 
18 (14.6) 
5 (4) 
6 (4.8) 
31 (25.2) 
18 (14.6) 
10 (8.1) 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Unknown 
 Bleeding/Thrombosis 
 Organ toxicity  
 Transplant related  
 SMN 
 Others 
 
11 (73.3) 
2 
4 
0 
4 
0 
0/0 (0) 
3 (20) 
0 
1 (6.7) 
0 (0) 
 
4 (44.4) 
0 
3 
1 
0 
0 
0/0 (0) 
0 (0) 
2 (22.2) 
0 (0) 
3 (33.3) 
 
19 (30.9) 
8 
4 
7 
0 
0 
0/2 (2.9) 
6 (8.7) 
22 (32.3) 
11 (16) 
6 (8.8) 
 
16 (44.4) 
7 
2 
4 
1 
2 
1/1 (5.5) 
0 (0) 
7 (19.4) 
3 (8.3) 
8 (22.2) 
 
50 (39.7) 
17 
13  
12  
5  
2 
1/3 (3.2) 
9 (7.1) 
31 (24.6) 
15 (11.9) 
17 (13.5) 
HSCT: Hematopoietic stem cell transplantation; NA: Not available; NCI: National Cancer 
Institute; SMN: Secondary malignant neoplasm; WBC: White blood cell(s) 
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Table 29- Causes of death of all the patients who died of transplant related toxicities (%) 
PROTOCOL 58831/2 58881 58951 TOTAL 
Total 2 (6.4) 22 (71) 7 (22.6) 31 (100) 
Cause of death
 
 Infection 
 Bacterial 
 Viral 
 Fungal 
 Pneumocystis jirovecii 
 Parasites 
 Unknown 
 Bleeding 
 GVHD 
 Conditioning regimen toxicity 
 Others 
 
0 (0) 
0 
0 
0 
0 
0 
0 
0 (0) 
0 (0) 
2 (100) 
0 (0) 
 
 
11 (50) 
0 
3 
5 
0 
2 
1 
2 (9.1) 
7 (31.8) 
0 (0) 
2 (9.1) 
 
4 (57.1) 
0 
3 
0 
0 
0 
1 
0 (0) 
2 (28.5) 
0 (0) 
1 (14.4) 
 
 
15 (48.4) 
0 
6  
5  
0  
2 
2  
2 (6.5) 
9 (29) 
2 (6.5) 
3 (9.6) 
GVHD: Graft versus host diseases 
 
 
 
 
 
 
 
Figures 18 and 19. Toxic deaths in HSCT and Infective Deaths in HSCT 
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V. DISCUSSION 
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1. DISCUSSION 
This study provides the largest and most comprehensive report focusing on treatment 
related deaths in pediatric patients with ALL treated with the EORTC-CLG trials.  
The strengths of this study include:  
1) The number of patients: 4916 patients from three different countries have been 
included in this research, representing one of the largest studies on this topic ever performed. 
This allows a comprehensive analysis.  
2) Expanded period of time: since all the EORTC-CLG trials have been included from 
1971 to 2008, a wide and detailed perspective about changes in incidence and types of death over 
this period can be given.  
3) Accuracy of the data: data for this study has been obtained from the EORT-CLG 
databases, a clean and concise deposit of all the information from the different ALL studies. The 
EORTC-CLG is one of the most reputed research groups in this field worldwide. Some of its 
investigations have widely contributed to the advancement in pediatric leukemia. A meticulous 
process of collecting, analyzing and interpreting the data has been put in place for each trial, 
ensuring the accuracy of the information presented in this study. All deaths have been 
investigated and 100% of the data regarding the type of death and ultimate cause of decease was 
available and has been evaluated.  
Nevertheless, this study has some limitations: 
1) Data from the 59851 trial, the latest one performed by the group from 1998 to 2008, 
was not mature enough at the time of collecting and analyzing this data. This issue precluded 
including data from this study in the statistical analysis to identify risk factors for treatment 
related deaths, one of the objectives of this research. Nonetheless, patients from the 3 other 
studies (58741, 58831/2, 58881) have been included in this statistical analysis, accounting for 
2984 patients. A descriptive analysis of treatment related deaths occurring in the 58951 trial has 
been presented, permitting to compare the profile of treatment related deaths in the most recent 
trial with those previous studies.  
2) The definition of treatment related mortality: we adopted a definition of treatment 
related mortality and causes of death used by the BFM, NOPHO and MRC groups
8,43,48
. There is 
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not a universally established definition in the literature and it may difficult the interpretation and 
comparison of results. 
 1.1 Treatment related deaths in pediatric acute lymphoblastic leukemia 
Over the last three decades we have witnessed a constant and substantial improvement in 
the outcome of children and adolescents affected by ALL. Greater than 95% of children with 
ALL will attain complete remission and around 80% will be long-term survivors
9, 11
. Despite the 
intensification of antileukemic chemotherapeutic agents, rates of mortality before and after first 
complete remission have decreased, hence accounting for only a small proportion of failures in 
the management of children and adolescents with ALL. In view of this increasing overall 
survival rate, avoidance of treatment-related fatalities and sequelae is a major aim in the optimal 
management of childhood ALL
10
.  
In this sense, the EORTC Children’s Leukemia Group has applied a risk-adapted therapy 
background in its protocols, aiming for a more intense treatment in those patients considered at 
higher risk of relapse, whereas less intensive regimens are given to those in lower risk groups. 
This is in line with one of the principles of the group that is to reduce the undesirable side effects 
of the treatment at short and long term and improving the quality of life of these children while 
maintaining the high rates of cure (www.eortc.org).  
1.2 Early death 
Despite notable improvements in supportive care at the time of initial diagnosis made 
during the decade of 1990 and early 2000, there are still a substantial number of patients that die 
before remission for other reasons than ALL. A progressive reduction in the number of deaths 
before remission has been observed in our study. In our series, the incidence of deaths before 
first remission went down from 2.2% in the protocol 58831/2 to 0.7% in the last study, the 
58951.  This result is similar to those reported by other collaborative groups (Appendix 1). A 
recent systematic review and meta-analysis of non-relapse mortality (NRM) in acute 
lymphoblastic leukemia performed over 59 randomized pediatric ALL studies and including 
49071 patients revealed an induction death rate of 1.38%
87
.  
Infection was the most frequent type of death before remission (62.9%). Among 
infections, bacterial (73%) and fungal organisms (19%) represented the most frequent ones 
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(Figure 13). In the literature percentages range between 11 and 64% predominately related to 
bacterial and fungal organisms
7,8,43,47,48
 and exceptionally to Pneumocystis jirovecii. We did not 
observe any death before remission related to Pneumocystis jirovecii. Bacterial organisms were 
mostly represented by Streptococcus (26%) and Pseudomonas (21%) while Aspergillus was the 
only fungal infective organism (20% of all infections).  
Besides infection, bleeding disorders were the second most frequent cause of death 
(20.4%), mainly intracranial (n=6) and gastrointestinal hemorrhages (n=3). Percentage ranges 
from 0% to 55.5%
7,48
 in the literature. Tumor burden related deaths have been low across the 
three trials (5.6%). In the literature, incidence of tumor burden related deaths range from 0%
8
 to 
11%
9,47
.  
We found that patients aged less than one year and those of female gender, NCI-High 
Risk group patients and those who had been treated in the 58831/2 protocol were at a 
significantly higher risk of dying before remission (Table 25).  
Regarding age we identified that patients aged less than one year had a significant 
increased risk of dying before remission compared with all other age groups together. Other 
investigators have also found that younger patients are more prone to die of treatment related 
complications before remission. Rubnitz et al found that children aged less than 1 and those aged 
more than 10 years presented a higher risk of death before remission in ALL studies performed 
in the same period as were those of the EORTC (1984-1999) when compared to patients aged 1 
to 9 years
7
. Hargrave et al found that female gender, WBC >50 x 10
9
/l and age <2 years were 
associated with a higher risk in some MRC trials
48
. 
Regarding gender, we did not find baseline characteristics that could explain the 
augmented risk of toxic deaths in the female population. Christensen et al also found that girls 
were significantly at an increased risk of treatment related deaths, particularly in the low-risk 
groups, B-cell precursor leukemia and in those with less than 100 x 10
9
/l WBC
43
. In a recent 
COG study in children with high risk-ALL, females had significantly more hospital days, delays 
in therapy, grade 3 or 4 toxicities and supportive care interventions than males. The cumulative 
incidence of treatment-related deaths was 2.6% for females and 1.2% for males
88
. Maybe the 
biological mechanism behind these findings may reflect gender differences in immunological 
response to infections or differences in toxicity following cytotoxic chemotherapy. Gender 
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differences in response to infection and inflammation have been described in some investigations 
using animal models as well as human studies
89,90
 but has never been implemented in 
recommendations for clinical management of infections. Few reports have suggested gender 
differences in mortality rate due to infections following measles vaccinations. One study 
described a non-specific reduction in mortality following standard measles vaccination, which 
was particularly associated with female sex
91
. Differences in liver function and related 
pharmacokinetics could also be contributing factors underlying the observed gender differences 
in treatment related deaths. While this finding has been suggested in other studies, this research 
is not able to shed light on the causes of this gender difference.  
Regarding NCI Risk, a large proportion among high-risk patients presented with a high-
burden of disease (>250 x10
9
/l WBC, n=8, 35%). Five of them died of intracranial hemorrhages 
and in two cases DIC was co-responsible of death along with an infection. Therefore, bleeding 
events and coagulation disorders represent a major concern in this particular population. The 
high burden of disease in this group of patients may explain its increased risk of death.  
Regarding participation to different protocols, it was identified that having been treated in 
the 58831/2 trial was significantly associated with an increased risk of death before remission 
when compared with the 58881. Percentages of early death were 2.9% and 0.9% respectively 
(p=0.000; OR 4.69; 95% CI 2.10-10.45). Pre-phase and induction regimens were superposable in 
both trials, so treatment differences could not explain by themselves this discrepancy. Types of 
death were also similar in both trials. When taking into consideration the last 58951 trial, that 
also used superposable pre-phase and induction regimens, there were not patients dying before 
anti-leukemia treatment could be initiated nor during the pre-phase, and the early death rate 
lowered to 0.7%. These two phases are critical, as patients may present in a poor clinical 
condition and with high-burden of disease.  
We therefore hypothesize that this decrease in early deaths can be explained by: 
i) The continuous improvement in supportive care measures in the last three 
decades, such as the implementation of guidelines for management of febrile 
neutropenia, early use of broad-spectrum antibiotics and the optimization in the 
use of supportive blood products. 
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ii) Better recognition of the clinical features making these patients more prone to die 
so earlier measures can be put in place, such as leukapheresis or earlier admission 
to intensive care unit. For instance, in our series, more patients with high burden 
of disease (i.e. WBC >100 x10
9
) were included in the 58881 trial than in the 
58831/2 (14.3% Vs 10.4% respectively, p=0.045), and despite this, the percentage 
of tumor burden related complications and bleeding lowered (35% Vs 30%). 
iii) A progressive learning in treating institutions over the years using similar 
protocols.  
iv) Improved national networks, so that sick patients are referred earlier to reference 
centers where treatment and supportive care can promptly be initiated.  
It is noteworthy that some patients were reported to have more than one cause of death 
besides infection, particularly bleeding complications, leukostasis and necrotizing enterocolitis. 
In these cases, infection may had precipitated the fatal event, in an otherwise, fragile patient.  
To summarize NCI-High Risk patients, those aged less than one year, female children 
and those treated in the 58831/2 trial were at an increased risk of death before remission in the 
EORTC-CLG ALL trials. Patients with these clinical characteristics should be carefully 
monitored in order to identify earlier signs of toxicity that may prevent them of a fatal outcome.  
1.3 Death in first complete remission 
In the same systematic review mentioned above, the remission death rate was 1.94% and 
total non-relapse mortality was 3.60%
87
.  In our series, 123 patients died in remission. Most 
frequent causes of deaths were infection (39.9%), transplant related mortality (26.9%) and 
secondary malignant neoplasms (13.9%).  
The 58741 trial run between 1971 and 1978 and it presented the higher mortality rate of 
the EORTC trials (8.1%, figure 12). If we exclude this trial, the mortality rate in remission is 2% 
in average for the three trials. This is in line with what has been reported by other collaborative 
groups with contemporary trials, where percentage ranges from 1.5%
50
 to 5.3%
47
.  
Reasons behind the differences in treatment related deaths in remission between the 
58831/2, 58881 and 58951 trials can be given: 
- The number of transplants performed in first remission has progressively increased from 
the 58831/2 trial to the 58881 and the 58951 (9, 83 and 98 respectively). Despite the increase in 
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number of transplants, the incidence of transplant related mortality slightly increased between 
the 58831/2 and the 58881 and notably reduced in the last trial the 58951 (22%, 26% and 7% 
respectively). As cure rates improved with intensity, transplant related mortality was higher in 
earlier protocols than in most recent ones. We identified that having been transplanted in first 
complete remission was significantly associated with an increased risk of death in remission in 
this period (p=0.000; OR 17.97; 95% CI 9.02-37.3). NCI-High Risk patients were more 
represented in the transplant group (83.7%) than the standard ones (16.3%), and therefore at an 
increased risk of developing complications related to this procedure. The difference in transplant 
related mortality between the last protocol (7.1%) and those two other may be explained by the 
selection of patients candidates for transplantation, as well as by the better donor selection 
process and the improvements in the supportive care in the BMT units. Christensen et al also 
found that being transplanted in first remission was associated with an increased risk of death
43
. 
In this population, infection remains the most frequent cause of death (48.4%, mainly viral and 
fungal), followed by GVHD (29%), bleeding (6.5%) and conditioning regimen related toxicity 
(6.5%).  
- Second malignant neoplasms caused 12% (n=15) of deaths in remission in our series 
and represent the third most frequent type of death in remission. Most frequent type of SMNs 
related death were AML (n=9, 60%) and solid carcinomas (n=4, 27%). The incidence of SMNs 
related deaths was higher in the 58881 (n=11, 73% of all SMNs related deaths occurred in this 
trial). Potential causes for developing SMNs are the use of radiotherapy, etoposide or alkylating 
agents
92
. In our studies, the value of radiotherapy was tested in a randomized fashion in the 
58832 trial, and it was demonstrated that the omission of cranial radiotherapy failed to increase 
the risk of CNS relapse or of any relapse. This observation led to the deletion of cranial 
radiotherapy from front-line therapy protocols in subsequent CLCG trials (58881 and 58951)
93
. 
In our series, only patients treated in the very high-risk group of the 58881 and 58951 trials did 
receive epipodophyllotoxins in first line (Etoposide cumulative doses 900mg/m
2
), but only one 
patient in the 58881 trial and one in the 58951 were high risk and further developed a secondary 
neoplasm. Specifically the 58881 protocol looked at the possible oncogenic effect of the high 
doses of 6-MP given intravenously during continuation therapy in patients assigned to this 
supplementary treatment by randomization our group compared the two arms, with and without 
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IV 6-MP, with regard to the occurrence of SMN. No difference could be found between the two 
groups. For all patients included in the trial (including those with lymphoblastic lymphoma) six 
patients in the no IV 6-MP arm developed a SMN and five patients in the IV 6-MP group. The 
type of SMN was similar in the two randomized groups
36
.  
- Third, deaths related to organ toxicity happened in the 58741 (n=3) and in the 58881 
(n=6) and none in the 58831/2 and 58951 trials. Those events happening in the 58741 were all 
severe hepatic toxicity related to the use of higher doses of MP-6 and MTX than in contemporary 
trials. In the 58881 protocol, in four cases a clear cause was identified: anthracycline 
cardiomyopathy induced (n=2), asparaginase toxicity (n=1) and methotrexate induced renal 
toxicity (n=1). Contemporary ALL trials included clear guidelines on cardiac toxicity 
monitoring, methotrexate toxicity management and asparaginase modifications in case of allergic 
reactions or organ toxicity. Besides this, an increased awareness and early recognition of 
therapy-induced toxicity has probably led to the reduction of deaths in this category.  
The incidence of infective deaths has decreased from the 58741 (n=11 [73%]) to the 
58831/2, 58881 and 58951 (n=4 [44%], n=22 [30.9%], n=16 [44.4%]) and the pattern of 
infections has changed. Notably, the number of cases of P. Jiroveciii has reduced from 4 cases in 
the 58741 to none in the 58831/2 and 58881 and only one in the 58951. This improvement is 
surely related to the introduction of specific prophylaxis in the 80’s94.  Besides this, patients in 
the 58741 were treated with high doses of steroids (up to 120mg/m
2
 of prednisone during 28 
days of induction) and non-conventional doses of Asparaginase (up to 150.000 IU/m
2
), which is 
significantly higher than the doses currently used in our contemporary trials. Varicella was a 
common cause of death in the 58741 trial while measles infection occurred in the 58831/2 and 
58881 trials. Aspergillus is the most common cause of fungal infection across all trials. 
Widespread MMR vaccination in the decades of the 80´s and 90´s has contributed to the 
reduction of these infections in immune-competent individuals and the risk of transmission to 
immune-deficient patients, therefore reducing the risk of dying from this complication, 
particularly in the ALL population (www.vacunasaep.org).  
Regarding risk factors, we identified that patients above 10 years were at an increased 
risk for death in remission. Adolescent are known high-risk subgroup for treatment related deaths 
in ALL.  Hunger et al found that patients aged 10+ years had a relative risk of death up to 3 times 
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fold compared to those aged 1 to 9.99 years in two time periods (1990-1994) and (2000-2005)
95
. 
Treatment related toxicities are more common in patients aged more than 10 years, particularly 
pancreatitis and thromboembolic events
96
. Adolescents do experience more toxic events when 
are treated in pediatric protocols than when they are treated with adult regimens due to the use of 
more intensified regimens
97
. Underlying biological differences and a different tolerance to the 
same chemotherapeutic agents, may make older patients more prone to experience fatal events.  
The 57841 trial was significantly associated with a higher risk of death in remission when 
compared with the two other protocols (p=0.000; OR 3.22; 95% CI 1.81-5.74). The therapeutic 
approach between the 58741 and the others radically change since the introduction of a BFM 
based schema from the 58831/2 trials and onwards. The 58741 trial has the highest incidence of 
infective deaths: 73.3% Vs 38.2 in the 58831/2-58881 trials. This trial was performed early in the 
decade of 1970, and neither supportive care measures nor adequate anti-microbial therapies were 
as we know nowadays. These differences may explain the high rate of mortality in that first trial.  
Death in remission remains an important issue in pediatric cancer. A cohort of 6402 
Italian patients with cancer aged less than 18 years at diagnosis were followed up after 
remission
98
. 890 died, mostly due to relapse (84.6%). Most frequent causes of death other than 
first cancer were second cancers (6.7%), infection (2.1%) and cardiac diseases (1.3%). Subjects 
after leukemia and lymphoma were more likely to die due to medical complications of therapy 
compared to patients with solid tumors. Second cancers were the second most frequent cause of 
death, with a 12-fold risk compared with the general population. Compared with the general 
population, these subjects were 32 times more likely than same-age subjects to die.  
To summarize patients above 10 years, those transplanted in first remission and those 
treated in the 58741 trial were at an increased risk of death in remission in the EORTC-CLG 
ALL trials. 
1.4 Definition of treatment related mortality 
We opted for a definition of treatment related mortality and the types and causes of death 
like the BFM, NOPHO or MRC groups have described it
8,43,48
 but this definition is not 
homogenously used in the scientific community. Chantal MC and co-workers conducted a 
systematic review of randomized therapeutic pediatric acute leukemia and adult/pediatric acute 
promyelocytic leukemia trials
99
. Only 6% of the pediatric studies clearly defined treatment 
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related mortality in the material section; of note, in pediatric studies specifically focused on 
treatment related mortality, only 70% of them clearly defined this concept. Between 18 and 30% 
of the studies include deaths after completing chemotherapy in the definition of treatment related 
mortality and between 18 and 70% included deaths after stem cell transplant into it. They also 
raised the question of inconsistency in defining attribution for cause of death. First because a 
reliable system of attribution related to treatment related mortality has never been developed and 
second, because patients will have multiple events close to death, such as organ dysfunction, 
infection, and hemorrhage and currently, there are no clear ways to classify the primary cause of 
death for these patients.  
In order to shed light into this issue, a recent systematic assessment from the International 
Pediatric Oncology Mortality Classification Group, has developed a definition of treatment 
related mortality in pediatric cancer patients
100
. Treatment-related mortality is defined in this 
paper as any death in the absence of progressive cancer. They also develop a cause of death 
attribution system and the clinical criteria for assigning probable cause-of-death and possible 
cause-of-death for each category. Such initiatives are necessary in order to homogenize the way 
in which physicians define treatment related mortality that will permit to compare results from 
different treatment regimens in pediatric patients.  
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VI. CONCLUSIONS 
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1. CONCLUSIONS 
Objective: To assess the types and causes of treatment related deaths in children with 
newly diagnosed ALL treated according to the first line EORTC-CLG ALL protocols 
58741 – 58831/2, 58881 and 58951 from 1971 to 2008. 
Conclusion: In this study we have described the incidence and type of treatment related deaths in 
children with newly diagnosed ALL treated in the EORT-CLG trials. The analysis of 4916 
patients has permitted to identify factors for increased likelihood of dying from toxicity. The 
results have been compared with those reported in the literature from collaborative groups.   
Objective: To define the incidence and causes of treatment related deaths in the four trials 
grouped in two categories: early death (death before first complete remission) and death in 
first complete remission. 
Conclusion:  
- Incidence of early deaths in our series is 1% on average across trials 58831/2, 58881 and 
58951. Most frequent types of death before remission are: 1) Infection: 62.9%, of which bacterial 
are 73% and fungal 19%; 2) Bleeding: 20.4%; 3) Tumor burden: 5.6%.   
- Incidence of death in first complete remission in our series is 3.5%. If we exclude the 58741 
trial that has the highest incidence of toxic deaths (8.1%) and was conducted early in the decade 
of the 70´s, the incidence lowers to 2%. Most frequent types of death in remission are: 1) 
Infection: 39.7%, of which bacterial are 36%, viral 26% and fungal 24%; 2) Bone marrow 
transplant related complications: 24.6%; 3) Secondary malignant neoplasms: 11.4%; 4) Organ 
toxicity: 7.1%.  
Objective: To assess whether the treatment era carries an impact in the incidence of 
treatment related deaths.   
Conclusion:  
- Incidence of all treatment related deaths have reduced from the 58741 protocol (8.1%) 
performed during the decade of the 70´s to the three other trials 58831/2, 58881 and 58951 
(3.4%, 3.9% and 2.5% respectively) performed in the decades of the 80´s, 90´s and 2000.  
- Incidence of early deaths progressively reduced between the 58831/2, 58881 and the 58951 
trials (2.2%, 0.9% and 0.7% respectively).  
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- Incidence of deaths in first complete remission reduced from the 8.1% in the 58741 trial to 
1.2% in the 58831/2, 3% in the 58881 and 1.8% in the last trial, the 58951.  
- The reduction in all treatment related deaths, deaths before remission and deaths in remission is 
statistically significant (p<0.001).  
- The multivariate analysis identified that: 
- Before remission, having been treated in the 588831/2 conferred a significant increase in 
the risk of dying from toxicity when compared to the 58881 trial (p=0.000; Odds ratio 
4.69; 95% CI 2.10-10.45) 
- In first complete remission, having been treated in the 58741 trial conferred a significant 
increase in the risk of dying from toxicity when compared to the other two trials, 58831/2 
and 58881 (p=0.000; Odds ratio 3.22; 95% CI 1.81-3.74).  
- Therefore, the time period in which patients were treated impacts in the risk of dying from 
toxicity in the EORTC-CLG trials.   
Objective: To identify risk factors of increased likelihood of treatment related deaths in 
children with ALL. 
Conclusion: 
- The multivariate analysis identified that: 
- Before remission, patients aged less than one year (p=0.000, OR 9.7; 95% CI 4.5-20.7), 
those of female gender (p=0.013; OR 2.92; 95% CI 1.26-6.80) and those NCI-High Risk 
(p=0.001; OR 5.25; 95% CI 1.99-13.79) were at a significantly increased risk of dying 
before remission 
- In first complete remission, patients aged more than 10 years (p=0.000; OR 2.45; 95% CI 
1.51-3.80) and those having been transplanted in first remission (p=0.000; OR 17.07; 
95% CI 9.02-32.30) were at a significantly increased risk of death in remission.  
Objective: To compare the incidence and type of treatment related deaths of the EORTC-
CLG ALL protocols with the results reported by other collaborative groups.   
Conclusion:   
- Publications from collaborative study groups focusing on treatment related mortality in ALL 
pediatric patients treated in front line protocols were retrieved and analyzed.  
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- Incidence of early deaths in our series is 1% on average across trials 58831/2, 58881 and 
58951. This is lower compared with what has been reported by other collaborative groups with 
contemporary trials, where percentage is 1.4%.  Most frequent causes are infection and bleeding 
disorders in our series; these are the most frequent causes reported by other groups.  
- Incidence of death in complete remission in our series is 3.5% on average across trials 58741, 
58831/2, 58881 and 58951. If we exclude the 58741 trial that has the highest incidence of 
toxicity and was performed early in the decade of the 70´s, the incidence lowers to 2%. This is 
similar compared with what has been reported by other collaborative groups with contemporary 
trials, where percentage is 1.94%. Most frequent causes are infection, toxicities derived from 
transplantation and secondary malignant neoplasms in our series; besides these causes, drug-
induced toxicity has been a frequent cause reported by other groups. 
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2. CONCLUSIONES 
Objetivo: Describir los tipos y causas de mortalidad relacionada con el tratamiento en 
niños con leucemia linfoblástica aguda de nuevo diagnóstico tratados en los protocolos de 
primera línea del grupo EORTC-CLG 58741, 58831/2, 58881 y 58951 desde 1971 a 2008.  
Conclusión: 
- En este estudio hemos descrito la incidencia y el tipo de muertes relacionadas con el 
tratamiento en niños de nuevo diagnóstico de leucemia linfoblástica (LLA) aguda tratados con 
los protocolos EORTC-CLG. El análisis de 4916 pacientes ha permitido identificar factores de 
riesgo para fallecer por causas tóxicas. Estos resultados han sido comparados con los publicados 
por otros grupos colaborativos.  
Objetivo: Definir la incidencia y causas de muerte relacionadas con el tratamiento en los 
cuatro ensayos clínicos agrupados en dos categorías: Muerte precoz o muerte antes de la 
primera remisión completa y Muerte en primera remisión completa.  
Conclusión: 
- La incidencia de muerte precoz en esta serie es del 1% de media entre los protocolos 58831/2, 
58881 y 58951. Las causas más frecuentes de muerte precoz son: 1) Infección: 62,9%, de las 
cuales el 73% es bacteriana y el 19% fúngica; 2) Hemorragia: 20,4%; 3) Carga tumoral: 5,6%.  
- La incidencia de muerte en primera remisión completa en esta serie es 3,5%. Si excluimos el 
protocolo 58741 que tiene la mayor incidencia de muerte tóxica (8,1%) y se llevó a cabo en la 
década de los 70, la incidencia baja al 2%. Las causas más frecuentes de muerte en remisión son: 
1) Infección: 39,7%, de las cuales el 36% es bacteriana, el 26% viral y el 24% fúngica; 2) 
Toxicidad relacionada con el trasplante: 24,6%; 3) Segundas neoplasias: 11,4%; 4) Toxicidad 
orgánica: 7,1%.  
Objetivo: Averiguar si la era de tratamiento impacta en la incidencia de muertes 
relacionadas con el tratamiento.  
Conclusión:  
- La incidencia de todas las muertes relacionadas con el tratamiento se ha reducido desde el 
protocolo 58741 (8,1%) llevado a cabo en la década de los 70 a los otros tres protocolos, el 
58831/2, 58881 y 58951 (3,4%, 3,9% y 2,5% respectivamente) llevados a cabo en las décadas de 
los 80, 90 y 2000 respectivamente.  
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- La incidencia de mortalidad precoces se ha reducido progresivamente entre los protocolos 
58831/2, 58881 y 58951 (2,2%, 0,9% y 0,7% respectivamente).  
- La incidencia de mortalidad en primera remisión se ha reducido desde el 8,1% del protocolo 
58741 al 1,2% en el 58831/2, 3% en el 58881 y 1,8% en el último protocolo, el 58951.  
- La reducción en la incidencia de todas las muertes relacionadas con el tratamiento, las muertes 
precoces y en primera remisión es estadísticamente significativa (p<0,001).  
- El análisis multi-variante ha identificado que: 
 - Previo a la remisión, el haber sido tratado en el protocolo 58831/2 confirió un mayor 
riesgo de mortalidad tóxica cuando se comparó con el 58881 (p=0,000; Odds ratio 4,69; 
IC 95% 2,10-10,45).  
 - En primera remisión, el haber sido tratado en el protocolo 58741 confirió un mayor 
riesgo de mortalidad tóxica cuando se comparó con los otros dos protocolos, el 58831/2 y 
el 58881 (p=0,000; Odds ratio 3,22%; IC 95% 1,81-3,74). 
 - Por tanto, el periodo de tiempo en el que los pacientes se trataron impacta en el riesgo 
de mortalidad relacionada con el tratamiento en los protocolos EORTC-CLG.  
Objetivo: Identificar factores de riesgo para fallecer de muerte tóxica en pacientes 
pediátricos con LLA.  
Conclusión: 
- El análisis multi-variante ha identificado que: 
 - Antes de la remisión, los pacientes menores de un año (p=0,000, OR 9,7; IC 95% 4,5-
20,7), aquellos de sexo femenino (p=0,013; OR 2,92; IC 95% CI 1,26-6,80) y aquellos 
del grupo de alto riesgo NCI (p=0,001; OR 5,25; IC 95% 1,99-13,79) tenían un riesgo 
significativamente más alto de experimentar mortalidad relacionada con el tratamiento 
antes de la remisión.  
 - En primera remisión, los pacientes de más de 10 años (p=0,000; OR 2,45; IC 95% 1,51-
3,80) y aquellos trasplantados en primera remisión (p=0.000; OR 17.07; 95% CI 9.02-
32.30) tenían un riesgo significativamente más alto de experimentar mortalidad 
relacionada con el tratamiento en primera remisión.  
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Objetivo: Comparar la incidencia, el tipo y la causa de mortalidad relacionada con el 
tratamiento de los protocolos EORTC-CLG con los resultados publicados por otros grupos 
colaborativos.  
Conclusión: 
- Se identificaron y analizaron publicaciones de grupos colaborativos centradas en el la 
mortalidad relacionada con el tratamiento en protocolos de primera línea en LLA.  
- La incidencia en nuestra serie de mortalidad precoz es del 1% de media entre los protocolos 
58831/2, 58881 y 58951. Esta incidencia es menor cuando se compara con la descrita por otros 
grupos con estudios contemporáneos, en el que el porcentaje es del 1,4%. En esta serie las causas 
más frecuentes son infección y sangrado que coincide con las causas más frecuentes descritas en 
la literatura.  
- La incidencia en nuestra serie de mortalidad en primera remisión es del 3,5% de media entre los 
protocolos 58741, 58831/2, 58881 y 58951. Si excluimos el protocolo 58741 que tiene la más 
alta incidencia de mortalidad tóxica y que se llevó a cabo en la década de los 70, la incidencia 
baja al 2%. Esta incidencia es similar a la descrita por otros grupos, que está alrededor del 
1,94%. En esta serie las causas más frecuentes son infección, toxicidades derivadas del trasplante 
y segundas neoplasias. Además de estas tres, en la literatura la toxicidad orgánica ha sido una 
causa frecuente descrita por otros grupos.  
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Appendix 1. Description of treatment related deaths reported by other groups 
 
DEATHS DUE TO TOXICITY IN ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC TRIALS 
GROUP 
(Reference) 
STUDY 
TYPE 
POPULATION TRIAL(S) 
TIME 
PERIOD 
NUMBER OF 
PATIENTS a 
(% Deaths in 
Induction-
First 
Remission) 
TREATMENT RELATED DEATH 
(%) 
CAUSES DEATH (Total) 
MRC (Atra 
A. et al) 
Retrospective 
Single 
institution 
(Hospital Sick 
Children, 
London, 
England) 
Age: 
Adults-Children (II 
and IV) 
1-14 years (III) 
1-14 years (PLOD) 
1-15 years (X) 
MRC UKALL II-IV 
PLOD 
MRC UKALL X 
1972-1978 
1979-1982 
1983-1989 
 
 
298 (3.7-6) 
214 (1.9-4.7) 
330 (0.6-5.2) 
 
Total: 842 
 
 
 
 
 
DBT/Induction: 17 (2) 
Early death (ED): 17 (2) 
 
 
During or After treatment: 35/7 (4.1/0.8) 
HSCT: 3 (0.4) 
Death in first CR (DCR): 45 (5.3) 
Overall: 62 (7.4) 
 
Infectionb:6/0/0/1 (7) 
Bleeding/Thrombosis: 3/0 
Tumor burdenc:2 
ALL progression: 5 
Early death (ED): 17 
Infection:9/17/1/2/7 (36) 
TRM: 3 
SMN: 4 
Othersd: 2 
Death in first CR (DCR): 45 
MRC 
(Hargrave 
D. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(United 
Kingdom) 
Age:  
< 14 years (VIII) 
1-15 years (X-XI) 
 
 
MRC UKALL VIII 
MRC UKALL X 
MRC UKALL XI 
 
 
1980-1984 
1985-1990 
1991-1997 
 
 
829 (2.8-6) 
1612 (2.4-2.6) 
2090 (1.2-1.3) 
 
Total: 4531 
 
 
 
 
 
DBT/Induction: 87 (1.9) 
Early death (ED): 87  (1.9) 
 
 
During or After treatment: 104 (2.3) 
HSCT: 18 (0.4) 
 
Death in first CR (DCR): 122 (2.7) 
Overall: 209 (4.6) 
 
Infection: 42/0/14/0/0 (56) 
Bleeding/Thrombosis: 15/1 
Tumor burden: 8 
Otherse:7 
Early death (ED): 87 
 
 
Infection: 24/34/11/13/0 (82) 
TRM: 18 
Others: 22 
Death in first CR (DCR): 122 
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MRC 
(Mitchel C. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(United 
Kingdom) 
Age:  
< 14 years (VIII) 
1-15 years (X-XI-
ALL97/99) 
 
 
MRC UKALL VIII 
MRC UKALL X 
MRC UKALL XI 
 
 
1980-1984 
1985-1990 
1991-1997 
1997-2002 
 
 
825 (*-7) 
1612 (*-4) 
2090 (*-2) 
1935 (*-4) 
 
Total: 6462 
 
 
 
 
 
DBT/Induction: - 
Early death (ED): 
 
During or After treatment: 232 
HSCT: - 
Death in first CR (DCR): 232 (3.6) 
Overall: 232 (3.6) 
 
 
 
 
 
 
 
During or After treatment: 191 
Second neoplasms: 41 
Death in first CR (DCR): 232 
JCCLSG 
(Tsurusawa 
M. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Japan) 
Age: ≤ 18 years 
ALL 811 
ALL 841 
ALL 847 
ALL 911 
 
1981-1984 
1984-1987 
1987-1990 
1991-1993 
 
 
207 (*-1) 
220 (*-0.5) 
371 (*-0.8) 
223 (*-4) 
Total : 1021 
 
DBT/Induction:- 
Early death (ED): - 
 
 
During or After treatment: 15 (1.5) 
HSCT: - 
Death in first CR (DCR): 15 (1.5) 
Overall: 15 (1.5) 
 
Early death (ED): - 
 
 
Infection: 12 
Others: 3  
Death in first CR (DCR): 15 
TCCSG 
(Tsuchida 
M. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Japan) 
Age: 1-18 years 
L81-10 
L84-11 
L89-12 
L912-13 
1981-1984 
1984-1989 
1989-1992 
1992-1995 
 
 
189 (*-*) 
484 (*-*) 
418 (*-*) 
347 (*-*) 
 
Total: 1438 
 
DBT/Induction: 24 (1.7) 
Early death (ED): 24 (1.7) 
 
 
During or After treatment: 41 (2.9) 
HSCT: - () 
Death in first CR (DCR): (2.9) 
Overall: 65 (4.5) 
- 
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DFCI 
(Silverman 
LB. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(DFCI) 
Age: ≤ 18 years 
 
 
 
DFCI 81-01 
DFCI 85-01 
DFCI 87-01 
DFCI 91-01 
DFCI 95-01 
 
 
 
1981-1985 
1985-1987 
1987-1991 
1991-1995 
1996-2000 
 
 
289 (*-*) 
220 (0.5-3.6) 
369 (2.2-1.9) 
377 (0.5-3.2) 
491 (0.8-0.6) 
 
Total: 1746 
DBT: - 
Induction: 11 (0.6) 
Early death (ED): 11 (0.6) 
 
 
During/After treatment: 40  (2.3) 
HSCT: - 
Death in first CR (DCR)f: 40 (2.3) 
Overall:  51 (2.9) 
- 
BFM 
(Schrappe 
M. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(BFM) 
Age: ≤ 18 years 
ALL-BFM 81 
ALL-BFM 83 
ALL-BFM 86 
ALL-BFM 90 
1981-1983 
1983-1986 
1986-1990 
1990-1995 
 
 
611 (*-*) 
653 (*-*) 
998 (*-*) 
2178 (*-*) 
 
Total: 4440 
DBT: - 
Induction: 47 (1.1) 
Early death (ED): 47 (1.1) 
 
 
During/After treatment: 74  (1.7) 
HSCT: - 
Death in first CR (DCR): 74 (1.7) 
Overall: 121 (2.8) 
- 
Austrian 
BFM  Study 
Group 
(Prucker C. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(BFM-Austria) 
Age: ≤ 18 years 
ALL-BFM (A) 81 
ALL-BFM (A) 84 
ALL-BFM (A) 86 
ALL-BFM (A) 90 
ALL-BFM (A) 95  
1981-1983 
1983-1986 
1986-1990 
1990-1995 
1995-1999 
 
 
141 (2.2-*) 
127 (2.2-*) 
142 (0.2-*) 
256 (0.2-*) 
230 (0.2-*)  
 
Total: 896 
 
 
 
 
DBT:  - 
Induction: 7 
Early death (ED): 7 (0.8) 
 
 
During/After treatment: 24 
HSCT: - 
Death in first CR (DCR): 24 (2.7) 
Overall: 31 (3.5) 
 
 
Infection: 2/0/1 (3) 
Bleeding/Thrombosis: - 
Tumor burden: - 
Others: 4 
Early death (ED): 7 
Infection: 2/2/2/3/8 
Toxicity: 1 
Bleeding/Thrombosis: 1/1 
Others: 4 
Death in first CR (DCR): 24 
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COALL 
(Harms DO. 
et al and 
Escherich 
G. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(COALL) 
Age: ≤ 18 years 
(In trials 89-92, 
infants were 
treated according to 
a different regimen 
and included in the 
analysis) 
COALL-82 
COALL-85 
COALL-89 
COALL-92 
COALL-97 
 
 
 
  1982-
1985 
1985-1989 
1989-1992 
1992-1997 
1997-2003 
 
 
 
 
 
 
129 (*-3.9) 
289 (*-2.1) 
205 (*-3.9) 
519 (*-2.3) 
667 (*-2.7) 
 
Total: 1818 
 
DBT: - 
Induction: 5 (0.3) 
Early death (ED): 5 (0.3) 
 
 
During/After treatment: 49 (2.7) 
HSCT: - 
Death in first CR (DCR): 49 (2.7) 
Overall: 54 (3) 
- 
AIEOP 
(Conter V. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Italy) 
Age: 1-15 years 
(Infants were only 
included in Studies 
87-88) 
Study 82 
Study 87 
Study 88 
Study 91 
Study 95 
1982-1987 
1987-1991 
1988-1992 
1991-1995 
1995-2000 
 
 
902 (2.2-3.3) 
632 (0.6-1.6) 
396 (1.3-1.8) 
1192 (1.3-1.9) 
1743 (0.7-1.6) 
 
Total: 4865 
DBT/Induction: 57 (1.2) 
Early death (ED): 57 (1.2) 
 
 
During or After treatment: 97 (2) 
HSCT: - () 
Death in first CR (DCR): 97(2) 
Overall: 154 (3.2) 
- 
CCG 
(Gaynon PS. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(COG) 
Age: <21 
 
CCG 100 series 
CCG 1800 series 
CCG 1900 series  
1983-1988 
1989-1995 
1996-2002 
 
3713 (0.8-1.1) 
5121 (0.7-1.8) 
4464 (0.9-2.2) 
Total : 13298 
 
 
 
 
DBT: -  
Induction: 107 (0.8) 
Early death (ED): 107 (0.8) 
 
 
During/After treatment: 230 (1.7) 
HSCT: - 
Death in first CR (DCR): 230 (1.7) 
Overall: 337 (2.5) 
- 
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DCOG 
(Slats AM. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Net
herla
nds) 
Age : <16 
 
 
DCOG ALL-6 
DCOG ALL-7 
DCOG ALL-8 
 
 
1984-1988 
1988-1991 
1991-1996 
 
 
 
190 (1.6-1.6) 
218 (0.9-2.8) 
467 (0.9-1.1) 
 
Total: 875 
 
 
 
 
DBT: 3 (0.3)  
Induction: 6 (0.7) 
Early death (ED): 9 (1) 
 
 
During/After treatment: 9 (1) 
HSCT: 5 (0.6) 
Death in first CR (DCR): 14 (1.6) 
Overall: 23 (2.6) 
 
Infection: 1  
Bleeding/Thrombosis: 5/0 
Tumor burden: 1 
Others: 2 
Early death (ED): 9 
Infection: 2/0/1/1/3(7) 
TRM: 5 
Bleeding: 1 
Others: 1  
Death in first CR (DCR): 14 
DCOG 
(Kamps 
WA. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Netherlands) 
Age : <16 
 
DCOG ALL-9 1997-2004 
 
Total : 859 
 (1-2.2.6) 
 
 
DBT: 1 (0.1) 
Induction: 9 (1) 
Early death (ED): 10 (1.2) 
 
 
During/After treatment: 20 (2.3) 
HSCT: 3 (0.3) 
Death in first CR (DCR): 23 (2.6) 
Overall: 33 (3.8) 
 
Infection: 5/0/1 (6) 
Tumor burden: 1 
Others: 2 
Early death (ED): 10 
 
Infection: 15 
TRM: 3 
Others: 5 
Death in first CR (DCR): 23 
 
 
St. Jude 
(Rubnitz J. 
et al) 
Retrospective 
Single 
institution 
(St. Jude, 
Memphis, 
USA) 
Age: ≤ 18 years 
Total Therapy Studies 
XI-XII-XIIIA-XIIIB-
XIV 
1984-1999 
Total: 1011 
(1.4-2.1) 
 
 
 
 
DBT: 0 
Induction: 14 (1.4) 
Early death (ED): 14  (1.4) 
 
 
During/After treatment: 10/6 (1.6) 
HSCT: 6 (0.6) 
Death in first CR (DCR): 22  (2.1) 
Overall: 36  (3.6) 
 
 
Infection: 1/2/8/0/0 (11) 
Bleeding/Thrombosis: 0 
Others: 3 
Early death (ED): 14 
 
Infectionh:7/2/1/0/0 (9) 
TRM: 6 
Others: 7 
Death in first CR (DCR): 22 
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POG (Salzer 
WL. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(POG) 
Age: ≤ 21 
ALinc14-15-16 
 (B-Precursor) 
8704-9404  
(T-Precursor) 
8398-8493-9107 
(Infant ALL) 
1986-1999 
 
1987-2001 
 
1984-1993 
 
 
6466 (0.8-1.7) 
 
705 (1.7-2.4) 
 
164 (5.5-7.3) 
 
Total: 7335 
 
DBT: - 
Induction: 70 
Early death (ED): 70 (1) 
 
 
During/After treatment: 142 (1.9) 
HSCT:  - 
Death in first CR (DCR): 142 (1.9) 
Overall: 212 (2.9) 
- 
INS (Stark 
B. et al) 
Retrospective 
Multi 
institutional 
cooperative 
(INS) 
Age : ≤ 21 
INS 84 
INS 89 
INS 98 
1984-1989 
1989-1997 
1998-2003 
 
 
134 (0-1.5) 
337 (0-3.2) 
315 (2.2-2.2) 
 
Total : 786 
 
 
 
 
DBT: - 
Induction: 7 (0.9) 
Early death (ED): 7 (0.9) 
 
 
During/After treatment: 20 (2.5) 
HSCT: - 
Death in first CR (DCR)i: 20 (2.5) 
Overall: 27 (3.4) 
 
 
 
 
- 
 
Early death (ED): 7 
 
 
Infection: 18 
Others: 2 
Death in first CR (DCR): 20 
 
CPH-BFM 
(Stary J, et 
al) 
Retrospective 
Multi 
institutional 
cooperative 
(CPH) 
Age: ≤ 18 years 
ALL-BFM 90 
ALL-BFM 95 
 
1990-1996 
1996-2002 
 
 
350 (4-5.4) 
380 (3.9-3.7) 
Total: 730 
 
 
 
 
DBT:  - 
Induction: 29 (4) 
Early death (ED): 29 (4) 
 
 
During/After treatment: 33 
HSCT: - 
Death in first CR (DCR)j: 33 (4.5) 
Overall: 62 (8.5) 
 
 
 
 
- 
 
Early death (ED): 7 
 
 
Infection: 25 
Others: 8 
Death in first CR (DCR): 33 
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NOPHO 
(Christensen 
MS. et al 
and Lund B 
M. et al) 
 
Retrospective 
Multi 
institutional 
cooperative 
(NOPHO) 
Age: 1-15 years 
 
NOPHO-ALL 92 
NOPHO-ALL 2000 
 
 
1992-2001 
2002-2007 
 
 
 
1645 (1-2) 
1090 (1.2-1.8) 
Total: 2735 
 
 
 
 
DBT: 5 (0.2) 
Induction: 34 (1.2) 
Early death (ED): 39 (1.4) 
 
 
During/After treatment: 39 (1.4) 
HSCT: 10 (0.4) 
Death in first CR (DCR): 49 (1.8) 
Overall: 88 (3.2) 
 
 
 
Infection: 26 
Bleeding/Thrombosis: 6 
Tumor burden: 7 
Early death (ED): 39 
Infection: 30 
TRM: 10 
Toxicity: 6 
Others: 3 
Death in first CR (DCR): 49 
 
TPOG 
(Liang D-C. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Taiwan) 
Age: ≤ 15 years TPOG-93 1993-1997 
Total : 201  
(3-3.5) 
 
 
 
Induction: 6 (3) 
Early death (ED): 6 (3) 
 
 
During or After treatment: 7 (3.5) 
HSCT: - 
Death in first CR (DCR): 7 (3.5) 
Overall: 13  (6.5) 
 
Infection: 5 
Bleeding/Thrombosis: 1 
Early death (ED): 6 
 
 
Infection: - 
Others: - 
Death in first CR (DCR): 7 
TPOG 
(Liang D-C. 
et al) 
Retrospective 
Multi 
institutional 
cooperative 
(Taiwan) 
Age: ≤ 18 years 
TPOG-97 
TPOG-2002 
1997-2001 
2002-2007 
 
 
602 (*-6) 
788 (*-0.6) 
 
Total : 1390 
 
DBT/Induction:- 
Early death (ED): - 
 
 
During or After treatment: 41 (2.9) 
HSCT: - 
Death in first CR (DCR): 41 (2.9) 
Overall: 41  (2.9) 
 
Early death (ED): - 
 
 
Infection: 35 
Others: 6  
Death in first CR (DCR): 41 
 
ALL: Acute lymphoblastic leukemia; CR: Complete remission; MRC: Medical Research Council; JCCLSG: Japanese Childhood Cancer and 
Leukemia Study Group;  TCCSG: Tokyo Children’s Cancer Study Group; DFCI: Dana-Farber Cancer Institute; BFM: Berlin-Frankfurt-Munich; 
COALL: German Co-operative study group for treatment of acute lymphoblastic leukemia in childhood; AIEOP: Associazione Italiana di 
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Ematologia ed Oncologia Pediatrica; CCG: Children´s cancer group; DCOG: Dutch Childhood Oncology Group; POG: Pediatric Oncology 
Group; INS: Israel National Studies in childhood ALL; CPH: Group for Pediatric Hematology in Czech Republic; NOPHO: Nordic society of 
paediatric haematology and oncology; TPOG: Taiwan Pediatric Oncology Group; CR: Complete remission; DBT: Death before treatment; ED: 
Early death; HSCT: Hematopoietic stem cell transplantation; DCR: Death in first complete remission; TRM: Transplant in first CR related 
mortality; SMN: Secondary malignant neoplasm 
a 
Number of patients included only eligible and evaluable patients who were finally included in the analysis in each trial by any single group. In 
brackets the percentage of deaths during induction and in first complete remission for each trial are depicted when this information could be 
extracted from the paper. This missing information is represented by *.*.  
b 
Infections have been divided in 5 groups and separated by slashes: Bacterial/Viral/Fungal/Pneumocystis carinii/Others or unknown. 
c 
Tumor burden related deaths included tumor lysis syndrome (TLS) and leukostasis with compromised organ function due to infiltrating blast cells 
(e.g. mediastinal mass).  
d 
Others in the group of DCR included adult respiratory distress syndrome (ADRS), aspiration, cardiac arrhythmias, sudden death, traffic 
accidents, suicide, iatrogenic causes and unknown causes. 
e 
Others in the group of ED included non infectious neurological insults (stroke, cerebral edema, brain hernia, encephalopathy), iatrogenic and 
unknown causes. 
f 
Deaths in CR were primarily due to infectious complications as explained in the paper (No numeric values provided). No information about death 
during induction to remission could be figured out from this report. 
g
 Deaths during induction were mostly due to infections.  
h
 One patient in this study had disseminated Varicella and Candida infections. 
i
 Secondary neoplasms were reported in this paper. Nevertheless, the outcome of this group of patients could not be figure out and therefore not 
plotted in the chart.  
j 
Secondary neoplasms were reported in this paper. Nevertheless, the outcome of this group of patients could not be figure out and therefore not 
plotted in the chart. 
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Appendix 2. Detailed description of the patients who died of toxicity on each EORTC protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A. Types of infective deaths in EORTC-CLG trials 
 
Early deaths (ED) 
DBT/Prephase/Induction 
Deaths in remission 
Hematopoietic stem cell 
transplantation 
Total (%) 
Type organism / 
Trial 
58831/2 58881 58881 58741 58831/2 58881 58951 58831/2 58881 58951  
Bacterial 9 6 13 2 0 8 7 0 0 1 46 (44.7) 
Pseudomonas spp. 3 3 2 0 0 0 1 0 0 0 9 
Escherichia Coli 1 0 3 1 0 1 2 0 0 0 8 
Klebsiella 1 0 0 1 0 0 0 0 0 0 2 
Streptococcus 4 3 2 0 0 0 0 0 0 0 9 
Staphylococus 0 0 1 0 0 1 0 0 0 0 2 
Mycoplasma 0 0 0 0 0 1 0 0 0 0 1 
Enterobacter 0 0 1 0 0 1 0 0 0 0 2 
Proteus 0 0 1 0 0 0 1 0 0 0 2 
Enterococus 0 0 0 0 0 0 1 0 0 0 1 
Lysteria 0 0 0 0 0 1 0 0 0 0 1 
Unknow bacteria 0 0 0 0 0 3 1 0 0 1 5 
Viral 0 0 0 4 3 4 2 0 3 3 19 (18.4) 
Varicella 0 0 0 4 0 0 1 0 0 1 6 
Measles 0 0 0 0 2 2 0 0 0 0 4 
HSV 0 0 0 0 0 0 0 0 1 0 1 
EBV 0 0 0 0 0 1 0 0 1 1 3 
Echo-Virus 6 0 0 0 0 1 0 0 0 0 0 1 
HBV 0 0 0 0 0 0 1 0 0 0 1 
Adenovirus 0 0 0 0 0 0 0 0 0 1 1 
Papilomavirus 0 0 0 0 0 0 0 0 1 0 1 
Influenza 0 0 0 0 0 1 0 0 0 0 1 
Fungal 3 1 3 0 1 7 4 0 5 0 24 (23.3) 
Aspergillus 3 1 3 0 1 4 3 0 4 0 19 
Candida 0 0 0 0 0 2 1 0 1 0 4 
Unknown fungal 0 0 0 0 0 1 0 0 0 0 1 
Pneumocystis carinii 0 0 0 4 0 0 1 0 0 0 5 (4.9) 
Toxoplasma 0 0 0 0 0 0 0 0 2 0 2 (1.9) 
Unknown 0 3 0 1 0 0 2 0 1 0 7 (6.8) 
Total 12 10 16 11 4 19 16 0 11 4 103 (100) 
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ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ARDS: Acute respiratory distress syndrome; DBT: Death before treatment; DIC: 
Disseminated intravascular coagulation; EBV: Epstein Barr Virus; GVHD: Graft versus host Disease; HSCT: Hematopoietic stem cell transplantation; 
HBV: Hepatitis B Virus; HSV: Herpes simplex virus; TLS: Tumor lysis syndrome; TRM: Transplant related mortality; VOD: Veno-occlusive disease.  
Table B. Types of non-infective deaths in EORTC-CLG trials  
 
Early deaths (ED) 
DBT/Prephase/Induction 
Deaths in remission 
Total (%) 
Death group / Trial 58831/2 58881 58951 58741 58831/2 58881 58951  
Tumor burden 2 1 0 0 0 0 0 3 (3.1) 
TLS 0 0 0 0 0 0 0 0 
Leukostasis 2 1 0 0 0 0 0 3 
Bleeding / Thrombosis 5 5 1 0 0 2 2 15 (15.6) 
Intracranial hemorrhage 3 3 0 0 0 0 0 6 
DIC 2 0 0 0 0 0 0 2 
Gastrointestinal hemorrhages 0 2 1 0 0 0 0 3 
Pulmonary hemorrhage 0 0 0 0 0 0 1 1 
Thrombosis 0 0 0 0 0 2 1 3 
Organ toxicity 0 0 0 3 0 6 0 9 (9.4) 
Pancreatitis  0 0 0 0 0 1 0 1 
Cardiotoxicity  0 0 0 0 0 2 0 2 
Hepatic toxicity 0 0 0 3 0 1 0 4 
Others 0 0 0 0 0 2 0 2 
TRM 0 0 0 0 2 22 7 31 (32.3) 
GVHD 0 0 0 0 0 7 2 9 
Infection 0 0 0 0 0 11 4 15 
Conditioning regimen toxicity 0 0 0 0 2 0 0 2 
Others 0 0 0 0 0 4 1 4 
Secondary neoplasms 0 0 0 1 0 11 3 15 (15.6) 
AML 0 0 0 0 0 7 2 9 
Sarcomas 0 0 0 0 0 1 0 1 
Brain tumors 0 0 0 1 0 0 1 2 
Others 0 0 0 0 0 3 0 3 
ALL progression 1 1 0 0 0 0 0 2 (2.1) 
Others 1 3 0 0 3 6 8 21 (21.9) 
Necrotising enterocolitis 1 0 0 0 0 0 0 1 
VOD 0 1 0 0 0 0 0 1 
ARDS 0 2 0 0 0 0 2 4 
Iatrogenia 0 0 0 0 1 1 0 2 
Histiocytic disorders 0 0 0 0 2 2 2 6 
Others 0 0 0 0 0 3 4 7 
Total 9 10 1 4 5 47 20 96 (100) 
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Appendix 3. Cumulative doses of chemotherapy of the EORTC-CLG ALL protocols 
 
Cumulative doses of chemotherapy – All protocols 
Drug/Trial 58741 58831 58832 58881 58951 
 
All 
patients 
Standard Risk 
Medium/High 
Risk 
Standard Risk 
Very 
High 
Risk 
Very Low Risk 
Average Risk 
(AR1 – AR2) 
Very 
High 
Risk 
BCNU  
(mg/m2) 
50 - - - - - - - 
Daunorubicin (mg/m2) 120 120 120 120 220 60 120-90 240 
Doxorubicin (mg/m2) - 60 120 120 - 60 120 - 
Mitoxantrone 
(mg/m2) 
- - - - 16 - - - 
Cyclophosphamide 
(mg/m2) 
140 
0 Vs 2000 
(According to 
randomization) 
3000 3000 2000 - 3000-4000 3000 
Ifosfamide  
(mg/m2) 
- - - - 800 - - - 
L-Asparaginase (IU/m2) 600000 145000 145000 120000 345000 
120000 Vs  
160000 
(According to 
randomization) 
120000 Vs  
160000 
(According to 
randomization) 
250000 
Vincristine  
(mg/m2) 
20 9 12 12 8 12 12 14 
Cytarabine 
(mg/m2) 
- 1800 2400 
1800 Vs 9800 
(According to 
randomization) 
22000 1800 1800 18000 
Etoposide 
(mg/m2) 
- - - - 900 - - 900 
IV Methotrexate 
(g/m2) 
- 2 10 20 50 20 20-55 40 
IT Methotrexate  
(Injections/Age 
dependant) 
- 6 6 10 10 6 1 1 
Triple IT 
(Injections/Age 
dependant) 
- - - 
- 
 
6 4 16 15 
 
